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Zusammenfassung 
 
Bereits seit ihrer Erstbeschreibung wird angenommen, dass Mitglieder der TRP-Kanal-Familie, die 
in Thrombozyten, im Endothel oder in kardialen Zellen exprimiert werden, bei zahlreichen 
kardiovaskulären Prozessen von Bedeutung sind. In dieser Arbeit habe ich die Rolle der TRP-
Kanäle für die Thrombozyten-Aggregation sowie für die Entwicklung einer Herzhypertrophie 
untersucht. Die pathologisch gesteigerte Zunahme der Herzgröße stellt eine adaptive Antwort des 
Herzens auf eine mechanische Überlastung dar und kann auch durch direkte Stimulation von G-
Protein gekoppelten Rezeptoren hervorgerufen werden. Charakterisiert ist sie durch erhöhte 
intrazelluläre diastolische Ca2+ Konzentrationen in Kardiomyozyten, welche Ca2+-abhängige 
Signalkaskaden in Gang setzen, die zum kardialem Remodelling führen. Die Mechanismen, die zu 
einer veränderten intrazellulären Ca2+-Homöostase führen sind nur ansatzweise verstanden, 
jedoch könnten Rezeptor-vermittelte Ca2+-Kanäle beteiligt sein, die durch neurohumorale 
Hypertrophie-induzierende Stimuli aktiviert werden. Der Ca2+-Einstrom aus dem Extrazellulärraum 
ins Zytosol ist auch für die Aktivierung und Aggregation von Thrombozyten und damit für die 
primäre Hämostase von großer Bedeutung. Hier erfolgt der Ca2+-Einstrom u.a. nach Aktivierung 
von ADP-Rezeptoren in der Plasmamembran. Es gibt zahlreiche Hinweise, dass TRPC-Proteine 
solche Rezeptor-aktivierte Ca2+-Kanäle bilden.  
   In dieser Arbeit wurden TRPC6-Proteine in Herz und Thrombozyten von Wildtyp-Mäusen, jedoch 
nicht von TRPC6-defizienten Mäusen nachgewiesen. Mittels RT-PCR-Experimenten wurden 
Transkripte von TRPC1, TRPC3, TRPC4 und TRPC6 in kardialen Fibroblasten und lediglich von 
TRPC1 in isolierten Kardiomyozyten detektiert. In Thrombozyten konnten TRPC1- und TRPC6-
Transkripte amplifiziert werden. Die neurohumoral-induzierte kardiale Hypertrophie durch 
Isoproterenol und Angiotensin II (AT II) war in TRPC1/TRPC4 (-/-)2 Mäusen signifikant reduziert, in 
TRPC3/TRPC6 (-/-)2 Mäusen jedoch unverändert. Ich konnte Unterschiede in der renalen 
Reninsekretion, in der Plasmaangiotensinogenkonzentration und in der Blutdruckregulation als 
Ursache ausschließen; darüber hinaus kann die reduzierte Hypertrophieantwort in TRPC1/TRPC4-
defizienten Mäusen nicht auf das Fehlen von TRPC1 oder TRPC4 alleine zurückgeführt werden. 
Der AT II-induzierte Anstieg der Herzfrequenz und der Ca2+-Einstrom in kardiale Fibroblasten ist in 
TRPC1/TRPC4 (-/-)2 Mäusen vermindert. Obwohl der zugrunde liegende  Mechanismus noch nicht 
vollständig verstanden ist, konnte ich zeigen, dass TRPC1 und TRPC4 kausal an der Entstehung 
einer neurohumoral induzierten Herzhypertrophie beteiligt sind. 
   In Mäusen mit Deletion von TRPC1, TRPC5 oder TRPC6 und TRPC4/TRPC6-doppelt 
defizienten Mäusen ist die Thrombozytenaggregation unverändert. Dagegen ist die durch ADP-, 
Thromboxan A2- und Thrombin-induzierte Aggregation in TRPC1/TRPC6 (-/-)2 und TRPC3/TRPC6 
(-/-)2 Mäusen deutlich abgeschwächt; diese Reduktion ist nach Inaktivierung von P2Y12 Rezeptoren 
durch Clopidogrel-Behandlung noch verstärkt, während die Kollagen-induzierte Aggregation 
unverändert ist. Ich schließe daher, dass TRPC1, TRPC3 und TRPC6 Proteine die ADP-induzierte 
und durch P2Y1 Rezeptoren vermittelte Thrombozytenaggregation entscheidend regulieren und 
dadurch den Kollagen-induzierten Signalweg über Orai/STIM Proteine komplementieren. 
 
Schlagwörter: TRPC-Proteine, Ca2+, Knockout-Mäuse, kardiale Hypertrophie, Thrombozyten-Aggregation. 
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Abstract 
 
Since its first description it was proposed that members of the TRP ion channel family expressed 
in platelets, endothelial and cardiac cells are involved in various cardiovascular processes. In this 
thesis I analyzed the role of TRPC channels in platelet aggregation and in the development of 
cardiac hypertrophy. Pathological cardiac hypertrophy is an adaptive response of the heart to 
mechanical load abnormalities, but can also be induced by direct stimulation of G protein coupled 
receptors. It is characterized by elevated intracellular diastolic Ca2+ levels which initiate Ca2+-
dependent signaling cascades. The mechanisms causing impaired intracellular Ca2+ homeostasis 
are still incompletely understood, but receptor-operated Ca2+ channels of the TRPC family might 
be activated by neurohumoral hypertrophic stimuli and could play a role here. Ca2+ entry from the 
extracellular space is also critical for platelet activation and aggregation which plays an important 
role in primary hemostasis. Here, Ca2+ entry follows activation of plasma membrane receptors 
including ADP receptors and TRPC proteins might contribute to this mode of platelet activation. 
   In this study TRPC6 proteins were identified in heart and platelets from wild type but not from 
TRPC6-/- mice. In RT-PCR experiments transcripts from TRPC1, TRPC3, TRPC4 and TRPC6 
were amplified from cardiac fibroblasts; however, only TRPC1 transcripts were amplified from 
isolated cardiomyocytes. TRPC1 and TRPC6 transcripts were amplified from platelets. 
Unexpectedly, neurohumoral cardiac hypertrophy induced by isoproterenol and angiotensin II 
(ATII) was not reduced in TRPC3/TRPC6 (-/-)2 mice. In contrast, the hypertrophic response was 
significantly reduced in TRPC1/TRPC4 (-/-)2 after isoproterenol and ATII treatment, respectively. I 
could rule out differences in renal renin secretion, basal plasma angiotensinogen levels or in blood 
pressure regulation during isoproterenol infusion; in addition, the reduced hypertrophy response in 
TRPC1/TRPC4 (-/-)2 mice is not due to deletion of either TRPC1 or TRPC4 proteins alone. An 
impaired ATII-induced signaling in TRPC1/TRPC4 (-/-)2 mice was observed and this could play a 
role possible through regulation of heart rate or Ca2+ signaling in cardiac fibroblast. Although the 
underlying mechanisms are not completely understood, TRPC1 and TRPC4 proteins were 
identified in this study as positive regulators of the neurohumoral-induced cardiac hypertrophy 
development.  
   In mice lacking either TRPC1, TRPC5 or TRPC6 and mice lacking both TRPC4 and TRPC6 
platelet aggregation was found to be unaltered. In contrast, ADP-, Thromboxane A2-, and 
thrombin- induced aggregation was significantly impaired in TRPC3/TRPC6 and TRPC1/TRPC6 
deficient mice, and the reduction in the aggregation response was amplified by inactivating P2Y12 
receptors with clopidogrel treatment. In contrast, collagen-induced aggregation was unaffected. 
Therefore, I propose TRPC1, TRPC3 and TRPC6 proteins as crucial regulators of ADP-induced 
platelet aggregation through P2Y1 receptor signaling which could complement the collagen-
triggered pathway that depends on Orai/STIM proteins. 
 
Keywords: TRPC proteins, Ca2+, knockout mice, cardiac hypertrophy, platelet aggregation. 
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1. Introduction 
 
It is a challenge to decipher the physiological and pathophysiological mechanisms 
underlying cardiovascular diseases (CVD) in order to develop new strategies of 
prevention and treatment regarding the increasing rates in CVD as well as the high 
morbidity and mortality associated to them. Cardiovascular diseases cause about 48% 
and 42% of all deaths in Europe and in the European Union, respectively (European 
cardiovascular disease statistics, 2008), and about 34% in the United States (CVD 
statistics from 2006, American Heart Association), making it an issue with a high socio-
economic impact.  
 
Members of the TRP ion channel family, including TRPC cation channels, have been 
proposed to be mediators of different physiological and pathophysiological cardiovascular 
processes (Inoue et al., 2006; Dietrich et al., 2007a; Abramowitz and Birnbaumer, 2009; 
Watanabe et al., 2009; Dietrich et al., 2010). It has been postulated that TRP channels 
play a role in cardiac hypertrophy development (Guinamard and Bois, 2007; Nishida and 
Kurose, 2008) and in platelet aggregation (Authi, 2007); however, no causal evidence 
about their role in cardiac hypertrophy development or platelet aggregation has been 
presented so far; therefore the role of TRPC channels in both processes was analyzed in 
this thesis.  
 
Cardiac hypertrophy is an adaptive response of the heart to mechanical load 
abnormalities. The hypertrophic response can be induced by stimulation of G protein 
coupled receptors (GPCR) such as angiotensin II receptor 1 (AT1) or β-adrenergic 
receptors. It is characterized by enhanced size of cardiomyocytes (CM) and elevated 
intracellular diastolic Ca2+ levels which initiates Ca2+-dependent signaling cascades and 
reactivation of fetal genes through the calcineurin-NFAT pathway (Heineke and Molkentin, 
2006). The mechanisms leading to impaired intracellular Ca2+ homeostasis are still 
incompletely understood, but receptor-operated cation channels of the TRPC family might 
be activated by neurohumoral hypertrophic stimuli. Additionally, cardiac hypertrophy and 
remodeling are regulated by other cells types. Cardiac fibroblasts are important mediators 
regulating the secretion of growing factors with direct impact on cardiomyocytes function, 
hypertrophy development and extracellular matrix formation (Brown et al, 2005). Recent 
reports proposed that Ca2+ entry mediated by TRPC proteins is involved in cardiac 
hypertrophy development. For example, specific cardiomyocyte over-expression of either 
TRPC3 or TRPC6 in mice leads to increased cardiomyocyte size, cardiac mass and heart 
failure (Kuwahara et al., 2006; Nakayama et al., 2006). 
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Platelets play an important role in primary cellular hemostasis and also in intravascular 
thrombus formation after atherosclerotic remodeling. Changes in intracellular Ca2+ 
concentration either due to Ca2+ entry from the extracellular space or due to Ca2+ release 
from internal stores are steps in activation and aggregation (Rink and Sage, 1990; Sage, 
1997). Ca2+ entry follows activation of plasma membrane receptors including Gq-coupled 
such as the P2Y1 receptor, the prostanoid receptor TP and Protease activated receptor 4 
(PAR4), which are activated by ADP, Thromboxane A2 (TxA2) and thrombin, respectively 
(Woulfe et al., 2004; Offermanns, 2006). In addition, collagen activates Glycoprotein (GP) 
VI and induces an intracellular signaling pathway that induces elevation of intracellular 
calcium concentration (Hagedornt et al., 2010). These cellular signaling pathways involve 
Phospholipase C (PLC) activation and subsequent Diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3) formation, second messengers that are known to mediate 
activation of TRPC channels (Clapham, 2007). It has been proposed that most proteins 
from the TRPC subfamily are expressed in platelets and might contribute to platelet 
activation as constituents of agonist-activated Ca2+ entry channels (Den Dekker et al., 
2001; Hassock et al., 2002; Tolhurst et al., 2005; Jardin et al., 2009). 
 
The main hypotheses that I addressed in my thesis were that the inactivation of one or 
more TRPC proteins lead to reduction in the development of cardiac hypertrophy and/or to 
impaired platelet aggregation, providing in that way causative evidence about the role of 
TRPC channels either for cardiac hypertrophy development or for platelet aggregation. 
The analysis of TRPC channels is hampered by the lack of appropriate channel blockers 
and agonists, and suitable antibodies to identify TRPC proteins in primary cells are not 
available in most cases (Freichel and Flockerzi, 2007). The use of TRPC-deficient mouse 
models provides a very useful tool to analyze antibody specificity and to determine the 
causal role of these proteins. I have been investigating the role of TRPC proteins for 
cardiac hypertrophy development and for platelet aggregation in mouse lines lacking 
either TRPC1, TRPC3, TRPC4, TRPC5 or TRPC6, as well as from TRPC compound 
knockout mice derived thereof. We used compound TRPC deficient mice because it has 
been proposed that different TRPC proteins can form heteromeric channels (Abramowitz 
and Birnbaumer, 2009) and the knockout of one TRPC protein can be compensated by 
other TRPC protein (Dietrich et al., 2005). Already, the use of TRP deficient mouse 
models had proven to be useful to unravel the physiological function of various TRP 
proteins (Wu et al., 2010a).  
 
The expression of different TRP proteins in murine heart and platelets was analyzed using 
heart and platelets from TRP-deficient mice as negative controls. Using an antibody 
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directed against mouse TRPC6 we identified TRPC6 proteins in heart and platelets from 
wild type (WT) but not from TRPC6 deficient mice. I amplified TRPC1 and TRPC6 
transcripts from isolated mouse platelets, and TRPC1, TRPC3, TRPC4 and TRPC6 
transcripts from cardiac cells obtained by Langendorff perfusion. In addition, I amplified 
TRPC1, TRPC3, TRPC4, TRPC5 and TRPC6 transcripts from cultured mouse cardiac 
fibroblasts. In cardiomyocytes isolated by Laser Capture Microdissection only TRPC1 
transcripts were detected. 
 
After establishing methods for the in vivo analysis of the neurohumoral-induced cardiac 
hypertrophy development in TRPC deficient mice I found that TRPC1/TRPC4 (-/-)2 mice, 
which lack both TRPC1 and TRPC4 proteins, had a reduced hypertrophy response after 
isoproterenol (Iso) or angiotensin II (ATII) treatment. This reduced response was not 
observed in TRPC1 or TRPC4 single knockout mice. In contrast, the Iso-induced and the 
ATII-induced hypertrophic responses were not diminished in TRPC3/TRPC6 (-/-)2 mice. In 
addition, the effects of constant Iso or ATII infusion on blood pressure and on heart rate 
were characterized. Isoproterenol increased heart rate by about 30% with a minor 
increase of ~3mmHg in mean arterial pressure (MAP). ATII significantly increased MAP by 
45mmHg and heart rate by ~7%. Isoproterenol produced a bigger increase in cardiac 
mass compared to ATII. In contrast, ATII generated a more pronounced fibrosis in 
comparison to Iso. Isoproterenol treatment produced comparable changes in MAP 
between WT and TRPC1/TRPC4 (-/-)2 mice, and the Iso-induced increase in heart rate 
was reduced in TRPC1/TRPC4 deficient mice. The cellular mechanisms that are 
responsible for the reduced hypertrophic response in TRPC1/TRPC4 (-/-)2 mice are 
currently investigated.  
 
Regarding the role of TRPC channels in platelet function, I performed in vitro aggregation 
analysis by a systematic screening of platelets from different TRPC deficient mouse lines. 
Platelet aggregation triggered by ADP, Thromboxane A2 analogue U46619, thrombin and 
collagen was first characterized with platelets from wild type mice. The deletion of TRPC1, 
TRPC3, TRPC4 or TRPC6 did not affect platelet counts in mice. Unexpectedly, the 
deletion of either TRPC1 or TRPC6 proteins did not affect platelet aggregation. From 
experiments with mouse lines lacking TRPC4/TRPC6 or TRPC5 proteins a relevance of 
TRPC4 and TRPC5 proteins for ADP-, TxA2-, thrombin- or collagen-induced aggregation 
of murine platelet seems dubious at this point. On the other hand, ADP-induced 
aggregation was impaired in platelets from TRPC1/C6 and TRPC3/TRPC6 deficient mice. 
Collagen-induced platelet aggregation was not different in both genotypes. This reduction 
was associated with impaired response through the ADP P2Y1 receptor, because 
 
Introduction  4  
 
differences in the aggregation response between WT and TRPC1/C6 and TRPC3/TRPC6 
deficient platelets were more pronounced when the P2Y12 receptor was blocked by pre-
treatment of the mice with Clopidogrel. Possibly, as secondary effect of a reduced ADP 
response, impaired aggregation responses to Thromboxane A2 analogue U46619 and 
thrombin were observed in both TRPC1/C6 and TRPC3/TRPC6 deficient platelets. In the 
future, we will study the impact of these findings to the in vivo aggregation as well as the 
mechanisms behind the defective ADP-induced platelet aggregation in TRPC1/C6 and 
TRPC3/TRPC6 mice.    
 
From these results it can be concluded that TRPC channels play a causative role in 
development of cardiac hypertrophy and in platelet aggregation. TRPC1 and TRPC4 
proteins together positively regulate the neurohumoral cardiac hypertrophy development 
in vivo induced by isoproterenol and angiotensin II. In contrast, and unexpected due to the 
evidence from knock-down studies in neonatal cardiomyocytes and transgenic 
overexpression of TRPC3 or TRPC6 proteins in mouse heart, proposing TRPC3 and 
TRPC6 channels as positive regulators of cardiac hypertrophy, no evidence of reduced 
cardiac hypertrophy in mice deficient for TRPC3 and TRPC6 channels was observed with 
our neurohumoral-induced cardiac hypertrophy. Concerning platelet aggregation, our 
results point out that TRPC1, TRPC3 and TRPC6 are required for ADP-induced platelet 
aggregation through P2Y1 receptor signaling.  
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2. Objectives  
 
2.1 Objectives for cardiac hypertrophy project 
 
The main objective of this part of my thesis was to analyze if TRPC proteins are causally 
involved in the development of the in vivo cardiac hypertrophy induced by neurohumoral 
mechanisms. To achieve this, it was first required that I establish in our group 
methodological tools for cardiac hypertrophy induction by isoproterenol or angiotensin II 
infusion, as well as the corresponding methods to quantify and analyze the extent of 
cardiac hypertrophy produced by both agents in mice. The methods included assessment 
of cardiac hypertrophy indexes, histomorphological analysis of cardiomyocyte cross 
sectional area and cardiac fibrosis, and measurements of in vivo ventricular function by a 
pressure transducer catheter. With a reliable set of established methods it was possible to 
test if mice deficient for one or more TRPC proteins develop cardiac hypertrophy to the 
same extent as the corresponding control mice after isoproterenol or angiotensin II 
infusion. Additional cardiac functions were analyzed using surface ECG and contraction of 
spontaneously beating right atria in organ bath apparatus.  
 
Another aim of this thesis was to study the expression of different TRPs in the mouse 
heart, and especially in cardiomyocytes and cardiac fibroblasts. For this it was also 
necessary that I set up methods to isolate both cardiac cell types. To this end I developed 
protocols for the isolation of mouse cardiomyocytes by Laser Capture Microdissection, the 
isolation and culture of mouse adult cardiac fibroblasts and the corresponding 
characterization of the culture by RT-PCR and immunocytochemistry. 
 
 
2.2 Objectives for platelet’s function project   
 
In the part of this thesis regarding the study of platelet function the first goal was to 
determine the role of TRPC proteins in platelet aggregation through stimulation with the 
four main platelet activating agonists ADP, Thromboxane A2, thrombin and collagen using 
platelets from wild type and TRPC deficient mice. The second goal was to analyze the 
expression of different TRPs in murine platelets by RT-PCR and by western blot analysis 
using platelets isolated from different TRPC deficient mice as controls. To accomplish 
both goals it was essential that I establish methods for the isolation of mouse platelets and 
for the in vitro analysis of platelet function by turbidimetric aggregometry.   
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3. Theoretical framework and state of the art 
 
3.1 The TRP ion channel’s family and the TRPC ion channel’s subfamily 
 
Since 40 years ago, when a spontaneous mutation in the Drosophila eye was described 
(Cosens and Manning, 1969) and the mutated gene called trp was cloned (Montell and 
Rubin, 1989), 28 trp homologues have been described in mammals. From those, 27 are 
expressed in humans because one (TRPC2) corresponds to a pseudogene (Clapham, 
2007). The TRP ion channel family has been divided, based on amino acid sequence 
homology, in 7 subfamilies as follows: TRPC (Canonical) subfamily with 7 members in 
mammals (TRPC1 to 7), TRPM (Melastatin) subfamily with 8 members (TRPM1 to 8), 
TRPV (Vanilloid) subfamily with 6 members (TRPV1 to 6), TRPA (Ankyrin) subfamily with 
one member (TRPA1), TRPN subfamily with no mammalian homologue (one member in 
invertebrates and zebrafish), TRPP (polycystin) with 3 mammalian members (TRPP2, 3 
and 5) and TRPML (mucolipin) also composed of 3 members (TRPML1 to 3). These 28 
channels share a main proposed organization of six putative transmembrane domains 
with both, C and N termini, being intracellularly located and is believed that TRP channels 
are assembled as homo- or hetero-tetramers to form cation selective channels (Montell, 
2005; Pedersen et al., 2005). Beyond a general topological organization, these channels 
have a great diversity in activation mechanisms and selectivities and they have been 
proposed to be key players in sensory physiology and homeostasis regulation. But, still it 
is not known for most of them how they are activated and which are the physiological 
functions in vivo (Clapham, 2003; Venkatachalam and Montell, 2007; Wu et al., 2010a); 
despite the fact that numerous TRP channels have been related to several diseases the 
knowledge about their causative role of pathophysiological conditions is still sparse (Nilius 
and Owsianik, 2010). 
 
General characteristics and regulation of TRPC channels. The members of the TRPC 
cation channel subfamily are the closest homologues of the Drosophila TRP and TRPL 
channels, and like those they are activated by signaling pathways that depends on 
Phospholipase C (PLC) activity. The subfamily is composed by TRPC1, TRPC2, TRPC3, 
TRPC4, TRPC5, TRPC6 and TRPC7 proteins and these members have been additionally 
subdivided into three groups, TRPC1/C4/C5, TRPC3/C6/C7 and TRPC2 (Minke, 2006). It 
has been proposed that TRPCs are part of the Store-Operated Ca2+ Entry (SOCE) being 
activated by store depletion, and also it has been shown that they have a role in the 
Receptor-Operated Calcium Entry or ROCE (Ambudkar and Ong, 2007). GPCR-mediated 
activation of the PLCβ and receptor tyrosine kinase-mediated activation of the PLCγ 
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signaling systems results in hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) 
with formation of the second messengers diacylglycerol (DAG) and inositol 1,4,5- 
trisphosphate (IP3). The fall of the Ca2+ concentration within the lumen of the 
endoplasmatic reticulum by the action of inositol 1,4,5-trisphosphate (IP3) on the IP3 
receptor (InsP3R) or through the use of Thapsigargin (TG), a specific inhibitor of the 
Sarco-Endoplasmatic Reticulum Ca2+-ATpase (SERCA), activates a entry of Ca2+ across 
the plasma membrane which is known as Capacitative Ca2+ Entry (CCE) or SOCE; on the 
other hand, Ca2+ entering through the PLC-activated channels is referred to as ROCE 
(Parekh and Putney, 2005; Trebak et al., 2007; Abramowitz and Birnbaumer, 2009).  
 
For each member of the TRPC channel subfamily some regulatory postulated 
mechanisms and characteristics reviewed by several authors (Clapham, 2003; Montell, 
2005; Pedersen et al., 2005; Alexander et al., 2007; Trebak et al., 2007; Venkatachalam 
and Montell, 2007) are presented.  
 
TRPC1. TRPC1 channels conduct non-selectively mono and divalent cations; they are 
activated by store depletion of intracellular Ca2+ stores with IP3 or by inhibition of the 
SERCA with TG, Diacylglycerol (DAG) analogue OAG in the absence of extracellular 
Ca2+, PLC, mechanical stretch, metabotropic receptors, glutamate receptors, and can be 
inhibited by Lanthanides, extracellular Ca2+, Gadolinium (Gd3+), SKF96365 that it is a 
cation channel blocker and 2-aminoethoxydiphenyl borate (2-APB) which is a blocker of 
IP3R (InsP3R).  
 
TRPC2. TRPC2 channels are more selective to conduct calcium compared to sodium with 
a PCa/PNa=2.7, calculated from measurements in vomeronasal sensory neurons (Lucas et 
al., 2003); they are activated by DAG, store depletion of Ca2+ stores by TG treatment and 
GPCR (Gq-PLCβ), and are inhibited by 2-APB.  
 
TRPC3. TRPC3 channels are slightly more selective for calcium than sodium with a ratio 
of PCa/PNa=1.6 measured in cultured bovine pulmonary artery endothelial cells expressing 
hTRPC3 (Kamouchi, 1999). TRPC3 are positively modulated by store depletion, DAG, 
GPCR (Gq/11-PLCβ), exocytosis, PLCγ, src Thymidine Kinase (TK), IP3, and can be 
inhibited by Lanthanides, Gd3+, Ni2+, SKF96365, 2-APB, flufenamic acid, phorbol ester and 
recently the pyrazole compound Pyr3 was proposed to be an specific TRPC3 antagonist 
(Kiyonaka et al., 2009).  
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TRPC4. TRPC4 channels have a selectivity for calcium compared to sodium (PCa/PNa) 
between 1.05 measured in embryonic kidney (HEK293) cells transfected with a TRPC4 
murine variant (Schaefer et al., 2000)  and 7.7 observed also in HEK293 cells, but 
transfected with a TRPC4 bovine variant (Philipp et al., 1996). TRPC4 channels are 
activated by GPCR (Gq/11-PLCβ), GTPγS, La3+, calmidazolium and, possibly, by store 
depletion, and TRPC4 channels are inhibited by Gd3+ and 2-APB.  
 
TRPC5. TRPC5 channels are more selective for conducting calcium compared to sodium 
with a PCa/PNa values between 1.79 obtained from HEK293 cells transiently expressing a 
TRPC5 murine variant (Schaefer et al., 2000), 9.5 (Montell, 2005) and 14.3 in recordings 
from HEK293 cells expressing also a TRPC5 from mouse (Okada et al., 1998). TRPC5 
channels are activated by store depletion, exocytosis, GPCR (Gq/11-PLCβ), GTPγS, La3+, 
sphingosine-1-phosphate, IP3, Gd3+, extracellular Ca2+, Rac, and modest elevation of 
intracellular [Ca2+], and TRPC5 channels are blocked by 2-APB, SKF96365, and DAG 
(OAG).  
 
TRPC6. TRPC6 channels conduct cations but with preference of divalent ones with a 
PCa/PNa=5 quantified in Chinese hamster ovary (CHO)-K1 cells over-expressing the 
hTRPC6 (Hofmann et al., 1999). TRPC6 channels are activated by DAG (OAG), src 
Timidine Kinase, 20-Hydroxyarachidonic acid (20-HETE), AlF4, flufenamate, GPCR (Gq/11-
PLCβ), GTPγS, intracellular Ca2+ and PIP3, and TRPC6 channels are inhibited by 
SKF96365, 2-APB, Lanthanides and phorbol esters.  
 
TRPC7. TRPC7 channels conduct preferentially divalent over monovalent cations with 
PCa/PNa=1.9 for spontaneous currents and PCa/PNa=5.9 for ATP-enhanced currents 
measured in HEK293 cells transfected with a TRPC7 mouse variant (Okada et al., 1999). 
These channels are activated by DAG, 20-HETE, store depletion, GPCR (Gq/11-PLCβ), 
changes in intracellular Ca2+ concentration, and TRPC7 channels are inhibited by La3+, 
SKF96365, amiloride, 2-APB, flufenamic acid and phorbol esters. 
 
Reported phenotypes from TRPC deficient mice. On the systemic level and up to the 
date only a few physiological roles for some TRPC channels based on the analysis of 
TRPC deficient mice have been proposed (see for review Freichel et al., 2005; Wu et al., 
2010a).  
 
TRPC1-/- mice. From the analysis of TRPC1 deficient mice no differences in the 
pressure-induced constriction of cerebral arteries and no differences in SOCE from 
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smooth muscle cells were observed, but increased body weight in TRPC1-/- mice was 
reported (Dietrich et al., 2007b). In contrast, it was reported that TRPC1-/- mice have a 
reduced SOCE in salivary glands associated with reduced saliva secretion (Liu et al., 
2007). In recent report it was claimed that TRPC1 deficiency led to an enhanced 
endothelium-derived hyperpolarizing factor (EDHF) type vasodilatation in resistance 
arterioles in vivo and also TRPC1 deficiency led to increased systolic blood pressure, 
observation from tail-cuff measurements under anesthesia from only four mice (Schmidt et 
al., 2010).  
 
TRPC2-/- mice. TRPC2 channels are important in pheromone signaling since an 
abnormal sexual and mating behavior was observed in TRPC2-/- mice (Stowers et al., 
2002; Kimchi et al., 2007).  
 
TRPC3-/- mice. TRPC3-/- mice seem to develop normal but they have impaired walking 
behavior, and cerebellar Purkinje cells from these mice lack slow synaptic potentials and 
mGluR-mediated inward currents, a phenotype that was not observed in TRPC1/TRPC4 
deficient mice (Hartmann et al., 2008). Another study of TRPC3 deficient mice showed the 
severity in acute pancreatitis induced by cerulein treatment was alleviated and pancreatic 
acini from these mice had diminished ROCE and SOCE related with altered exocytosis 
and intracellular trypsin activation (Kim et al., 2009).  
 
TRPC4-/- mice. TRPC4-/- mice are fertile and have no signs of disease, but vascular 
endothelial cells from these mice have an impaired store-operated calcium function that 
leads to impaired agonist-induced vasorelaxation (Freichel et al., 2001). Similarly, calcium 
entry induced by thrombin stimulation is reduced in endothelial cells from lung of TRPC4 
knockout mice, and it is associated with reduced vascular permeability in these mice 
(Tiruppathi et al., 2002), plus a reduced thrombin-induced activation of the nuclear factor-
κB (NF-κB), factor that is important for the pathogenesis of inflammation and tissue injury 
(Bair et al., 2009). In other study using TRPC4 deficient mice was shown that serotonin-
mediated gamma-Aminobutyric acid (GABA) release is altered in thalamic interneurons 
(Munsch et al., 2003).  
 
TRPC5-/- mice. TRPC5 deficient mice were recently reported by Riccio and coworkers 
(2009). TRPC5 mice breed and grow normally, and have no basic motor functions 
impairment; but, TRPC5-/- mice have a diminished innate fear level linked to reduced 
responses mediated by synaptic activation of group I metabotropic glutamate and 
cholecystokinin 2 receptors in neurons from the amygdala.  
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TRPC6-/- mice. Analysis of TRPC6 knockout mice showed that they are viable, fertile and 
have no obvious phenotype. These mice have an elevated blood pressure measured by 
telemetric devices that was correlated with enhanced agonist-induced contractility from 
isolated aortic rings and cerebral arteries, increased basal calcium entry in smooth muscle 
cells (SMC) and up-regulation of TRPC3 and TRPC7 expression (Dietrich et al., 2005). In 
another report it was shown that TRPC6-/- mice do not present the acute hypoxic 
pulmonary vasoconstriction response, leading to partial occlusion of alveolar ventilation 
and provoking severe hypoxemia in these mice (Weissmann et al., 2006). In addition, 
TRPC6 knockout mice have increased airway hyperresponsiveness by metacholine, 
increased agonist-induced contractility of tracheal rings and TRPC3 upregulation in 
tracheal SMC, however, the allergic response in TRPC6 deficient mice was reduced (Sel 
et al., 2008). Our group analyzed TRPC6, TRPC4 and TRPC4/TRPC6 knockout mice and 
showed that both channels determine the muscarinic receptor-induced cation current in 
intestinal SMC, a finding that was associated with a slower intestinal transit in double 
knockout mice (Tsvilovskyy et al., 2009). It was recently reported that TRPC6 deficient 
mice have reduced exploration in open field and star maze experiments, postulating a role 
of TRPC6 in behavior (Beis et al., 2011).  
 
TRPC7-/- mice. TRPC7-/- mice have not been reported so far.  
 
 
3.2 Development of cardiac hypertrophy  
 
Cardiac hypertrophy represents an increase of myocardial mass that is caused by a 
variety of stimuli.  In many cases it is an adaptative response to an overload of the 
cardiovascular system. When the working load increases, the cardiomyocytes enlarge to 
preserve the cardiac function and the related remodeling process can be classified in 
three forms: 1) physiological hypertrophy, for example, associated with exercise or 
pregnancy; 2) developmental hypertrophy, which implies the normal cardiac growth during 
aging; and 3) pathological hypertrophy that is linked to disease-inducing stimuli and 
detrimental cardiac function states. Both the physiological and the developmental 
hypertrophy are characterized by homogeneous growth of ventricular wall and 
interventricular septum in proportion to the increase of heart chamber dimensions which is 
named eccentric hypertrophy. On the other hand, pathological hypertrophy or concentric 
hypertrophy is characterized by the increase in ventricular wall and septum thickness 
associated with a net decrease in ventricular chamber size and collagen accumulation 
(Gupta et al., 2007). In pathological conditions myocardial hypertrophy predisposes to 
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heart failure, arrhythmia and sudden death, and irrespective of mechanisms and loading 
conditions, the evolution of cardiac hypertrophy to ventricular dysfunction is an irreversible 
on-going process dependent upon several factors (Olivetti et al., 2000). 
 
Models to study cardiac hypertrophy development and remodeling. Different 
experimental animal models have been described to study cardiac hypertrophy 
development and remodeling. Three of them have been reviewed by Gupta and 
collaborators (2007) and briefly described as: 1) pressure overload by banding of the 
ascending or abdominal aorta which creates a mechanically induced cardiac pressure 
overload. 2) Volume overload used to reproduce conditions observed in aortic and/or 
mitral valve regurgitant disease; in general the model is induced by an aorto-caval shunt 
and cardiac hypertrophy develops within 4–5 weeks with compromised left-ventricular 
contractility and increased end-diastolic pressure. 3) Transgenic mouse models in which 
altered expression of individual proteins leads to cardiac hypertrophy and remodeling. 4) 
In addition, the neurohumoral induced-hypertrophy models are used to mimic altered 
levels of substances like ATII or catecholamines which are involved in cardiac hypertrophy 
development (Grieve et al., 2006). A more detailed description about neurohumoral-
induced hypertrophy is presented under section 3.2.2. 
 
Signals that trigger the cardiac hypertrophy response. Between the initial triggering 
factors that lead to cardiac hypertrophy, there are two main groups: 1) biomechanical and 
stretch-sensitive mechanisms; and 2) neurohumoral mechanisms that are associated with 
release of hormones, cytokines and peptide growth factors. Cardiac hypertrophy is 
coupled with molecular and biochemical responses of different cardiac cell types such as 
cardiomyocytes and fibroblasts; it is related with changes in the expression profile and the 
reactivation of genes usually expressed only in the fetal heart such as atrial natriuretic 
peptide (ANP), B-type natriuretic peptide (BNP), and the cytoskeletal proteins α-actin and 
β-myosin heavy chain (Hannan et al., 2003). The metabolic remodeling and the altered 
energy demand produced during hypertrophy drives to an increase in the oxidative stress 
and disturbed calcium handling in cardiac myocytes (Zhang, 2002; Ritchie and Delbridge, 
2006).  
 
Different signaling pathways have been characterized from in vitro and in vivo models as 
mediators of the hypertrophic response, including signaling through GPCR (ATII 
receptors, ET-1 receptors, and adrenergic receptors), small GTPases (Ras, RhoA, and 
Rac), mitogen-activated protein kinase (MAPK) cascades, protein kinase C (PKC), 
Calmodulin kinase II (CaMKII), gp130-signal transducer and activator of transcription, 
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insulin-like growth factor I (IGF-I) receptor pathway, fibroblast growth factor and 
transforming growth factor β (TGF-β) receptor pathways, Ca2+/calcineurin/NFAT signaling, 
among others (Sugden and Clerck, 1998; Molkentin and Dorn, 2001; Heineke and 
Molkentin, 2006).  
 
The Ca2+-Calcineurin-NFAT pathway in cardiac hypertrophy development. Calcium is 
an important second messenger in cardiac function. It is critical for the excitation-
contraction coupling process that regulates the contraction and relaxation of the heart 
(Bers, 2002); but, calcium is also important in the activation of signal transduction 
pathways responsible for hypertrophic cardiac growth and heart failure, for example, 
controlling gene transcription by calcium/calmodulin dependent signaling (Frey et al., 
2000; Frey et al., 2004; Roderick et al., 2007). One key integrator of the hypertrophy 
signaling regulated by calcium is the Ca2+-calmodulin-activated phophatase calcineurin 
(Wilkins and Molkentin, 2002). Molkentin and collaborators (1998) showed that the 
overexpression of an active form of calcineurin or of the Nuclear factor of activated T-cells 
3 (NFAT3) in mouse heart produced cardiac hypertrophy and heart failure. This 
calcineurin-dependent hypertrophy was prevented by pharmacological blocking of 
calcineurin with Cyclosporine A (CsA). CsA also prevented cardiac hypertrophy in rats 
subjected to abdominal aortic banding (Sussman et al., 1998). Transgenic mice 
expressing a calcineurin inhibitory domain in the heart develop reduced hypertrophy 
induced by abdominal aortic banding or by isoproterenol infusion (De Windt et al., 2001), 
and mice deficient for the catalytic subunit β of calcineurin (CnAβ) have reduced 
hypertrophy responses either induced by abdominal aortic banding, isoproterenol infusion 
or ATII infusion (Bueno et al., 2002). However, pharmacological blockage of calcineurin 
has failed to inhibit cardiac hypertrophy in some cases (Müller et al., 1998; review by 
Wilkins and Molkentin, 2004) and, additionally, in physiological hypertrophy models the 
NFAT-Calcineurin pathway is not a key component (Wilkins et al., 2004). It is postulated 
that NFAT is a mediator of calcineurin signaling as transcriptional effector; it has been 
shown that deletion of NFATc3 in mice produces a significant reduction in three 
hypertrophy models: Calcineurin transgene-induced hypertrophy, abdominal aortic 
banding or ATII treatment (Wilkins et al., 2002), and indeed, different NFAT isoforms are 
expressed in cardiomyocytes and regulate cellular hypertrophy (van Rooij et al., 2002).  
 
Calcium sources that contribute to cardiac hypertrophy development. The 
mechanisms whereby calcium leads to calcineurin activation under repetitive calcium 
concentration changes during contraction cycle are still not completely understood, and 
the sources the calcium elevation are controversial (Houser, 2009). Houser and Molkentin 
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(2008) proposed that calcineurin-NFAT signaling and resultant pathological hypertrophy 
occurs in specific localized subcellular microdomains. 
 
Beyond the calcium derived from Ca2+-induced-Ca2+ release and from the sarcoplasmic 
reticulum during each contractility event, also plasmalemmal channel complexes that 
mediate Ca2+-entry from the extracellular space into the cytosol have been postulated as 
mediators of the hypertrophic response (Wilkins and Molkentin, 2004; Molkentin 2006). Up 
to now there is evidence supporting all these different calcium entry pathways which 
probably regulate the calcineurin/NFAT-mediated cardiac hypertrophy. 
 
1) L-type Ca2+ channels in special membrane domains. From experiments with 
neonatal rat ventricular myocytes (NRVM) it was shown that stretch induced calcineurin 
activity and cellular hypertrophy were suppressed by blocking L-type channels with 
nifedipine (Zobel et al., 2007). Besides this, calcineurin can bind to the C and N termini of 
L-type channels (α11.2) and its function is increased in NRVM expressing an active form 
of calcineurin (Tandan et al., 2009). In addition, in rat atrial preparations changes in 
pacing frequency increases basal Ca2+ levels without altering the amplitude of the Ca2+ 
transients, an observation linked to calcineurin-NFAT dependent activation and 
expression of the hypertrophy marker BNP (Tavi et al., 2004), following these 
observations, Colella and co-workers (2008) showed that in NRVM calcineurin/NFAT 
mechanisms are activated by changes in frequency of Ca2+ oscillations and NFAT activity 
was prevented by using Verapamil, a blocker of voltage-gated Ca2+ channels. 
 
2) T-type calcium channels. Regarding T-Type channels Chiang and co-workers (2009) 
showed that Cav3.2-/- mice or mice treated with ethosuximide as T-Type channel blocker 
did not increase cardiac mass after transverse aortic banding or ATII treatment. 
Furthermore, calcineurin activation induced by aortic banding was abolished in Cav3.2-/- 
mice, but other hypertrophy associated effects like fibrosis development were similar to 
wild type mice. Curiously, the hypertrophic markers α-MHC, β-MHC, ANF, BNP were 
significantly enhanced in Cav3.2 deficient mice under these conditions.  
 
3) Ca2+ release from the nucleus. Evidence supporting a role of Ca2+ pools independent 
from those linked to contraction events was presented by Wu and collaborators (2006) 
using adult rabbit cardiomyocytes, they proposed that ET-1 can produce a local Ca2+ 
release from the nucleus via InsP3-receptors which produces CaMKII activation and 
subsequent exporting of the transcription suppressor histone deacetylase (HDAC5) due to 
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phosphorylation, and finally the myocyte enhancer factor-2 (MEF2), which is associated 
with the hypertrophy development, is derepressed.  
 
4) SOC entry alone or in conjunction with IP3R-mediated release from the 
endoplasmic reticulum. Among the Ca2+ pools independent from those linked to 
contraction it has been proposed that other hypertrophic Ca2+ source is SOCE through 
TRPC channels (Toko et al., 2007). This mechanism in cardiac myocytes is plausible 
since it was shown that SOCE contributes to the translocation of NFAT from the cytosol to 
the nucleus and to the development of cellular hypertrophy after ATII or PE stimulation in 
cultured NRVM (Hunton et al., 2002) and, furthermore, SOCE has been described in 
cardiomyocytes from adult rats (Hunton et al, 2004) and from mice (Nakayama et al., 
2006), and in the mouse sinoatrial node (Ju et al., 2007). Also, several cation channels 
that exhibit features of TRPC channels were reported in cardiomyocytes.  
 
However, reported evidence from different Ca2+-pools contributing to the development of 
cardiac hypertrophy requires careful interpretation because as stated by House and 
Molkentin (2008): “microdomains in which Ca2+-mediated signaling might take place could 
be very different in adult myocytes in vivo compared with cultured neonatal myocytes”. 
This also can be applied to transgenic models where the native protein levels are altered 
by over-expression of a determined protein; this can alter the normal interaction between 
protein partners, as well as the normal Ca2+ handling within the cells.  
 
 
3.2.1 TRP channels in cardiac hypertrophy development 
 
Expression of TRPC channels in the heart. TRPC proteins are proposed to mediate 
store-operated Ca2+ entry in cells of the cardiovascular system (Freichel et al., 1999). 
Indeed, the expression of several TRPs including all TRPC channels has been reported in 
the heart (Table i1) and in cardiomyocytes (Table i2). Although, the protein expression 
analysis of TRPCs reported so far did not include tests of antibody specificity with cells or 
tissue from TRPC-deficient mice, except in a work of Seth and coworkers (2009) that used 
heart lysates from wild type and TRPC1-/- mice. More over, the purity of cardiomyocyte 
preparation used so far has not been clearly proven. 
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Table i1. Reported expression of TRPC channels in mammalian heart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRPC Western blot RT-PCR References
Garcia and Schilling, 1997 (Rat)
Kuwahara et al., 2006 (Mouse)
Bush et al., 2006 (Human, only mentioned)
Kunert-Keil et al., 2006 (Mouse)
Ohba et al., 2006 (Mouse)
Ohba et al., 2007 (Rat)
Ju et al., 2007 (Mouse, atria and SAN)
Shan et al., 2008 (Mouse)
Seth et al., 2009 (Mouse, WT vs. TRPC1-/- mice)
Kunert-Keil et al ., 2006 (Mouse)
Ohba et al., 2006 (Mouse)
Ju et al., 2007 (Mouse, SAN).
Garcia and Schilling, 1997 (Rat)
Kuwahara et al., 2006 (Mouse)
Bush et al. 2006 (Mouse and rat)
Nakayama et al., 2006 (Mouse)
Kunert-Keil et al., 2006 (Mouse)
Ohba et al., 2006 (Mouse)
Ohba et al., 2007 (Rat)
Ju et al., 2007 (Mouse, atria and SAN)
Shan et al., 2008 (Mouse)
Seth et al., 2009 (Mouse, WT vs. TRPC1-/- mice)
Wu et al., 2010 (Mouse)
Garcia and Schilling, 1997 (Rat)
Kuwahara et al., 2006 (Mouse)
Bush et al., 2006 (Human, only mentioned)
Ju et al., 2007 (Mouse, atria and SAN)
Liu et al., 2009 (Rat)
Seth et al., 2009 (Mouse, WT vs. TRPC1-/- mice)
Wu et al. 2010 (Mouse)
Bush et al., 2006 (Human)
Ohba et al., 2007 (Rat)
Liu et al., 2009 (Rat)
Garcia and Schilling, 1997 (Rat)
Kuwahara et al., 2006 (Human and Mouse)
Bush et al., 2006 (Human, mentioned only)
Kunert-Keil et al., 2006 (Mouse)
Ohba et al., 2006 (Mouse)
Ohba et al., 2007 (Rat)
Ju et al., 2007 (Mouse, atria and SAN)
Seth et al., 2009 (Mouse, WT vs. TRPC1-/- mice)
Wu et al. 2010 (Mouse)
Kunert-Keil et al., 2006 (Mouse)
Satoh et al., 2007 (Rat, northern blot)
Ju et al., 2007 (Mouse, atria and SAN)
TRPC7 not defined X
TRPC5 X X
TRPC6 X X
X X
TRPC4 X X
TRPC1 X X
TRPC2 not defined X
TRPC3
Expression analysis of TRPC proteins by Western blot analysis and/or transcripts by RT-PCR was 
described in this selection of reports in the heart. In any of these reports where the protein 
expression was analyzed by western blot were included protein preparations of TRPC deficient 
mice as control for antibody specificity, except for Seth et al., (2009). WT: wild type; SAN: Sino-
Atrial Node. 
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Table i2. Reported expression of TRPC channels in mammalian cardiomyocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRPC Western blot RT-PCR References
Nakayama et al., 2006 (Mouse, adult CM)
Onohara et al., 2006 (NRVM, only mentioned)
Ohba et al., 2007 (NRVM)
Brenner and Dolmetsch, 2007 (NRVM)
Ju et al., 2007 (Mouse, ICC of pacemaker cells)
Seth et al., 2009 (Mouse, ICC of CM from WT and TRPC1-/- mice)
Alvarez et al., 2008 (Rat, CM)
TRPC2 not defined X Brenner and Dolmetsch, 2007 (NRVM)
Onohara et al., 2006 (NRVM)
Bush et al., 2006 (NRVM)
Nakayama et al., 2006 (Mouse, adult CM)
Kunert-Keil et al., 2006 (Mouse, in situ hybridization of CM)
Brenner and Dolmetsch, 2007 (NRVM)
Ju et al., 2007 (Mouse, ICC of pacemaker cells)
Alvarez et al., 2008 (Rat, CM)
Onohara et al., 2006 (NRVM, only mentioned)
Nakayama et al., 2006 (M, adult CM)
Brenner and Dolmetsch, 2007 (NRVM)
Ju et al., 2007 (Mouse, ICC of pacemaker cells)
Alvarez et al., 2008 (Rat, CM)
Onohara et al., 2006 (NRVM, only mentioned)
Nakayama et al., 2006 (Mouse, adult CM)
Brenner and Dolmetsch, 2007 (NRVM)
Onohara et al., 2006 (NRVM, only mentioned)
Kuwahara et al., 2006 (NRVM)
Kunert-Keil et al., 2006 (Mouse, in situ hybridization of CM)
Brenner and Dolmetsch, 2007 (NRVM)
Ju et al., 2007 (Mouse, ICC of pacemaker cells)
Onohara et al., 2006 (NRVM)
Brenner and Dolmetsch, 2007 (NRVM)
Alvarez et al., 2008 (Rat, CM)
TRPC7 X X
TRPC5 X X
TRPC6 X X
TRPC3 X X
TRPC4 X X
TRPC1 X X
Expression analysis of TRPC proteins by Western blot analysis and/or transcripts by RT-PCR was 
described in this selection of reports in cardiomyocytes. Only Seth et al., (2009) used TRPC 
deficient mice as control for antibody specificity. CM: cardiomyocytes, NRVM: Neonatal Rat 
Ventricular Myocytes, ICC: Immunocytochemestry. 
 
 
Proposed roles for TRPC channels in cardiomyocytes. A nonselective cation current 
(IATP) which exhibits several features of over-expressed TRPC3/C7 channels has been 
described in adult rat cardiomyocytes (Alvarez et al., 2008). An ATII-induced TRPC like 
current was measured in NRVM (Onohara et al., 2006). SOCE described in adult mouse 
cardiomyocytes was enhanced in cardiomyocytes with overexpression of TRPC3 
channels (Nakayama et al., 2006). A nonselective current in adult mouse cardiomyocytes 
from hypertrophied hearts was attributed to TRPC1 channels (Seth et al., 2010). 
Increased expression of TRPC4/C5 and SOCE activity was observed when the type 2 
Sarco-Endoplasmatic Reticulum Ca2+-ATpase (SERCA2) was knockdown in neonatal 
cardiac myocytes (Seth et al., 2004). NFAT consensus sites in the promoter of the TRPC6 
gene have been reported (Kuwahara et al., 2006), and currents with characteristics of 
TRPC channels have been reported in cardiac fibroblasts (Rose et al., 2007). 
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Concomitant with the expression analysis of different TRPC proteins in the heart there is 
evidence from in vivo and in vitro models proposing a role of these channels in cardiac 
hypertrophy and remodeling; for instance, the main models used so far are NRVM and 
transgenic mice overexpressing TRPC proteins in the heart. Several reports propose a 
contribution of TRPC-mediated Ca2+ entry and/or depolarization of the cell membrane to 
cellular hypertrophy of NRVM (Bush et al., 2006; Kuwahara et al., 2006; Onohara et al., 
2006; Brenner and Dolmetsch, 2007; Nishida et al., 2007; Ohba et al., 2007). However, it 
is still lacking a causal link between TRPC protein function and cardiac hypertrophy 
development. In addition, specific agonists or antagonists that regulate cation entry 
mediated by individual TRPC proteins are not available.  
 
In different rodent models of cardiac hypertrophy it has been reported increased 
expression of TRPC1 (Ohba et al., 2006; Ohba et al., 2007; Seth et al., 2009), TRPC2 
(Ohba et al., 2006), TRPC3 (Bush et al., 2006; Ohba et al., 2006*; Brenner and 
Dolmetsch, 2007; Seth et al., 2009; Koitabashi et al., 2010) and TRPC6 (Kuwahara et al., 
2006; Ohba et al., 2006; Nishida et al., 2007; Seth et al., 2009; Koitabashi et al., 2010). 
Additionally, increased expression of TRPC1 and TRPC5 in human failing hearts 
(Sucharov and Bristow, 2005; Bush et al., 2006; Kuwahara et al., 2006), increased 
TRPC6 mRNA in human hearts with dilated cardiomyopathy (Kuwahara et al., 2006) and 
down regulation of TRPC4 in ventricular myocytes in biopsies from patients with ischemic 
cardiomyopathy based on a microarray screening (Gronich et al., 2010) were reported. 
Major observations related with these expression changes are presented below. 
 
Knock-down of TRPCs in cardiomyocytes as cellular model. In vitro models using 
cardiac cells pointed that TRPC3 expression induces cellular hypertrophy in NRVM and it 
activates the calcineurin-NFAT signaling (Bush et al., 2006). It was shown using siRNA in 
NRVM that TRPC3 mediates the expression of ANP and BNP, but it does not mediate 
changes in cell size or beating frequency (Brenner and Doltmetsch, 2007). Similarly, in 
NRVM the ET-1 induced NFAT activation and protein synthesis were significantly reduced 
after treatment with siRNAs directed against TRPC6 (Nishida et al., 2007). From the 
mechanistic point of view it was proposed that stimulation of NRVM with ATII leads to the 
activation of TRPC3/TRPC6 channels through DAG, its activation causes slow increases 
in the membrane potential with the subsequent increase in L-type channel activity and, 
finally, dephosphorylation of NFAT by calcineurin (Onohara et al., 2006). In adult 
cardiomyocytes from TRPC3/TRPC6 (-/-)2 mice it was shown that the peak of ATII-
                                                 
* In this report from Ohba et al. (2006) the expression of different TRPC channels was analyzed in transgenic 
mice overexpressing a dominant negative form of the Neuron-restrictive silencer factor (dnNRSF under α-
MHC promotor) that exhibited dilated cardiomyopathy; they reported that TRPC3 protein levels were 
increased in these mice, but TRPC3 transcripts were decreased.  
 
Theoretical framework and state of the art  18  
induced Ca2+ transients and ATII L-type currents observed in cells from wild type mice 
were abolished in cells from TRPC3/TRPC6 deficient mice (Klaiber et al., 2010). However, 
the mechanisms behind this reduction remain elusive and the contribution of individual 
TRPC proteins to agonist-induced Ca2+ entry or to membrane depolarization has not been 
demonstrated in primary adult cardiomyocytes. 
 
Initial evidence pointing a role of TRPC1 channels in cardiac hypertrophy came from the 
fact that the TRPC1 murine gene has a NRSE (Neuron-Restrictive Silencer Elements)-like 
sequence; this kind of sequences are target of Neuron-Restrictive Silencer Factors 
(NRSF) that are involved in regulation of cardiac genes and cardiac remodeling. TRPC1 
upregulation in transgenic α-MHC-dnNRSF mice was correlated with increased NFAT 
activity in NRVM overexpressing TRPC1 (Ohba et al., 2006). In NRVM it was shown that 
increases in cell size and in expression of ANP and BNP triggered by ET-1, ATII or PE, as 
well as the ET-1 induced SOCE were attenuated by TRPC1 knockdown (Ohba et al., 
2007). Others reported that the hypertrophic response mediated by the serotonin receptor 
5HT2A was suppressed by TRPC1 knockdown (Vindis et al., 2010). Using NRVM it was 
proposed that TRPC7 channels could mediate the myocardial apoptosis response 
triggered by ATII (Satoh et al., 2007). 
 
Role or TRPs in cardiac fibroblasts. Within the past years an increasing attention has 
been given to the role of cardiac fibroblasts which are involved in myocardial development 
and in pathologies characterized by changes in the extracellular matrix such as fibrosis. 
Fibroblasts regulate the environment in which cardiac myocytes are embedded through 
paracrine signaling by cytokines like IL-1, IL-6, TGFβ, and also by direct communication 
from cell-to-cell interaction, and they have a critical role in cardiac hypertrophy, cardiac 
remodeling, and atrial fibrillation (Baudino et al., 2006; Souders et al., 2009; Kakkar and 
Lee, 2010). Expression of TRPC channels in cardiac fibroblasts has been reported (Table 
i3) but the functional role of TRPCs in cardiac fibroblasts is still unknown (Yue et al., 
2011). In rat ventricular fibroblasts a non selective cation current triggered by stimulation 
of the C-type natriuretic peptide (CNP) receptors was characterized as sensitive to TRPC 
blockers and was linked to PLC and DAG signaling, and to TRPC expression in these 
cells (Rose et al., 2007). Spontaneous Ca2+ oscillations in human fibroblasts can be 
abolished by SOC blocking by La3+ or PLC inhibition (Chen et al., 2010) and it was 
reported that in atrial human fibroblasts a TRP protein (TRPM7) conducts the calcium 
responsible for fibroblast differentiation and proliferation by TGF-β1 stimulation (Du et al., 
2010). From experiments with rat fibroblasts TRPC6 has been postulated as regulator of 
ET-1 induced myofibroblast differentiation in neonatal cardiac fibroblasts; fibroblasts 
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expressing active Gα12 or Gα13 proteins or stimulated by ET-1 presented increased 
TRPC6 expression, enhanced Ca2+ influx and increased NFAT activation; these 
responses were reduced by knockdown of TRPC6, but interestingly, the myofibroblast 
formation was enhanced by TRPC6 inhibition (Nishida et al., 2007).  
 
 
Table i3. Reported expression of TRPC channels in mammalian cardiac fibroblasts. 
 
 
 
 
 
 
 
 
 
 
 
 
TRPC Western blot RT-PCR References
Rose et al., 2007 (Rat, acute isolated)
Nishida et al., 2007 (Rat, neonatal fibroblasts)
Chen et al., 2010 (Human)
Du et al., 2010 (Human atrial cells, Mouse)
TRPC2 not defined X Rose et al., 2007 (Rat, acute isolated)
Rose et al., 2007 (Rat, acute isolated)
Nishida et al., 2007 (Rat, neonatal fibroblasts)
Chen et al., 2010 (Human)
Du et al., 2010 (Human atrial cells, Mouse)
Rose et al., 2007 (Rat, acute isolated)
Chen et al., 2010 (Human)
Du et al., 2010 (Human atrial cells, Mouse)
TRPC5 not defined X Rose et al., 2007 (Rat, acute isolated)
Rose et al., 2007 (Rat, acute isolated)
Nishida et al., 2007 (Rat, neonatal fibroblasts)
Chen et al., 2010 (Human)
Du et al., 2010 (Human atrial cells, Mouse)
Rose et al., 2007 (Rat, acute isolated)
Nishida et al., 2007 (Rat, neonatal fibroblasts)
TRPC1 not defined X
TRPC3 X X
TRPC4 not defined X
TRPC6 X X
TRPC7 X X
Expression analysis of TRPC proteins by Western blot analysis and/or transcripts by RT-PCR was 
described in this selection of reports in cardiac fibroblasts. In any of these reports where the protein 
expression was analyzed by western blot were included protein preparations of TRPC deficient 
mice as control for antibody specificity. 
 
 
Mouse models with cardiomyocyte-specific overexpression of TRPCs. In 2006 two 
independent groups showed that overexpression either of TRPC3 or TRPC6 proteins 
under control of the cardiomyocyte specific α-MHC promoter in mice leads to cardiac 
hypertrophy. Transgenic α-MHC-TRPC3 mice develop cardiac hypertrophy with aging. 
They present increased ATII/PE- and transverse aortic banding (TAC)-induced 
hypertrophy, associated with increased NFAT activation and increased SOCE; in addition, 
after 14 days of aortic banding TRPC3-transgenic develop cardiac failure (Nakayama et 
al., 2006). This hypertrophic phenotype was attenuated by the specific overexpression in 
cardiomyocytes of the Plasma Membrane Ca2+ ATPase 4b (PMCA4b); the authors 
interpreted this finding as a result of the removal of Ca2+ excess provoked by TRPC3 
overexpression (Wu et al., 2009). Additionally, it was reported that a pyrazole compound 
(Pyr3) which blocks overexpressed TRPC3 channels can attenuate TAC-induced 
hypertrophy in mice (Kiyonaka et al., 2009). Since TRPC6 regulates and it is regulated by 
the calcineurin-NFAT pathway, Kuwahara and coworkers (2006) analyzed the effect of 
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TRPC6 overexpression in mouse cardiomyocytes. Transgenic α-MHC-TRPC6 mice with 
the higher expression levels die between 5-12 days after birth, possibly due to severe 
cardiomyopythy; transgenic mice with intermediate expression levels develop 
cardiomegaly and congestive heart failure around 30 weeks of age; and those mice with 
lower expression levels have no obvious defect, but they have a significant higher 
response to aortic banding measured by HW/BW.  
 
From other two in vivo approaches it was postulated that cardiomyocytes from 
hypertrophied hearts after aortic banding have an increased Ca2+ influx or a non-selective 
current associated with TRPC channels and not L-type or the Na+/Ca2+ exchanger (Seth 
et al., 2009; Wu et al., 2010). The first approach attributed the non-selective current to 
TRPC1 channels because this current was not detected in cardiomyocytes from TRPC1-/- 
mice; furthermore, TRPC1-/- mice had reduced TAC- and ATII-induced hypertrophy 
responses (Seth et al., 2009). The second approach presented evidence showing that 
transgenic mice with specific cardiomyocyte expression of dominant-negative constructs 
either of TRPC3, TRPC4 or TRPC6 had reduced pathological hypertrophy induced by 
TAC or ATII/PE infusion, and also cardiomyocytes from some of these transgenic mice 
had reduced hypertrophy-induced Ca2+ entry (Wu et al., 2010b).  
 
Not only TRPC channels from the TRP family, but also other members have been 
proposed to play role in pathological hypertrophy and cardiac remodeling. It was recently 
reported from our group that mice deficient for the TRPM4 channel are hypertensive, 
observation associated with higher circulating catecholamine levels and mild cardiac 
hypertrophy development at six months of age in TRPM4-/- mice that could be secondary 
to hypertension (Mathar et al., 2010). A second example came from mice overexpressing 
TRPV2 under a cardiac promoter; these mice exhibit enlarged hearts, increased fibrosis 
and myocardial structural defects, depending on expression levels (Iwata et al., 2003).  
 
 
3.2.2 Neurohumoral induced cardiac hypertrophy 
 
In hypertrophy experiments with rodents neurohumoral agonists such as ATII or 
isoproterenol (Iso) have effects on: 1) heart weight, 2) cardiomyocyte size, 3) cardiac 
fibrosis, 4) blood pressure, 5) heart rate, 6) circulating or local components of the Renin-
Angiotensin-Aldosterone System (RAAS) and cytokines, 7) cardiac contractility and 8) 
body weight. A summary of these effects produced by different doses of isoproterenol and 
ATII is presented below.  
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Cardiac hypertrophy induced by chronic isoproterenol infusion. A wide range of 
isoproterenol doses has been described to study the effect of β-adrenergic stimulation on 
the cardiovascular system. From a selection of reports the isoproterenol effects can be 
summarized as follows: 
 
1) Effects of isoproterenol infusion on heart weight. Changes in heart weight are 
analyzed by hypertrophy indexes such heart weight/body weight (HW/BW) and heart 
weight/tibia length (HW/TL). In mice treated with Iso in a range of doses among 0.027 and 
120mg/kg/day used from 7 up to 14 days the HW/BW and the HW/TL index were 
increased between 24% and 61% (Friddle et al. 2000; Rothermel et al., 2000; De Windt et 
al., 2001; Bueno et al., 2002; Braz et al., 2003; Kedzierski et al., 2003; Vega et al., 2003; 
Patterson et al., 2004; Song et al., 2006; Zhang et al., 2007; Shen et al., 2008). A dose of 
30mg/kg/day Iso produced increases between 31% and 59% in HW/BW after 5 days 
(Jaffré et al., 2004; Monassier et al., 2008). The same dose produced increments in 
HW/BW between 20% and 25% after 7 days (Keys et al., 2002; Maass et al., 2004) or 
increments of 17% after 14 days (Iaccarino et al., 1999). Isoproterenol-induced cardiac 
hypertrophy in rats has been also reported (Hayes et al., 1984; Allard et al., 1990; 
Kitagawa et al., 2004; Shizukuda et al., 1998).  
 
2) Effects of isoproterenol infusion on cardiomyocyte size. Isoproterenol in mice 
applied between 0.672 and 30mg/kg/day during 7 to 14 days produced increments of 30% 
to 70% in cardiomyocyte size (Iaccarino et al., 1999; Friddle et al. 2000; Zhang et al., 
2007; Shen et al., 2008). Similar increments were reported in rats (Kitagawa et al., 2004). 
 
3) Effects of isoproterenol infusion on cardiac fibrosis. Cardiac fibrosis is measured 
by changes in the mRNA expression of collagen or by staining of collagen fibers by Sirius 
red or Masson’s Trichrome. In mice a dose of 15mg/kg/day (7 days) produced no fibrosis 
evidence (Friddle et al. 2000) but the same dose after 11 days generated a 2 times higher 
expression of collagen in the heart (Zhang et al., 2007). Doses of 30 or 60mg/kg/day (7 to 
26 days) also produced fibrosis in mice (Kudej et al., 1997; Bueno et al., 2002; Wang et 
al., 2005; Wittköpper et al., 2010). Isoproterenol treatment can also increases cardiac 
fibrosis in rats (Allard et al., 1990; Shizukuda et al., 1998; Kitagawa et al., 2004). 
 
4) Effects of isoproterenol infusion on blood pressure. Systolic blood pressure (SBP) 
measured by tail-cuff in mice treated with 15mg/kg/day (11 days) or 30mg/kg/day Iso (5 
days) was not significantly different (Zhang et al., 2007; Monassier et al., 2008). From 
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blood pressure measurements via carotid catheterization it was observed that 
30mg/kg/day (7 days) produced an increment of 40mmHg in mean arterial pressure 
(MAP) (Keys et al., 2002). In rats it was reported that isoproterenol increased (Allard et al., 
1990), decreased (Leenen et al., 2001) or had no effect on blood pressure (Kitagawa et 
al., 2004; Shizukuda et al., 1998; Nagano et al., 1992). 
 
5) Effects of isoproterenol infusion on heart rate. Doses between 15 and 30mg/kg/day 
used in a period of 5 to 14 days raised heart rate in mice between 23% and 56% (Jaffré et 
al., 2004; Zhang et al., 2007; Monassier et al., 2008; Wittköpper et al., 2010). Comparable 
results were reported in rats (Allard et al., 1990; Nagano et al., 1992; Leenen et al., 2001). 
 
6) Effects of isoproterenol on circulating or local RAAS components and cytokines. 
In mice, 30mg/kg/day (5 or 7 days) produced increments in plasma levels of Interleukin-1β 
(IL-1β), IL-6, tumor necrosis factor-α (TNFα) and TGF-β1 (Jaffré et al., 2004; Jaffré et al., 
2009). In rats it was observed that isoproterenol increased Aldosterone serum levels 
(Allard et al., 1990) and produced augmentation of plasma and cardiac ATI and ATII 
concentrations, and plasma and ventricular renin activity (Leenen et al., 2001; Nagano et 
al., 1992). 
 
7) Effects of isoproterenol on cardiac contractility. It was reported that in mice 
15mg/kg/day (10 days) produced an increase of peak velocity of left outflow tract and a 
decrease of the ejection time in echocardiography measurements (Kedzierski et al., 
2003). A dose of 30mg/kg/day (7 days) reduced significantly both fractional shortening 
and systolic ejection volume in mice (Jaffré et al., 2009). 
 
8) Effects of isoproterenol on body weight. It was reported that in mice a dose of 
15mg/kg/day (7 days) of isoproterenol produced no changes in body weight (Friddle et al. 
2000). However, with 30mg/kg/day (13 days) a significant increase of 22% in body weight 
from treated mice was observed, and it was associated with gain of brown fat and muscle, 
and higher food intake (Kudej et al., 1997). 
 
Mechanisms contributing to the isoproterenol induced cardiac hypertrophy. 
Isoproterenol has a direct effect on the heart increasing the heart frequency (positive 
chronotropic) and also the contraction force (positive inotropic). Beyond this, isoproterenol 
can stimulate cardiac fibroblast leading to the secretion of growth factors involved in 
cardiac hypertrophy development. Isoproterenol stimulates renin secretion from kidneys 
resulting in an increase on circulating levels of angiotensin II that can act on the heart 
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stimulating cardiomyocytes and fibroblasts. It also may affect blood pressure by direct 
effects on blood vessels and by increasing circulating angiotensin II. Changes in blood 
pressure might also be involved in cardiac hypertrophy development. In addition, mast 
cells within the heart can produce Renin and mediate the conversion of ATI to ATII by 
action of the enzyme chymase (Reid et al., 2007). Then, mast cells also contribute to the 
production of ATII that stimulates cardiac myocytes and fibroblasts leading to the 
hypertrophy development.  
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Figure i1. Pathways contributing to the isoproterenol-induced cardiac hypertrophy. 1. 
Isoproterenol has a direct effect on the heart 2. Isoproterenol stimulates renin secretion from 
kidneys resulting in an increase on circulating levels of angiotensin 3. Isoproterenol may affect 
blood pressure directly and by increasing circulating angiotensin II. ATI: Angiotensin I; ATII: 
Angiotensin II; ACE: Angiotensin Converting Enzyme. 
 
 
Other effects during the isoproterenol-induced hypertrophy are the increment of cardiac 
reactive oxygen species (ROS) (Monassier et al., 2008), the decrease in β-adrenoreceptor 
density and in Adenylyl cyclase activity in the heart (Kudej et al., 1997) and reduced 
cardiac NFAT activity (Nakayama et al., 2006). Finally, an important contribution to 
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understand the mechanisms behind isoproterenol-induced hypertrophy was made by the 
group of L. Maroteaux. They showed that the direct isoproterenol stimulation to the 
cardiomyocytes is not responsible for the hypertrophic growth. They proposed that the 
isoproterenol stimulates the non cardiomyocyte cells, possibly cardiac fibroblast, and that 
these cells mediate the hypertrophy development through the secretion of different 
cytokines (IL-1β, IL-6, TNF-α and TGF-β1) and ATII signaling controlled by the serotonin 
receptor 5-HT2B on these cells (Jaffré et al., 2009). A schematic summary about the 
pathways contributing to the isoproterenol-induced cardiac hypertrophy is presented in 
Figure i1. 
 
Cardiac hypertrophy induced by chronic Angiotensin II infusion. Different ATII doses 
to induce cardiac hypertrophy have been reported; in general, ATII produces smaller 
increments in cardiac mass, but it produces higher fibrosis and blood pressure elevation. 
Some effects mediated by ATII that contribute to hypertrophy are also mentioned in Figure 
i1. From several reports the effects of different ATII regimes are summarized:  
 
1) Effects of ATII infusion on heart weight. ATII applied between 0.2 and 4.6mg/kg/day 
in a period around one to four weeks generate increments in HW/BW between 5% and 
31% when applied to mice (Friddle et al., 2000; Bendall et al., 2002; Braz et al., 2003; 
Kedzierski et al., 2003; Francois et al., 2004; Crowley et al., 2006 ; Frank et al., 2007; Kilié 
et al., 2007; Tozakidou et al., 2010). A dose of 3 mg/kg/day (14 days) produced in mice a 
19% increase in HW/BW (Song et al., 2006). In mice, reported increments in HW/TL 
treated with 0.3 or 0.432mg/kg/day ATII during 14 days were 20% (Pillai et al., 2006) and 
14% to 19% (Bueno et al., 2002; Wilkins et al., 2002), respectively. Also it has been 
reported that ATII applied to produced similar increaases in hypertrophy indexes (Harada 
et al., 1998; Phillips, 1999; Moser et al., 2002; De Smet et al., 2003; Huentelman et al., 
2005).  
 
2) Effects of ATII infusion on cardiomyocyte size. ATII increases cardiomyocyte size in 
mice from 10% to 30% when applied between 0.3 and 1.44mg/kg/day over 14 days 
(Bendall et al., 2002; Stagg et al., 2004; Pillai et al., 2006; Frank et al., 2007; Kilié et al., 
2007). 
 
3) Effects of ATII infusion on cardiac fibrosis. ATII produces increments in cardiac 
fibrosis when applied in mice. ATII doses between 0.006 and 1.44mg/kg/day applied from 
7 up to 21 days produced significant increments between 60% and 600% in cardiac 
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fibrosis (Ichihara et al., 2001; Kuriso et al., 2003; Crowley et al., 2006). ATII also induced 
a significant increase of myocardial fibrosis in rats (Huentelman et al., 2005).  
 
4) Effects of ATII infusion on blood pressure. From measurements of blood pressure 
by tail cuff in mice receiving a wide ATII dose range between 0.006 and 3mg/kg/day it has 
been reported either no effects or increasing effects (Ichihara et al., 2001; Bendall et al., 
2002; Bueno et al., 2002; Gavazzi et al., Francois et al., 2004; 2006; Pillai et al., 2006; 
Kilié et al., 2007; Chiang et al., 2009). Only a few groups reported telemetric 
measurements of blood pressure in conscious mice during ATII infusion. It was reported 
that 0.15mg/kg/day (21 days) is as a sub-pressor dose (Brancaccio et al., 2003). In 
contrast, 1.44mg/kg/day ATII (21 days) showed the maximum increment after 3 days of 
about 46mmHg in MAP that was maintained over the treatment (Crowley et al., 2006). 
Similarly, 4.61mg/kg/day ATII (14 days) changed MAP by 21mmHg after 24h and 
maintained an increase of about 37 mmHg (Tozakidou et al., 2010). Also telemetric 
recordings of MAP in rats have been reported (Phillips, 1999; De Smet et al., 2003). 
 
5) Effects of ATII infusion on heart rate. In mice 0.2mg/kg/day (Monassier et al., 2008) 
or 1.44mg/kg/day ATII applied for 14 days (Kuriso et al., 2003) did not alter heart rate. But 
in other report 1.3mg/kg/day ATII (28 days) decreased heart rate (Francois et al., 2004). 
In rats ATII either has no effect or increases heart rate (De Smet et al., 2003). 
 
6) Effects of ATII on circulating or local RAAS components or cytokines. In mice it 
was observed that ATII reduced the kidney renin mRNA (Tozakidou et al., 2010). In rats 
ATII changes in plasma renin activity, plasma aldosterone and plasma ET-1 have been 
reported (De Smet et al., 2003). 
 
7) Effects of ATII infusion on cardiac contractility. A dose of 1.3mg/kg/day ATII (28 
days) produced in mice evidence of heart failure and 40% mortality (Francois et al., 2004); 
however, it was reported that 1.44mg/kg/day ATII (14 days) produced no evidence of 
edema in mice (Stagg et al., 2004). 
 
8) Effects of ATII infusion on body weight. ATII can alerter differently the body weight 
in mice. A dose of 0.288mg/kg/day (14 days) produced in mice no changes in body weight 
(Friddle et al., 2000); however, 1.44mg/kg/day ATII after 5 days produced a significant 
increase in body weight (Crowley et al., 2006). On the other hand, higher doses between 
3 and to 4.6 mg/kg/day (7 to 14 days) produced weight loss (Gavazzi et al., 2006; 
 
Theoretical framework and state of the art  26  
Tozakidou et al., 2010). In rats a reduction of body weight was reported and in some 
cases attributed to a reduced food intake (Brink et al., 1996; Ju et al., 1996). 
 
Other neurohumoral-induced cardiac hypertrophy models. Neurohumoral-induced 
cardiac hypertrophy models using other agonists have been reported with increasing 
effects on HW/BW between 7% to 38%; some groups reported the use of Phenylephrine 
(PE) (Iaccarino et al., 1999; Braz et al., 2003; Maass et al., 2004; Niizeki et al., 2008), 
Nor-epinephrine (Maly et al., 2001; Moser et al., 2002; Keys et al., 2002) or in multiple 
combinations as PE plus ATII (Nakayama et al., 2006; Van Berlo et al., 2010; Wu et al., 
2010b) or isoproterenol combined with PE (Saadane et al., 2000; Maass et al. 2004). 
 
 
3.3 Platelet’s function 
 
3.3.1 Platelet’s signaling and thrombosis  
 
The hemostatic system has evolved to keep blood flowing under physiological conditions, 
but also to react rapidly to vessel injury by clotting. Platelets, also named thrombocytes, 
derive from Megakaryocytes, circulate in blood and are critical for primary hemostasis. 
Platelets are important for the formation of blood clots or primary hemostasis, as platelet 
aggregates are an essential constituent of the arterial thrombus, and as a platform for 
activation of coagulation proteins like thrombin and fibrin via the intrinsic pathway 
(Colman, 2006). In blood vessels that are damaged by atherosclerotic lesions platelets 
are activated leading to formation of a thrombus which can detach and finally occlude 
vessels in heart and brain causing myocardial infarction and stroke; this is thought to 
occur when the equilibrium of normal hemostasis is broken due to impaired anti-coagulant 
mechanisms or these mechanisms are overwhelmed by the severity of the initial injury 
(Mackman, 2008). 
 
Signaling that initiates and modulates thrombus formation. The formation of the 
platelet plug can be explained in three phases: initiation, extension and perpetuation.  
 
Initiation phase. After blood vessel injury, platelets are rapidly recruited to the injury site 
to form a monolayer through the interaction of specific platelet cell-surface receptors 
integrin α1β1 and GPVI with collagen and GPb/IX/V complex and integrin αIIbβ3 (also 
known as GPIIb-IIIa) with the von Willebrand factor. 
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Extension phase. After the formation of the platelet’s monolayer on the vessel wall the 
receptor-mediated binding of additional platelets leads to platelet aggregation which 
results in rapid growth of the thrombus. At this stage platelets become activated; important 
in this phase are the rapid responses of surface receptors to soluble agonists such as 
Thrombin, ADP and TxA2. A major pathway of activation involves the cleavage and, 
consequently, the activation of protease-activated receptors (PAR) by thrombin, which is 
activated by the blood coagulation cascade. Activated platelets then release the content of 
their granules including ADP, Serotonin, ATP and Calcium, which further promotes the 
amplification of the coagulation response by platelet recruitment, adhesion and 
aggregation.  
 
Perpetuation phase. This phase includes the late events of clot formation that stabilize 
the platelet plug, prevent premature disaggregation and regulate clot retraction. In 
addition, during the coagulation cascade fibrin is produced and this step is important for 
the stabilization of the thrombus (Abrams, 2005; Woulfe et al., 2006; Jackson, 2007). 
 
Agonists involved in platelet activation. Platelet activation and aggregation signaling 
are mediated by different agonists, including collagen, ADP, TxA2 and Thrombin; the 
agonist-induced inside-out activation of integrin complex αIIbβ3 is considered the final 
common pathway of platelet activation, mandatory for primary hemostasis and occlusive 
thrombus formation (Hagedorn et al., 2010). Collagen can act through GPVI-Fcγ-chain 
signaling and PLCγ (Watson et al., 2001; Samaha and Kahn, 2006). ADP, TxA2 and 
Thrombin, in turn, stimulate GPCRs on the platelet surface that are critical to initiation of 
various intracellular signaling pathways, including activation of PLCβ by heteromeric Gq-
proteins (Offermanns et al., 1997). In both cases, there are various common intracellular 
signaling pathways, including activation of PLC, PKC, and phosphoinositide (PI)-3 kinase, 
and DAG formation. Both, calcium and PKC contribute to activation of small G proteins 
which are important for fibrinogen binding (Crittenden et al., 2004; Smyth et al., 2009). 
Beyond Gq proteins, other heteromeric G-proteins are involved in platelet signaling, for 
example, ADP also stimulates P2Y12 receptors which are coupled to Gi proteins 
(Wettschureck and Offermanns, 2005). 
 
ADP receptors in platelets. P2Y1 ADP receptors are receptors coupled to Gq proteins 
and its activation leads to elevation of the intracellular Ca2+ concentration; ADP P2Y12 
receptors are Gi coupled receptors and its activation decreases cyclic adenosine 
monophosphate (cAMP) formation, but it does not produce elevation of the intracellular 
Ca2+ concentration (Offermanns, 2006). In platelets from mice deficient for the Gq coupled 
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ADP receptor P2Y1 the ADP-induced increase in intracellular Ca2+ concentration as well 
as the platelet shape change are absent, but the ADP inhibition of cAMP formation is 
preserved. Platelets from P2Y1-/- mice do not aggregate in vitro after stimulation with 
different concentrations of ADP and also they have impaired responses after stimulation 
with some concentrations of collagen, thrombin or the thromboxane analogue U46619, 
possibly due to impaired amplification of the aggregation response mediated by the 
secreted ADP after stimulation with these three agonists. P2Y1-/-mice have prolonged tail 
bleeding times and are protected from thromboembolism induced by collagen and ADP 
injection. This observation was related to reduced thrombin generation in the knockout 
mice (Fabre et al., 1999; Léon et al., 1999; Léon et al., 2001). In contrast, platelets 
deficient for the Gi coupled ADP receptor P2Y12 have normal elevation of the intracellular 
Ca2+ concentration and shape change after ADP stimulation, however this stimulus does 
not inhibit the cAMP formation. In addition, P2Y12 deficient platelets have impaired 
collagen and thrombin induced in vitro aggregation, and P2Y12 deficient mice have 
prolonged bleeding times and thrombi formation and stability are impaired (Foster et al., 
2001; André et al., 2003).  
 
Thromboxane A2 receptor in platelets. Platelets deficient for the TxA2 prostanoid 
receptor TP, which is coupled to Gq or G12/G13 proteins, do not aggregate after stimulation 
with the TxA2 receptor agonist U46619. Mice lacking the TP receptor have prolonged tail 
bleeding times and different to WT mice they do not have the cardiovascular collapse and 
sudden death associated with systemic platelet aggregation, pulmonary thrombosis and 
coronary spasm induced by intravenous injection of U46619 or arachidonic acid (Thomas 
et al., 1998; Cheng et al., 2002).  
 
Thrombin receptors in platelets. Thrombin acts on platelets through PAR receptors 
which are coupled to different G proteins. In human platelets are expressed PAR1 and 
PAR4 receptors that are coupled in most cases to Gq, G12/G13 proteins. In mice PAR4 
receptors are also expressed and are coupled to Gq, G12/G13 proteins; in addition, in 
murine platelets the PAR3 receptor is expressed and its believed to function as a cofactor 
for cleavage and activation of PAR4 and it does not mediate transmembrane signaling by 
itself (Kahn et al., 1999; Nakanishi-Matsui et al., 2000; Offermanns, 2006). Platelets from 
PAR4 deficient mice show increase in the intracellular Ca2+ concentration, no shape 
change, ATP secretion or aggregation in response to thrombin. PAR4 KO mice have 
extended bleeding times and are protected from thrombosis in a model of arteriolar 
thrombosis using mesenteric arteries (Sambrano et al., 2001). Platelets deficient for the 
thrombin receptor PAR3 have impaired aggregation and ATP secretion induced by 
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thrombin, but bleeding times in the mice were reported normal (Kahn et al., 1998). Others 
reported that PAR3 deficient mice have prolonged bleeding times, defects in thrombus 
formation and are protected against thromboembolism (Weiss et al., 2002). 
 
Collagen receptors in platelets. Collagen acts on the GPVI which triggers the activation 
of PLCγ. Collagen and the Collagen Related Peptide (CRP) stimulation can produce 
changes in the intracellular Ca2+ concentration of platelets (Roberts et al., 2004; Varga-
Szebao et al., 2008a). From the analysis of platelets deficient for GPVI is known that they 
have abolished in vitro aggregation triggered by collagen, and impaired aggregation 
induced by convulxin and by ADP; GPVI deficient platelets do not adhere in vitro to 
collagen; however, GPVI-/- mice have no defective tail bleeding times and are only 
partially protected to pulmonary thromboembolism trigger by collagen/epinephrine 
injection (Kato et al., 2003; Lockyer et al., 2006)  
 
The understanding of the signaling involved in thrombus formation and coagulation 
permitted the development of pharmacological strategies to inhibit different steps of 
platelet aggregation. Current pharmacological strategies to prevent thrombus formation 
have been focused on the use of anticoagulants such as heparin and the following three 
classes of inhibitors of platelet aggregation: 1) Acetyl Salicylic Acid (ASA) or aspirin, which 
inhibits irreversibly the thromboxane production by blocking the Cox-1 enzyme; 2) 
Thienopyridines, such as Clopidogrel or Ticlopidine, that irreversible inhibit the ADP 
receptor P2Y12 then reducing the amplification of the aggregation response by released 
ADP; and 3) GPIIb-IIIa or integrin αIIbβ3 antagonists (integrilin, abciximab and tirofiban) 
that bind to the integrin on unstimulated platelets and on platelets after stimulation, but are 
administrated only in acute coronary syndromes or after coronary artery interventions 
(Phillips et al., 2005; Mackman, 2008). Despite the positive outcome reached with the 
actual pharmacological strategies to regulate platelet function and in the prevention of 
arterial thrombosis, there are restrictions like limited efficacy and safety. Therefore, it is 
necessary to consider additional strategies to find new drug targets which can be 
identified by the analysis of mice with targeted disruption of proteins expressed in platelets 
(Jackson and Schoenwaedler, 2003; Nieswandt et al., 2005).   
 
Calcium signaling involved in platelet activation. One important aspect of platelet 
activation is the calcium entry that is triggered by the above mentioned agonists ADP, 
TxA2, thrombin and also collagen. Elevation of the intracellular Ca2+ concentration is 
required for platelet activation and it is increased by depletion of intracellular Ca2+ stores 
and Ca2+ influx from the extracellular medium; furthermore, calcium signals between 
adherent platelets through platelet-platelet contacts serve to propagate the signaling 
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through the developing thrombus (Nesbitt et al., 2003). Most platelet agonists are able to 
release stored Ca2+ from the dense tubular system, and as in other cells the activation of 
PLC isoforms and generation of IP3 which activates IP3 receptors leads to the 
subsequent release of Ca2+ from intracellular stores. This mechanism is reasonably well 
understood, but much less is known about the generation of Ca2+ influx in platelets (Rink 
and Sage, 1990; Sage 1997). Calcium influx in non-excitable cells mainly is regulated by 
depletion of intracellular Ca2+ stores and subsequent Ca2+ entry (SOCE); this mechanism 
has been also described in platelets (Rosado and Sage, 2002; Rosado et al., 2004), but 
beyond SOCE other calcium entry mechanisms independent of Ca2+-store depletion, like 
Receptor Operated Calcium Entry or ROCE, are present in platelets (Rosado and Sage, 
2000a) and are regulated differently by distinct PKC isoforms (Gilio et al., 2010a; Harper 
and Poole, 2010).  
 
STIM1 and Orai1. Recently, it has been postulated that two new proteins, the Stromal 
Interaction Molecule 1 (STIM1) and Orai1 (CRACM1), are essential components of the 
SOCE in non-excitable cells, especially in cells from the immune system like lymphocytes. 
STIM1 senses the Ca2+ content of intracellular stores through the presence of an EF-hand 
domain that binds Ca2+ and it is projected into the lumen of the store. After store depletion, 
Ca2+ is released from the EF-hand domain, and STIM1 moves to the plasma membrane to 
activate the plasma membrane SOCE channel, Orai1. Orai1 belongs to a family of 
channel proteins that have four putative transmembrane domains and contain the pore 
forming subunits of SOCE channels in some cell types (see for review Cahalan et al., 
2007; Parekh, 2010). In platelets both STIM1 and Orai1 are expressed.  
 
Role of STIM1 in platelets. Platelets from mice expressing an activating EF hand motif of 
STIM1 have increased intracellular Ca2+ levels that end up in a pre-active state of platelets 
resulting in defective collagen responses; in addition, STIM1 mutant heterozygous mice 
(Stim1Sax/+) have reduced platelet counts, prolonged bleeding times and defective 
thrombus formation (Grosse et al., 2007). STIM1 deficient platelets have defective SOCE 
triggered by Thapsigargin (TG), reduced agonist-induced Ca2+ entry and diminished in 
vitro aggregation induced by collagen, but not by ADP or thrombin. Wild type mice 
transplanted with bone marrow cells from STIM1-/- mice were protected from arterial 
thrombosis without presenting higher bleeding times (Varga-Szabo et al., 2008a).  
 
Role of Orai1 in platelets. Mouse platelets deficient in Orai1 have reduced SOCE 
induced by TG treatment. These platelets have also defects in agonist-induced Ca2+ entry. 
In Orai-/- platelet activation, granule release and in vitro aggregation induced by 
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stimulation of the GPVI pathway with collagen or a CRP were impaired; however, after 
ADP or thrombin stimulation these parameters were normal in Orai-/- platelets. Mice 
transplanted with bone marrow cells from Orai1-/- mice presented reduced cerebral 
ischemia and no differences in tail bleeding times (Braun et al., 2009). In humans a 
mutation of Orai1 (Orai1R91W) proteins is present in patients with severe combined 
immunodeficiency (SCDI) and it abrogates SOCE and CRAC channel currents in T cells. 
Using mice transplanted with fetal liver cells from a mouse model expressing a mutated 
inactive form of Orai1 (Orai1R93W) equivalent to the one presented in humans, it was 
shown that Orai1R93W/R93W platelets have reduced SOCE after TG stimulation and reduced 
calcium entry after stimulation of PAR4 or GPVI receptors, but the aggregation responses 
in vitro induced by collagen, ADP or PAR4 activating peptide were similar to control 
platelets (Bergmeier et al., 2009).  
 
Stim1 and Orai1 are not the only components SOCE in platelets. Further analysis of 
platelets deficient for STIM1 or Orai1 supported the evidence of impaired GPVI-dependent 
Ca2+ signaling and phosphatidylserine exposure, but only in the absence of thrombin as 
co-stimulatory factor. In addition, SKF96365 which blocks cation channels and TRPC-
mediated cation entry among other channels (Singh et al., 2010) was able to inhibit Ca2+ 
and procoagulant responses in STIM1 or Orai1 deficient platelets, pointing for a second 
Ca2+ entry involved in these pathways, and not related with STIM2 because platelets 
deficient for this protein have unaffected GPVI-dependent Ca2+ signaling and thrombus 
formation (Gilio et al., 2010b). Therefore, Orai1-mediated Ca2+ entry is particularly 
important for GPVI-ITAM–mediated platelet activation by collagen, but not for agonists 
acting on G-protein coupled receptors, such as thrombin or ADP. Platelet activation 
through GPCRs would require and additional Ca2+ entry than Orai1 which could be formed 
by TRPC proteins (Authi, 2009). Indeed, it has been shown in HEK-293 cells that STIM1 
can gates TRPC1 or TRPC3 channels (Huang et al., 2006; Zeng et al., 2008); and, in 
human platelets has been proposed that STIM1 and Orai1 interacts with different TRPC 
channels (C1, C3 or C6) to modulate SOCE and non-SOCE triggered by thrombin or ADP 
stimulation (López et al., 2006; Jardín et al., 2008a; Jardín et al., 2009; Galán et al., 
2009). 
 
 
3.3.2 TRPC channels and platelet’s function  
 
Expression of TRPC channels in platelets. Almost all TRPC channels have been found 
to be expressed in human and mouse platelets (Table i4), and also in their precursor cells, 
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megakaryocytes (Table i5). It has been proposed that in human platelets different TRPC1 
proteins can interact (Brownlow and Sage, 2005). But the expression and function of 
TRPCs in platelets is still a controversial topic, especially due to the specificity of the 
antibodies used and lack of proper controls (Sage et al., 2002; Authi et al., 2002 Varga-
Szabo et al., 2008b). Expression of TRPC in megakaryocytes is mentioned in addition 
because primary megakaryocytes are regarded as a bona fide surrogate for studies of 
platelet signalling, including patch clamp recordings of ionic conductances (Carter et 
al.,2006). 
 
Proposed roles for TRPC channels in human platelets. Until now, the function of 
TRPC channels in platelets has been principally investigated in human platelets and only 
little is known about their role in murine platelets (Authi, 2007; Dietrich et al., 2010). Much 
less is known about the individual contribution of TRPC proteins for Ca2+ entry in platelets 
due to the lack of specific agonists or antagonists for these proteins. One of the firsts 
reports only linked the expression of TRPC channels (C1, C4 and C6) in human platelets 
with the SOCE evoked by thapsigargin or by thrombin in these cells (den Dekker et al., 
2001).  
 
TRPC1. Studies carried out on human platelets and TRPC1 proteins proposed it as an 
important part of the Ca2+ entry by SOCE, since it was shown, first, that both the SOCE in 
human platelets and the coupling between IP3R type II with TRPC1 proteins were 
inhibited by blockage of IP3Rs (Rosado and Sage, 2000b; Rosado and Sage, 2001). 
Second, the calcium entry in human platelets to refill the stores after thapsigargin or 
thrombin treatment was blocked by pre-incubation of platelets with an antibody against an 
extracellular epitope of the hTRPC1 channel (Rosado et al., 2002; Harper and Sage, 
2007). It remains to be shown whether this antibody selectively blocks hTRPC1 channels.  
 
TRPC4. TRPC4 expression in human platelets has been reported and it was postulated to 
be the part of the pH-dependent SOC entry of human platelets and megakaryocytes, 
because the SOCE observed in platelets after raising the cytoplasmic pH was blocked by 
the unspecific channel blocker SKF96635 (Wakabayashi et al., 2006). 
 
TRPC6. TRPC6 channels are also expressed in human platelets and it was proposed that 
TRPC6 is a SOCE-independent and nonselective cation entry channel stimulated by 
thrombin and OAG. (Hassock et al., 2002). Another group suggested that TRPC6 
channels are important for both SOCE and store independent calcium entry in human 
platelets, based on the observation that an antibody against hTRPC6 reduced Ca2+ and 
Mn2+ entry (Jardín et al., 2008b). However, the specificity of these antibodies has not been 
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demonstrated so far. TRPC6 proteins were also linked to the increased OAG-induced 
Ca2+ entry in platelets triggered by very high glucose concentrations (Liu et al., 2008). 
 
Table i4. TRPC expression in mammalian platelets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRPC Western blot RT-PCR References
Rosado and Sage. 2000 (Human)
Den Dekker et al. 2001 (Human)
Hassock et al. 2002 (Human)
Brownlow and Sage. 2005 (Human)
Wakabayashi et al. 2006 (Human)
Varga-Szabo et al. 2008 (Mouse WT vs. TRPC1-/- mice)
Liu et al. 2008 (Human, immunofluorescence assays)
Tolhurst et al. 2008 (Human)
TRPC2 not defined not defined
Brownlow and Sage. 2005 (Human)
Wakabayashi et al. 2006 (Human)
Liu et al. 2008 (Human, immunofluorescence assays)
Den Dekker et al. 2001 (Human)
Brownlow and Sage. 2005 (Human)
Wakabayashi et al. 2006 (Human)
Liu et al. 2008 (Human, immunofluorescence assays)
Brownlow and Sage. 2005 (Human)
Liu et al. 2008 (Human, immunofluorescence assays)
Den Dekker et al. 2001 (Human)
Hassock et al. 2002 (Human)
Brownlow and Sage. 2005 (Human)
Wakabayashi et al. 2006 (Human)
Varga-Szabo et al. 2008 (Mouse WT vs. TRPC1-/- mice)
Liu et al. 2008 (Human, immunofluorescence assays)
TRPC7 not defined not defined
TRPC6 X X
TRPC4 X X
TRPC5 X X
TRPC1 X X
TRPC3 X X
Expression of TRPC transcripts (RT-PCR) and/or proteins (Western blot analysis) was described in 
this selection of reports in platelets. Only Varga-Szabo et al. (2008) compared expression between 
protein fractions of platelets preparations from wild type and TRPC-deficient mice (WT vs. KO). 
 
 
Table i5. TRPC expression in mammalian megakaryocytes 
 
 
 
 
 
 
 
 
 
 
 
TRPC Western blot RT-PCR References
Berg et al. 1997 (Human)
Den Dekker et al. 2001 (Human)
Carter et al. 2006 (Mouse)
Wakabayashi et al. 2006 (Human)
Tolhurst et al. 2008 (Mouse)
TRPC2 not defined X Berg et al. 1997 (Human)
Berg et al. 1997 (Human)
Den Dekker et al. 2001 (Human)
Wakabayashi et al. 2006 (Human)
Den Dekker et al. 2001 (Human)
Wakabayashi et al. 2006 (Human)
TRPC5 not defined not defined
Den Dekker et al. 2001 (Human)
Carter et al. 2006 (Mouse)
Tolhurst et al. 2008 (Mouse)
TRPC7 not defined not defined
TRPC6 not defined X
TRPC3 X X
TRPC4 X X
TRPC1 X X
Expression of TRPC transcripts (RT-PCR) and/or proteins (Western blot analysis) was described in 
this selection of reports in megakaryocytes. In any of these reports the use of TRPC-deficient mice 
was reported as control of antibody specificity. 
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Additionally, some of these observations about TRPC1 function in human platelets could 
not be repeated by others (Authi, 2007; Varga-Szabo et al., 2008b).  
 
TRPs in murine platelets. In murine cells, a first link between TRP channels and platelet 
function came from experiments that showed an ADP-induced cation channel in mouse 
megakaryocytes permeable for Na+ and Ca2+. In these cells the Ca2+ conductance was 
increased by treatment with Phenylarsine oxide, a compound that is supposed to 
potentiate TRPC channels (Tolhurst et al., 2005). Using murine megakaryocyte the same 
group detected the expression of TRPC1 and TRPC6 as well as other TRP channels 
(TRPM1, TRPM2 and TRPM7) and described that these ADP-evoked currents displayed 
a current-voltage relationship similar to currents displayed by cells overexpressing TRPC6 
proteins. In the same report roles for TRPM2 and TRPM7 in ADP-ribose-activated 
currents and Mg2+-dependet currents were postulated, respectively (Carter et al., 2006).  
 
TRPC1-/- mice and platelet function. Varga-Szabo and collaborators used platelets from 
wild type, TRPC1-/- or TRPC6-/- mice to demonstrate the expression of TRPC1 and 
TRPC6 proteins in these cells. However, Ca2+ entry after store depletion by thapsigargin 
and agonist-evoked Ca2+ entry by thrombin and CRP stimulation were not impaired in 
platelets from TRPC1-/- mice. Platelet aggregation and αIIbβ3 activation and degranulation 
induced by different agonists like ADP, CRP, thrombin, and U46619 were comparable 
between TRPC1-/- platelets and WT platelets. Also TRPC1 deficient platelets formed 
stable thrombi on collagen surfaces and TRPC1-/- mice presented no differences in 
bleeding time or thrombosis after injury of mesenteric arterioles. In addition, TRPC1 
deficiency did not rescue the platelet phenotype presented by the STIM1 mutant 
(Stim1Sax/+) when both mice were crossed since it was expected that the basal increased 
intracellular Ca2+ concentrations in STIM1 mutant platelets would be compensated by the 
absence of TRPC1 channels (Varga-Szabo et al., 2008b). Moreover, it has been shown in 
TRPC-deficient mice that the deletion of one TRPC protein can be compensated by 
upregulation of other TRPC (Dietrich et al., 2005) or by redundant protein functions, fact 
that can obscure the analysis of single TRPC deficient mice and the interpretation of the 
related observations. 
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4. Materials and methods 
 
More detailed informations about materials, reagents (catalog number and company) and 
solutions are listed in Appendices A and B.  
 
4.1 Mice 
 
All animal experiments mentioned here were reviewed and approved in accordance with 
the Saarland University Ethic Regulations and the animal welfare committees of 
Saarland’s State. The experiments in this work were made using mouse lines lacking 
TRPC1, TRPC3, TRPC4, TRPC5, TRPC6 proteins and corresponding wild type (WT) 
control mice. In addition to the single knockout mice, TRPC compound knockout mice 
derived thereof, such as TRPC1/TRPC4 (-/-)2, TRPC1/TRPC6 (-/-)2, TRPC4/TRPC6 (-/-)2, 
TRPC3/TRPC6 (-/-)2, TRPC1/TRPC4/TRPC6 (-/-)3 and TRPC1/TRPC3/TRPC6 (-/-)3 were 
used. The generation of TRPC1-/-, TRPC3-/-, TRPC4-/- and TRPC6-/- mice were 
previously described (Dietrich et al., 2007b; Hartmann et al., 2008; Freichel et al., 2001; 
Dietrich et al., 2005). TRPC5 deficient mice were generated in our Institute (Freichel, 
Stolz, Weißgerber, unpublished). Mice were bred and kept in a specific pathogen free 
(SPF) facility. They were maintained in a 12 hour light-dark cycle, and water and standard 
food (V1534-3, ssniff Spezialdiäten GmbH, Germany) were available to consume ad 
libitum. 
 
All cardiac hypertrophy experiments were carried out with male mice within an age of 2.5 
to 6 months. For platelet experiments mice from both genders were used (2 to 6 months 
old). Most TRPC-deficient mouse lines had a mixed 129SvJ/C57Bl6/N genetic 
background, for these mice the wild control mice of the F1 generation from 129SvJ and 
C57Bl6/N intercrosses were used. C57Bl6/N mice were used as controls when the 
experiments were done with TRPC6 deficient mice that were back crossed for at least 6 
generations to the C57Bl6/N background. In some experiments I used litter-matched 
controls where platelets from TRPC5+/Y and TRPC5-/Y were compared. The study groups 
were carefully matched in terms of age, gender and specially, in terms of weight in case of 
cardiac hypertrophy experiments (see 4.2.1) because of the effect of some treatments on 
mouse weight. The breeding strategy for TRPC1/TRPC4 (-/-)2 mice was directed to obtain 
the F1 offspring of the intercrossing between female mice from lines with a 129SvJ 
background (backcrossed at least for six generations) with male mice from lines with a 
C57BL6/N background (backcrossed at least for six generations). Only the F1 generation 
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of mice from these breedings were used for the experiments and compared with wild type 
controls from the F1 generation from 129SvJ and C57Bl6/N intercrosses.  
 
To identify the genotype from each mouse, a biopsy from the tip of the tail at the end of 
each experiment was taken. Briefly, each tail was digested with 100µl from the tail-Lysis 
buffer over night at 56°C, afterwards the Proteinase K inactivation was done by 95°C 
incubation for 20 minutes and finally 2µl from the sample was used in a 50µl PCR 
reaction. The PCR reactions were performed in two different thermocyclers, GeneAmp® 
PCR System 9700 (Applied Biosystems) and MyCyclerTM (Bio-Rad). The products were 
run in 2% agarose gels stained with Ethidium Bromide (13µl from a 1% stock solution in a 
300ml gel). To visualize the products and digitalize pictures from the PCR results a gel 
imaging system (GelDocTM, BioRad) was used. The utilized primers and PCR conditions 
for genotyping are summarized in Table m1.   
 
 
4.2 Neurohumoral cardiac hypertrophy induction and analysis 
 
4.2.1 Micro-osmotic pump implantation and cardiac hypertrophy evaluation  
 
As model to induce cardiac hypertrophy the chronic treatment either with isoproterenol or 
angiotensin II was chosen. To avoid the stress and possible errors from repetitive injection 
of such agents, and to ensure a constant delivery of the hypertrophy inducing agents, the 
substances were infused via Alzet micro-osmotic pumps (DURECT Corporation, USA). 
The osmotic pumps models 1003D, 1007D and 1002 were used for 3, 7 and 14 days of 
infusion, respectively.  
 
The main isoproterenol-induced hypertrophy model consisted on a treatment during 7 
days with a dose of 30mg/kg/day referred here as Iso-30 (Keys et al., 2002; Maass et al., 
2004; Jaffré et al., 2009). Also doses of 60mg/kg/day (Iso-60) or 8.7mg/kg/day over 7 
days (Song et al., 2006) in two initial series of experiments were applied. In case of 
angiotensin II treatment the main protocol was the infusion of a dose of 3mg/kg/day over 
14 days (ATII-3) (Song et al., 2006), which showed increased blood pressure after seven 
days of treatment according to Gavazzi and coworkers (2006). In some experiments I 
used a subpressor dose of angiotensin II (0.3mg/kg/day during 14 days) referred here as 
ATII-0.3. This dose is considered to induce hypertrophy without significant elevation of 
blood pressure (Grieve et al., 2006). 
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Table m1 (A). Primer sequences and PCR conditions used for genotyping TRPC deficient 
mice. 
Gene/TRP PCR  condition
Expected 
product size 
(bp)
TRPC1-WT C1_01 GAG ACT GTT GTC ACA AGA TGC 1 549
C1_03 TCA GTT AAT GTC CCA TTC CGG C
TRPC1-KO C1_02 ACT TTG AGG GCA AAG GTT GCC 1 617
C1_04 AGA GGC CAC TTG TGT AGC GC
TRPC3-WT C3LoxF GCT ATG ATT AAT AGC TCA TAC CAA GAG ATC 2 300
C3LoxR  GGT GGA GGT AAC ACA CAG CTA AGC C
TRPC3-KO C3LoxF2 GAA TCC ACC TGC TTA CAA CCA TGT G 2 329
C3LoxR  GGT GGA GGT AAC ACA CAG CTA AGC C
TRPC4-WT KO-15 ACA GTG CTC TGA ACC CAC GG 1 293
KO-40 CTC GCA CCG GAT GCC TTT GC
TRPC4-KO KO-15 ACA GTG CTC TGA ACC CAC GG 1 375
NeoPa GCC TGC TCT TTA CTG AAG GCT CT
TRPC5-WT C5_08 CTA GCC TAG ACA TAC AAC ACA G 1 203
C5_09 GAC AGC TGA GCT CCC TAT TG 
TRPC5-KO C5_09 GAC AGC TGA GCT CCC TAT TG 1 244
C5_10 CAA GGC CAT CAA TTA CCA GAC
TRPC6-WT TRP6_03 CAG ATC ATC TCT GAA GGT CTT TAT GC 1 245
TRP6_04  TGT GAA TGC TTC ATT CTG TTT TGC GCC
TRPC6-KO TRP6_01 ACG AGA CTA GTG AGA CGT GCT ACT TCC 1 300
TRP6_02 GGG TTT AAT GTC TGT ATC ACT AAA GCC TCC
Primers (5'-3')
 
 
 
Table m1 (B). Primer sequences and PCR conditions used for genotyping TRPC deficient 
mice. 
Temperature Time Cycles Temperature Time Cycles
94°C 1.5min 1X 94°C 1.5min 1X
94°C 30s 94°C 30s
65°C (-0.5°C per cycle) 30s 67°C (-0.5°C per cycle) 30s
72°C 30s 72°C 30s
94°C 30s 94°C 30s
60°C 30s 62°C 30s
72°C 30s 72°C 30s
72°C 5min 1X 72°C 5min 1X
4°C hold 4°C hold
 Genotyping PCR condition 2
10X
22X
 Genotyping PCR condition 1
10X
26X
 
(A) Primers utilized to determine the mouse genotype (Wildtype: WT or Knockout: KO) with the 
corresponding sequences and expected size for each pair. (B) Conditions of the PCR reactions 
used for TRPC mouse genotyping. 
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Before each series of pump implantation the weight of the mice was monitored around the 
week 8 of age to have a closely matched group. It was defined to have mice with a 
minimum weight of 26g and maximum of 30g because I found that this reduces the 
variation in the HW/BW index. When the mice reached the right weight range they were 
placed in single clean cages and they were weighed the day before the micro-osmotic 
pump insertion. Each series of experiments consisted of about 14 to 20 mice, half of the 
group were WT mice and half KO mice. In each experimental round 2-4 mice were used 
as control mice treated with saline solution (NaCl 0.9%) to asses whether a significant 
hypertrophic response was achieved by the neurohumoral stimulus. In some cases, when 
it was possible, three groups of mice were used per series (one WT and two KO groups) 
to reduce the number of mice used in the experiments. 
 
The day before implantation the osmotic pumps were loaded, either with treatment 
solutions using saline solution as vehicle or only with saline. The filling of the pumps was 
done following the manufacturer instructions under aseptic conditions. Prior to filling the 
pumps the next steps were done: first, calculation of the amount of angiotensin II or 
Isoproterenol depending on the dose and the weight from each mouse (see formula 1).  
 
[Cf] = (BW x D)/Q  (1) 
Cf refers to final concentration in the pump, BW is the body weight of the mouse in 
grams, D represents the dose (µg/g/h), and Q refers to the volume delivery rate of 
the pump (µl/h) given by the manufacturer for each pump lot.  
 
The Isoproterenol stock solution (100mg/ml) was kept in 2ml aliquots below -20°C and 
only freshly thawed aliquots were used once; angiotensin II was always ordered some 
days before the experiments, kept under -20°C and solved just before preparing the 
pumps. Second, each pump with its corresponding flow moderator was individually 
transferred into a sterile 2ml reaction tube; afterwards the weight from each pump plus 
moderator was obtained. Third, the pumps were filled carefully starting with those 
containing only saline solution. Afterwards each pump was weighed again and the 
difference between empty and full pump served to verify the complete filling of the pumps.  
Finally, sterile saline was added (~1.5ml) to each reaction tube and the pumps were 
incubated over night at 37°C in saline solution in order to assure the immediate delivery of 
the solution after implantation.  
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The implantation of the micro-osmotic pumps was done under Isoflurane* anesthesia. The 
isofluran was vaporized with a mixture of O2/N2O (1:2) using a vaporizer (Vapor 19.3, 
Abbot) at a concentration between 1.5 to 2%. The induction of the anesthesia was done in 
an Isoflurane 2.5% pre-saturated Plexiglas chamber. After the induction phase the mice 
were transferred on a temperature controlled plate to keep them warm at 37°C during the 
operation. The warming plate was adapted to connect a mask delivering the Isoflurane 
during the procedure where the nose and mouth from the mouse was placed. Before 
starting the experiment it was verified that there were not detectable reflex from the paw 
sole and the tip of the tail. One drop of Bepanthen cream (Bayer) was applied gently on 
each eye to protect them during surgery.   
 
For the pump insertion the hair from an area of about 1.5x1cm from the lower part of the 
nape was removed, first using a hair clipper (ER240, Panasonic) and then with a peeling 
cream (elca®med, ASID-BONZ, Germany). This area was cleaned afterwards with EtOH 
70% and sterile saline solution. Next, a ~8mm transversal incision on the peeled nape 
was made and from this a subcutaneous pocket (~2.5-3cm) on the right flank of the 
mouse was made using blunted scissors (14018-14, F.S.T.). Subsequently, 0.5ml of pre-
warmed sterile saline solution (~37°C)  was injected inside the pocked using a 1ml syringe 
and the pump was inserted with the cap facing the inside of the pocket. Before suturing, it 
was verified that the pump had enough space to accommodate once the mouse would be 
awake and also it was checked that the skin was not tied around the implantation area. 
Finally, the incision was stitched up with 3 to 4 independent stitches using a polyester 5-0 
RB-1-plus suture (Mersilene, Johnson & Johnson), each suture was secured with one 
drop of tissue adhesive (Vetbond, 3M) and the wound was cleaned with antiseptic iodine 
solution (Braunol®, Braun).  
 
The mice were weighed after pump implantation and placed back into the cage. In 
addition, two tissue papers were placed inside the cage. The mice were monitored during 
the recovery from the anesthesia and two hours thereafter to check that they removed the 
eye cream, if not, the cream was carefully removed with a cotton swab rinsed with sterile 
saline. Every day the mice were checked, twice a day for the first 2 days. The recovery 
was monitored qualitatively by inspection and assessment of typical mouse behavior, 
including nest building and brightness of the hair; this first aspect seems to be a good 
                                                 
* Isoflurane was selected as anesthetic because it has reduced cardiovascular effects in 
comparison with other anesthetics (Janssen et al. 2004). For example, from personal observations 
the heart rate under Isoflurane from 19 WT mice was 477±51 BPM compared with 292 ±117 BPM 
from 8 mice under Ketamine/xylazine anesthesia. Also, Isoflurane narcosis can be regulated faster 
and there is a rapid recovery after removal of the mice from the isofluran delivering mask in 
comparison with injected anesthetics.   
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indicator because all saline treated mice start to build a nest at the same day of 
implantation; for the Isoproterenol or angiotensin II treated mice the process took between 
24 to 48h.  
 
In some cases, one day before the end of the hypertrophy induction ECG recordings 
under Isoflurane anesthesia were done (see below for details). In addition, that day all the 
sampling tubes, materials, solutions and data collection tables were prepared. At the end 
of the treatment, depending if the pump model was for 3, 7 or 14 days, the procedure was 
the following: the mice were weighed and the weight from the pump obtained before 
implantation was subtracted. The mouse organs were removed, as described by others 
(Patterson et al. 2004) under terminal Avertin (2,2,2-tribromoethanol, Fluka) anesthesia 
that was given intraperitoneally (i.p. 25µl/g) using a 26G1/2” needle (MicrolanceTM, BD). 
After checking the absence of reflexes, a midline abdominal incision was performed 
followed by a clam-shell bilateral thoracotomy, then both abdominal and thoracic cavities 
were exposed and the renal artery was punctured in order to reduce the blood flow going 
into the heart. To arrest the heart ~1ml ice cold saline solution was injected slowly into the 
left ventricle using a 27G3/4” needle (MicrolanceTM, BD) inserted into the apex of the 
ventricle. The heart was quickly excised and placed into ice cold saline solution, where the 
excess of fat tissue and surrounding vessels was removed. Immediately, lungs, liver and 
spleen were dissected from the mouse and placed into a Petri dish. Before weighing the 
organs the excess of blood was gently removed by placing the organs into a paper tissue 
and then each organ was weighed (wet weight).  After getting the wet weight, each heart 
was divided as following: the atria were put into one 1.8ml vial (CryoTubeTM vial, nunc) 
and transferred into liquid nitrogen. The ventricles were cut transversally into two halves, 
the distal half was also placed into one 1.8ml vial and was snap frozen in liquid nitrogen, 
the other ventricular half was transferred into a 2ml reaction tube containing 
Paraformaldehyde (PFA) 4% (pH 7.4) to fix the tissue over 2 days at 4°C. The frozen 
samples have been kept at -80°C until their analysis. The heart was processed in this way 
with the purpose of performing further analysis like western blot and histological analysis 
of cardiac hypertrophy parameters, such as cardiomyocyte cross sectional area and 
percentage in interstitial fibrosis.   
 
Lungs, liver and spleen were dried at 70°C over 48h to obtain at the end the dry weight. 
The water content from lungs, liver and spleen was obtained from the difference between 
wet and dry weights from each organ. The tibia was removed and carefully cleaned from 
skin and muscle to get the tibia length. From each mouse the tip of the tail (~3mm) was 
collected in order to verify the genotype. The wet weight from each organ was normalized 
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to both body weight and tibia length to perform the analysis of the following ratios: heart 
weight (mg)/ body weight (g) (HW/BW), heart weight/ tibia length (mm) (HW/TL), lung 
weight (mg)/ body weight (LW/BW), lung weight/ tibia length (LW/TL), liver weight (mg)/ 
body weight (LivW/BW), liver weight/ tibia length (LivW/TL), spleen weight (mg)/ body 
weight (SplW/BW), spleen weight/ tibia length (SplW/TL). 
 
 
4.2.2 Heart histology: Quantification of cardiomyocyte cross sectional area and 
heart fibrosis. 
 
The heart samples were fixed in PFA 4% as mentioned. After two days (48h) of  fixation at 
4°C the samples were transferred into universal embedding cassettes (07-8100 
BioCassettes, BioOptica). The samples were rinsed with freshly prepared PFA, 
dehydrated through increasing Ethanol-Xylene steps in an automatic embedding system 
(Tissue-TEK® VIP, Miles Scientific) and finally placed into steel tiles for inclusion of 
paraffin samples (07-BM24245, BioOptica) using as tissue embedding medium Paraplast 
regular kept at 60°C. The program used for dehydration and embedding was: 
 
1. Ethanol 70% 1h/40°C  
2. Ethanol 80% 1h/40°C  
3. Ethanol 90% 1h/40°C 
4. Ethanol 96% 1h/40°C  
5. Ethanol 96% 1h/40°C  
6. Ethanol 100% 1h/40°C  2X 
7. Xylene 96% 1h/40°C  2X 
8. Paraplast  1h/60°C  4X 
 
The paraffin tissue blocks were prepared manually to ensure the correct placing of the 
heart to get transversal sections from the middle region of the ventricles. This procedure 
was made by placing the cut edge of the heart facing down in stainless steel embedding 
molds (15x15x5mm, 07BM15155, BioOptica) and adding liquefied Paraplast from a 
Paraffin dispenser (EG1120, Leica). During this procedure the molds were kept on a warm 
plate (60°) and to assure that the Paraplast was liquefied the tank temperature was preset 
at 60°C 24h in advance. The bases of the embedding cassette, facing up, were placed on 
top of the molds and, finally, after some minutes when the paraffin was not completely 
liquid, the molds were transferred into a cuvette with ice to complete the Paraplast 
polymerization. 
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When the blocks were polymerized 5µm sections were cut with a 2040 AutoCut 
microtome (Reichert-Jung). Consecutive tissue sections were mounted on glass slides 
(regular pre-cleaned microscope slides, R. Langenbrinck) and fixed to the slide by 
incubation at 90°C during 30 minutes. From each heart at least 10 sections were obtained 
to get enough material for staining either with Hematoxylin-Eosin (H-E) or picrosirius red. 
 
The Hematoxylin-Eosin protocol for the deparaffinization, rehydration, staining, and 
dehydration was:  
 
1. Xylene  3min  2X 
2. Ethanol 99% 3min  2X 
3. Ethanol 96% 3min  2X 
4. Ethanol 70% 3min  2X 
5. Rinse in distilled water 
6. Staining in Mayer Hemalaum solution for ~5 minutes 
7. Clear with run tap water for 10 minutes 
8. Stain in Eosin Y-solution between 5-10 minutes 
9. Rinse in distilled water 
10. Rinse 2X in 70% EtOH, 2X 96% EtOH and 1X 99%EtOH. 
11. Ethanol 99% 3min  2X 
12. Xylene  3min  2X 
13. Mount and cover the samples with cover slips using either DePex or Eukitt resins. Let 
the samples dry over night.  
 
For the picrosirius red staining the following deparaffinization, rehydration, staining and 
dehydration steps were done:  
 
1. Xylene  3min  2X 
2. Ethanol 99% 2min  2X 
3. Ethanol 96% 2min  2X 
4. Ethanol 70% 2min  2X 
5. Distilled water 5min 
6. Distilled water 10min 
7. Staining in Picrosirius red solution for 60 minutes 
8. Rinse briefly two times in 0.5% acetic acid 
9. Ethanol 96% 2min  1X 
10. Ethanol 99% 2min  1X 
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11. Xylene  3min  2X 
12. Mount and cover the samples with cover slips using either DePex or Eukitt resins. Let 
the samples dry over night.  
 
Quantification of cardiomyocyte cross sectional area. After staining the heart 
samples, three to five H-E stained sections per mouse were analyzed through the left 
ventricle free wall. The mean cross-sectional area per mouse was obtained by measuring 
~100 transversally cut cardiomyocytes with a centrally located nucleus; these criteria of 
morphometrical analysis have been already used by others (Kilié et al., 2007). The 
images were obtained using an inverted microscope (Axiovert 40 CFL, Zeiss) coupled to a 
digital color camera (MRc5, Zeiss) and with a 40X immersion oil objective (Fluar40X, 
Zeiss). The images were digitalized and analyzed with the AxioVision software (versions 
4.5 to 4.8, Zeiss) using the measuring tools to obtain the cardiomyocyte cross sectional 
area. The absolute mean values and the relative increase in comparison with the 
corresponding control were compared and analyzed.  
 
Quantification of cardiac fibrosis. To determine the interstitial collagen fraction, 
picrosirius red stained transversal sections from the left ventricle were analyzed. Ten 
pictures per heart were made through the entire left ventricular region in order to have a 
representative mean value from the complete ventricle. To take the photos from each 
series, light intensity, contrast and acquisition parameters were not changed once they 
were standardized. The pictures were obtained using an inverted microscope (Axio 
Observer A.1, Zeiss) with an Axio Imager condenser (0.8/1.4, Zeiss) and coupled to a 
digital color camera (MRc5, Zeiss). A 10X objective (ACHROPLAN, Zeiss) was used to 
cover the left ventricle in 10 images. The pictures were digitalized and analyzed with the 
segmentation tool from the AutoMeasure module (AxioVision software 4.8.1, Zeiss). The 
principle of the segmentation allowed separating each picture into three different layers, 
the first including all the pixels from the picture, the second containing only the pixels that 
corresponded to the background or region without tissue and the third one with the red 
pixels that matched to the Sirius red stained collagen fibers. At this point the program 
permitted to exclude manually the perivascular areas from the analysis. The total number 
of background pixels was subtracted from the total number of pixels in the picture and this 
value represented the complete analyzed ventricular area. Then, the collagen fraction per 
specimen was obtained by calculating the ratio, in percentage, corresponding to 
picrosirius red stained tissue in relation to the total cardiac tissue from the corresponding 
section. At the end from each heart the area of fibrosis in percentage was obtained. The 
mean values of Sirius red stained tissue and the relative increase compared with the 
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corresponding saline controls were compared and analyzed. During the complete 
sampling and analysis procedure the operator was blind to the genotype and treatment of 
each specimen. 
 
 
4.2.3 Telemetric blood pressure recording during isoproterenol or angiotensin II 
treatment 
 
To evaluate the effect of chronic treatment of Isoproterenol or angiotensin II on blood 
pressure we implanted telemetric blood pressure transmitters in mice. After one week of 
recovery from the transmitter implantation surgery blood pressure was recorded 
continuously during one week to obtain base line levels. Afterwards, osmotic pumps were 
implanted and blood pressure recorded during the treatment. The blood pressure 
transmitter implantation and blood pressure measurements were made by Ilka Mathar 
from our laboratory as described (Mathar et al., 2010). Shortly, a radio telemetry system 
(PA-C10, Data Science International) was used to monitor blood pressure in conscious, 
unrestrained mice. The pressure sensing catheter was inserted under Isoflurane 
anesthesia into the left carotid artery and the transducer unit was implanted into a 
subcutaneous pouch along the right flank.  After the recovery period we collected, stored 
and analyzed arterial pressure recordings with the Dataquest A.R.T. software 3.0. We 
acquired data of basal blood pressure with a 10s scheduled sampling every 3 minutes, 
24h mean values for mean arterial blood pressure (MAP) and heart rate (HR) were 
calculated. 
 
 
4.2.4 Intraventricular pressure measurements (Millar Mikro-Tip catheter) 
 
Intraventricular pressure measurements were made under anesthesia either by Avertin 
i.p. 25µl/g or by Isofluran 1.8-2.5%. For these measurements the mice were intubated and 
air ventilated using a mechanic ventilation system (MiniVent type 845, Hugo Sachs 
Elektronik-Harvard Apparatus). The ventilation was set at 125 strokes per minute and a 
volume of 180µl. The mice were placed on their back on a warm plate at 37°C. After 
checking the absence of reflexes the skin from the left chest was removed to visualize the 
thoracic musculature. The left pectoralis major muscle was partially blunt dissected, pulled 
and fixed to the right side together with the sternalis muscle using a suture thread. 
Afterwards, the pectoralis minor was also blunt dissected until the intercostalis muscles 
were visualized. Finally a small incision through the 2nd and 3rd intercostal space was done 
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and from this incision a small window (~4x4mm) was opened by removing part of the third 
rib and intercostalis permitting the exposure of the left ventricle. During the procedure it 
was very important to reduce the vessel damage to avoid the bleeding and related 
changes in pressure that could alter the measurements. The chest cavity was entered at 
the middle of the third intercostal space to visualize the heart. The pericardium was gently 
removed from the left ventricle by pulling it to one side. The introduction of the catheter 
directly in the left ventricle was performed through a hole made on the left ventricle tip 
using a 23G 1” needle (MicrolanceTM, BD).  
 
The Intraventricular pressure was measured with a 1.4F Mikro-Tip Catheter pressure 
transducer (SPR 671, Millar Instruments). The catheter was connected to the 
corresponding control unit (TC-510, Millar Instruments) that works as a passive interface 
between the pressure sensor and the recording systems to have balance and calibration 
controls of the transducer. The control unit was then connected to an Amplifier (MIO-0501 
DC, FMI-Föhr Medical Instruments, Germany) which was calibrated in such way that 1V 
was equivalent to 100 mmHg. Finally, the amplifier was coupled to a PowerLab 8/S 
(ADInstruments). The ventricular pressure was recorded for 3 minutes using the LabChart 
software v5.5.5 (ADInstruments).  For the analysis the Blood Pressure Module (ChartPro 
v5.5.5 or LabChart v6.0) set for ventricular pressure was used. The analysis was 
performed from a selection of the recording where the signal was stable (usually some 
seconds after the insertion of the catheter until the end of the recording). In the Blood 
Pressure Module settings it was determined to include only pressure cycles higher than 
20mmHg. A mean pressure cycle (Figure m1) made from 10 cycles was obtained to 
calculate the following parameters: Maximum Pressure (mmHg), Minimum Pressure 
(mmHg), End Diastolic Pressure (mmHg), Mean Pressure (mmHg), difference between 
Maximum and Minimum Pressure (mmHg), Systolic Duration (s), Diastolic Duration (s), 
Cycle Duration (s), Heart Rate (BPM), Maximum dP/dt (mmHg/s), Minimum dP/dt 
(mmHg/s), Tau (τ) or exponential time constant of relaxation (s), Contractility Index (1/s) 
and Pressure Time Index (mmHg.s). The Contractility index is defined as the Maximum 
dP/dt divided by the pressure on the time of Maximum dP/dt. The Pressure-time index 
(Tension-time index) is the average ventricular pressure during systole multiplied by the 
systolic duration. At the end the mean value for each of the parameters mentioned before 
was obtained for every recording.  
 
Before starting, the calibration from the setup was checked connecting the pressure 
transducer to a pressure manometer and different pressures were given and compared 
with the obtained measurements. After each measurement session the catheter was 
 
Materials and methods  46 
cleaned by incubation for 15min in a 1% enzymatic solution (Terg-A-Zyme® Alconox Inc, 
USA) and finally rinsed with abundant d-diH2O. 
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Figure m1. Measurement of left intraventricular pressure from the mouse heart. Original trace 
from a measurement of the pressure inside a mouse left ventricle using a Pressure Millar Catheter. 
The mean parameters used to analyze each pressure cycle are shown. EDP: End diastolic 
pressure. 
 
 
4.2.5 Plasma angiotensinogen determination  
 
Ten wild type and nine TRPC1/TRPC4 (-/-)2 mice were used to determine the plasma 
levels of angiotensinogen. 60 to 80µl of blood were obtained via submandibular bleeding 
from conscious mice as described by Golde and collaborators (2005), using an 18G 11/2” 
needle (MicrolanceTM, BD). Blood was collected into EDTA containing sampling tubes 
(SARSTEDT ref. 41.1504.005) and centrifuged 10min at 1200G in a microcentrifuge (1-
14, sigma, Germany). The plasma was transferred into a 1.5ml reaction tube, centrifuged 
again (1200G/10min) and transferred once more into a new reaction tube. These 2 
centrifugation and transferring steps were used to have complete clear plasma.  
 
The angiotensinogen concentration was determined using a mouse total angiotensinogen 
assay kit (JP27413, IBL, Germany) and the procedure was made following the 
manufacturer instructions. The assay was a sandwich ELISA that included 2 kinds of 
antibodies, the anti-mouse AGT (135) rabbit IgG Affinity Purity placed on a 96-well 
precoated plate and the labeled antibody (HRP conjugated anti-mouse AGT (405) rabbit 
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IgG Fab’ Affinity Purify). The coloring agent (Chromogen) used was Tetra Methyl 
Benzidine and the sample measurements were done with a plate reader (infinite®-200 
TECAN, Austria) at 450nm.  
 
As recommended by the manufacturer the samples were diluted with EIA buffer (provided 
in the kit) before placing them on the 96-well plate. The plasma was diluted 1250 folds 
and to achieve these serial dilutions were performed. First 10µl plasma were added to 
90µl EIA buffer, then from this dilution 10µl were added to 90µl buffer and finally from this 
second dilution, 20µl were added to 230µl buffer. For the angiotensinogen determination 
100µl from the diluted samples were used in each well and from every sample the 
measurements were done in duplicate; also this was made with the standard and the 
reagent blank (only EIA buffer). The standard was prepared with the recombinant mouse 
angiotensinogen provided within the kit and serial dilutions were made to have the 
subsequent concentrations in ng/ml: 0, 0.16, 0.31, 0.63, 1.25, 2.5, 5 and 10, as mentioned 
in the assay manual. When the samples and the standard were ready, the general steps 
for the measurement were: 1) placing 100µl of sample per well of the precoated plate; 2) 
incubation for 1h at 37°C; 3) washing of the wells during 25s and repeated 10 times; 4) 
incubation with the labeled secondary antibody for 30min at 37°C, except the reagent 
blank wells; 5) washing as in step three but 9 times; 6) addition of 100µl from the 
Chromogen solution per well and incubation for 30min, at room temperature in the dark; 7) 
stopping the reaction with the provided 1N H2SO4 solution; 8) cleaning the bottom of the 
plate and verifying the absence of bubbles in each well; and 9) measuring at 450nm with 
the plate reader and obtaining the absorbance values. 
 
The absorbance value from the test sample blank (only EIA buffer and labeled antibody) 
was subtracted from all the obtained values and the mean value from each pair of 
measurement was obtained. The standard curve was plotted and a linear regression was 
made because the high linearity of the standard curve between 0.16 and 10ng/ml reported 
by the developers of the mouse angiotensinogen ELISA assay (Kobori et al., 2008) and 
confirmed by the determined regression. To calculate the angiotensinogen concentration 
in the samples, the absorbance value from each sample and the slope and intercept 
obtained from the linear regression were used in a linear equation where the 
concentration, in ng/ml, was defined as:  
 
[concentration] = (absorbance – intercept)/slope 
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This method was used in addition to plot the standard curve on a log-log scale using the 
Origin software and reading the concentration for unknown samples. Finally, the 
concentrations obtained were multiplied by the dilution factor to get the angiotensinogen 
concentration in the plasma from every mouse.  
 
 
4.2.6 Isolation of adult mouse cardiomyocytes and mouse cardiac fibroblast culture 
 
The initial steps of the procedure for isolation of adult mouse cardiomyocytes (CMs) and 
cardiac fibroblasts (FBs) were basically the same. The resulting protocol is an adaptation 
from the isolation protocol learned in the laboratory from Prof. Peter Lipp (Homburg, 
Germany) during one of the Spezialpraktika from the Graduate School GK1326 (“Mouse 
cardiomyocytes isolation protocol for Ca2+ imaging experiments”) in combination with 
published methods (Goshima, 1969 and 1974; Eghbali et al., 1988; Hilal-Dandan et al., 
2000; Ostrom et al., 2003; O’Connell et al., 2003; Fredj et al., 2005; Nakayama et al., 
2006; Brenner and Dolmetsch, 2007; Viero et al., 2008) and personal experience during 
the protocol establishment. In summary, the procedure consisted of heart isolation and 
cannulation, heart perfusion and tissue digestion, mechanical disruption of the tissue and 
cell separation, a summary of the cell isolation is presented in Figure m2.  
 
Depending on the main isolated cell type and the final use of the cells (i.e. RNA isolation 
or fibroblast culture) there were some variations in critical steps like the digestion time of 
the heart and the washing steps of the cells; these steps are mentioned below. Also, it is 
useful to mention that not always all steps and solutions were required. The working 
solutions were prepared always fresh using autoclaved d-diH2O and the bottles and 
materials were sterile when the intention was to culture cells. The main solution (solution 
A) used was modified Tyrode’s buffer. Using solution A the following solutions were 
prepared: 1) Solution A+ gassed (~15min with O2/CO2) kept at room temperature for 
cleaning and stabilization of the heart. 2) Solution A kept at 37°C to solve the enzyme 
cocktail* (Liberase, Roche) for digestion of the heart. 3) Solution A++extra (O2/CO2 
equilibrated) containing serum albumin and Ca2+ to inhibit the digestion enzymes. 4) Cold 
macrophage (MF) solution without serum and Ca2+ for a pre-plating step used to separate 
fibroblasts from macrophages since it was reported that with this conditions macrophages 
and not fibroblast can attach to a plastic surface facilitating the separation of both cell 
populations (Landeen et al., 2007). 
                                                 
* Until 2009 it was used the Liberase Blendzyme 4 from Roche (2mg in a final volume of 12ml) but 
because the product was replaced, the new product used was Liberase TM Research Grade (2mg 
in a final volume of 15ml). 
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Figure m2. Summary of the isolation procedure used to obtain mouse cardiac fibroblasts 
and cardiomyocytes. After digestion of the heart the tissue is homogenized and passed through a 
nylon filter to remove remaining debris. The cardiomyocytes (CMs) are separated from other 
cardiac cells and fibroblasts (FBs) by decanting the cells suspension and/or centrifugation steps. 
The supernatant, rich in fibroblasts, is washed and cultured. The pellet is pre-plated to remove 
adherent cells (i.e fibroblasts or macrophages) and finally a cardiomyocyte enriched suspension is 
collected. LCM: Laser Capture Microdissection, ICC: Immunocytochemistry. 
 
 
The perfusion system (Figure m3, A) was always rinsed with at least 1 liter of autoclaved 
d-diH2O before and after its use. At the end of the preparation a cleaning step with 100ml 
EtOH 90% was also made with a final drying step of the tubing to avoid contamination of 
further preparations. The perfusion system was built with two independent tubes going 
into the cannula, one tube for the solution used to clean and stabilize the heart with the 
Tyrode’s solution, and the second tube just to carry the digestion solution. When the 
tubing system was cleaned some solution A was passed first through the tube that carries 
the digestion solution (Liberase solution) in order to have this part of the tube filled with 
solution A to avoid air bubbles. The same was done with the other part of the perfusion 
system, but with solution A+ and this was made as second step, because in this way the 
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common end of the tubes contained only solution A+, that it was the first one used to 
perfuse the heart. After preparing the perfusion system, the warming bath was turned on 
(40°C to have at the end of the tube for Liberase solution 36.5°C, it depends on the tube 
size and length). It is important to calibrate the temperature in a way that at the end of the 
tubing the solution temperature is between 36 to 37°C.  
 
Before excision of the heart the mouse was anesthetized with Avertin (i.p) and 20µl/g of 
Heparin (1000U/ml) were injected (i.p). Once there was no detectable reflex from the paw 
sole and the tip of the tail the mouse was placed on its back, the limbs were fixed and the 
abdomen and thorax were cleaned with abundant EtOH (70%). A transversal incision on 
the lower part of the abdomen was made, then two longitudinal incisions from the first one 
were done in direction to the head in order to perform a clam-shell bilateral thoracotomy, 
the ribs were removed and the heart was exposed. To facilitate the blood removing from 
the heart, a small incision was made on the renal artery and afterwards a paper tissue 
was placed on top to absorb the blood. The pericardium was removed gently and 1ml ice 
cold solution A was slowly injected inside the left ventricle to arrest the heart and to 
remove part of the blood. Before the heart explantation the valve from the perfusion 
system carrying solution A+ was opened (set to ~1drop/s).  
 
The heart was rapidly excised with part of the aorta. This was done by pulling up gently 
the heart by fixing it from the tip and releasing the heart cutting first the pulmonary vein 
and artery from above and finally the aorta (close to the aortic arch) and vena cava. The 
heart was rapidly placed in ice cold solution A, where the excess of fat tissue around the 
aorta was removed. The aorta was cannulated, avoiding the damage of the aortic valve, 
with a self made 18G blunt cannula and fixed to it with two threads (USP 8/0 metric 0.4, 
Suprama, Germany). The heart was transferred to the perfusion system and was 
retrogradely perfused with the solution A+ at RT (previously equilibrated with O2/CO2) 
between 5-7 min, depending how fast the drops coming out were free of blood. The 
solution A+ was changed to the digestion solution (37°C and ~1drop/s) and the perfusion 
was carried out during 7-15 min*. This solution was recovered and recirculated during the 
perfusion. When the heart became “swollen and soft” it was removed from the cannula 
                                                 
* The perfusion time with the Liberase solution depends on the size of the heart, the age of the 
mouse, the appropriate cannulation and the designated use of the cells. Sufficient digestion of the 
heart is achieved when it becomes more pale and when the tissue from the ventricle is easily 
disrupted with forceps. When the digestion is too fast pay attention to the quality of the cells, can 
be that the Liberase concentration is too high. During this step check constantly the heart to avoid 
over-digestion of the tissue. If the interest is to get mainly fibroblast there is no problem that the 
heart is completely soft, but if the interest is to get a high percentage of healthy cardiomyocytes this 
digestion time is critical and has to be reduced to the minimum. 
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and placed into a sterile plastic Petri dish (35x10mm)  containing ~2ml Liberase solution 
(37°C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B
Solution A+
Liberase
(36.5˚C)
Heating bath
Roller pump
37˚C
 
 Figure m3. Perfusion system used for cardiac cell isolation and silicone isolators for 
fibroblast culture. (A) Diagram of the system used to retrogradely perfuse the mouse heart for the 
isolation of cardiomyocytes and fibroblasts. (B) Graphic showing the use of silicone isolators (red) 
on top of round glass coverslips (grey) to culture cardiac fibroblasts. To transfer the cells on 
coverslides with silicone isolators this is done by gently pipetting the cell suspension on one edge 
as depicted in B (lower picture); in this way the formation of bubbles is avoided. 
 
 
 
The next steps, dissociation of cardiac cells and fibroblast culture, were done under the 
flow bench using sterile cell culture techniques. The ventricles were separated from the 
atria using fine scissors sterilized by flaming and they were transferred into a new Petri 
dish (35x10mm) containing 2ml A++extra solution (O2/CO2 equilibrated). The ventricles 
were minced into small pieces 2-3mm. The tissue was partially dissociated by gently 
♨ O2/CO2
Bubble
trap
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pipetting several times (~1min). The suspension was transferred into a 15ml 
polypropylene tube, the Petri dish was rinsed with 2ml solution A++extra and this was 
pooled with the suspension in the 15ml tube. Finally, solution A++extra was added to 
complete 10ml and the dissociation and homogenization of the tissue were continued for 
about 3 to 5 minutes until the suspension was homogeneous. The homogenate was 
filtered through a 150µm sterile filter (ref. 06-4-2319, CellTrics, Partec) and collected into 
a new 15ml polypropylene tube.  
 
The cardiomyocytes were allowed to sediment (10min at 37°C). The supernatant rich in 
cardiac fibroblasts was transferred into a new 15ml polypropylene tube and centrifuged at 
40G/1min/RT in order to retire remaining CMs. The supernatant was changed into a new 
15ml tube. If there was interest to collect cardiomyocytes for immunocytochemistry (ICC), 
RNA isolation or Laser Capture Microdissection (LCM) the pellets containing CMs were 
pooled and solution A++extra was added to complete 10ml, this suspension was 
transferred into a plastic Petri dish (60x10mm) and the cells were pre-plated in a cell 
incubator 37°C, 5%CO2 (HERA cell 150, Heraeus, Germany) to remove adherent cells like 
FBs. After 2h the cardiomyocytes were collected and counted manually using an improved 
Neubauer chamber (BRAND, Germany). The handling of the cardiomyocytes varied 
depending on their use, see below.  
 
The FBs containing supernatant was centrifuged (250G/10min, RT) in a Jouan 
multifunction centrifuge (CR3i, Thermo Electron Corporation). The supernatant was 
discarded and the cell pellet was resuspended in 5ml M199 (Gibco, Invitrogen) 
supplemented with FCS, kanamycin and penicillin/streptomycin (M199-complete). The cell 
suspension was transferred into a 25cm2 culture flask (vented cap, BD Biosciences) and 
kept during 2h in the cell incubator (37°C). After this period, the medium was removed and 
the flask was rinsed two times with medium (M199-complete) to remove non adherent 
cells and debris. Finally, the cells were cultured with 4ml of M199-complete, the medium 
was changed every 24h until they were confluent. Cells from one heart were usually 
confluent after 5-7 days of plating. The cells were regularly monitored with an inverted 
Nikon microscope (Eclipse TS100) using the 10X and 20X objectives (LWD 20X/0.40 Ph1 
ADL ∞/1.2 and 10X/0.25 Ph1 ADL ∞/1.2 WD 6.2, Nikon). 
 
In some preparations one differential plating step was used in between the FBs 
resuspension and its culture. The aim of this step was to reduce the population of 
macrophages in the culture as mentioned before. Instead of resuspending the cells in 
M199-complete, the cells were resuspended in 5ml cold MF-solution, placed into a Petri 
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dish (35x10mm) and incubated for 30 minutes (~6°C). After that period the non-adherent 
cells were recovered and 5ml solution A++extra were added (complete 10ml). The 
suspension was centrifuged (250G/10min). The supernatant was discarded and the cells 
were resuspended in M199-complete; the following steps were the same as mentioned in 
the previous paragraph.  
 
Once the fibroblasts were confluent the cells were detached from the culture flask using 
Trypsin to split them for expansion of the culture or to transfer cells into coverslips. Briefly, 
for a 25cm2 culture flask the medium was removed and the cells were rinsed with 5ml pre-
warmed (37°C) DPBS Ca2+/Mg2+ free (Gibco, Invitrogen) supplemented with EDTA 
(0.2mM). The DPBS was removed and 1ml 1X Trypsin/EDTA solution was added, then 
the flask was placed back into the incubator during 3-5 minutes and 9ml of medium 
(M199-complete) were added to stop the Trypsin activity. The suspension was transferred 
into a polypropylene tube (15 or 50ml) and the cells were pelleted by centrifugation at 
250G for 5min. The medium was remove and discarded, the cell pellet was resuspended 
into 2ml of medium and 10µl were taken to count the cells with the Neubauer chamber. 
Afterwards, 8ml medium (M199-complete) were added (or a different volume depending if 
the cells were going to be seeded into coverslips or were taken for RNA isolation) and the 
suspension was placed into a new 75cm2 culture flask (vented cap, BD Biosciences) with 
10ml medium. To increase the cell density on coverslips and the number of coverslips that 
can be obtained from one heart (20mm diameter), autoclaved silicone isolators (press to 
seal S7060-25EA, 1.0mm x 20mm, Sigma) on top of each glass coverslip were used 
(Figure m3, B). The coverslips used were sterilized by autoclaving and flamed before 
placing the isolator. Every coverslip with its isolator was placed inside a 35x10mm culture 
dish (Falcon, BD Biosciences). The final cell suspension volume used on each coverslips 
was 300µl. Cell culture medium was changed 24h after splitting to remove remaining 
Trypsin and cell debris. Medium was changed every 48h when the cells were cultured in 
flasks or 6-well plates, and every 24h when the cells were on coverslips with silicone 
isolators to avoid problems with the cells due to the reduced volume and the evaporation 
of the medium. 
 
 
4.2.7 RNA isolation from cardiomyocytes and cardiac fibroblasts and RT-PCR  
 
The cells used for RNA isolation (RT-PCR) were resuspended in cold DPBS Ca2+/Mg2+ 
free instead of culture medium. They were washed two times (250G/5min for fibroblasts or 
40G/1min for cardiomyocytes), pelleted into a new sterile tube (1.5 or 2ml reaction tube) 
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and 300µl of RTL buffer (with 1% β-Mercaptoethanol) from the total RNA purification kit 
were added to each sample. The samples were used directly afterwards or kept at -80°C 
until RNA isolation. For RNA isolation the RNeasy Micro Kit (74004, Qiagen) was used. 
The procedure was done following the manufacture instructions and using RNase-free 
materials and reagents. Shortly, the volume was completed to 350µl with RTL buffer (with 
1% fresh β-Mercaptoethanol), the samples were subjected to 30s vortex, 350µl 70% EtOH 
(prepared with sterile RNase-free water) were added and the solution was mixed well by 
pipetting. The complete solution was transferred into a RNeasy MinElute spin column 
placed into a 2ml collection tube and centrifuged for 25s at 9000G (microcentrifuge, 1-14, 
sigma, Germany). The flow-through collected in the 2ml tube was discarded, 350µl Buffer 
RW1 were added to the column and the column with collection tube were centrifuged at 
9000G/25s, once more the flow-through was discarded. Thereafter, the DNase digestion 
step was included, for this the DNase was always prepared freshly by adding 10µl DNAse 
I stock solution to 70µl RDD buffer per sample and it was mixed gently by inverting the 
tube. 80µl DNase solution were added directly on top of the spin column membrane and 
the sample was incubated for 15min at RT. Following the DNase treatment 350µl buffer 
RW1 were added to the column, it was centrifuged as before to wash the membrane and 
the column was placed into a new 2ml collection tube and the other tube containing the 
flow-through was discarded. Another two washing steps of the membrane were made, first 
by adding 500µl buffer RPE, centrifuging at 9000G for 25s and discarding the flow-through 
and the second, by adding 500µl of 80% EtOH, centrifuging 25s at 9000G, discarding 
carefully the flow-through and finalized with one additional centrifugation (9000G/25s) step 
and discarding of the collection tube. To dry the column, this was placed into a new 2ml 
collection tube, but the lid was not closed, then both were centrifuged for 2min at 
maximum speed (12470G or 13000rpm) and the collection tube was discarded. Finally, 
the elution of total RNA from the column was made by placing the column into a new 
1.5ml collection tube, adding 41µl RNase-free water, centrifuging at maximum speed for 
1min and the last two steps were repeated to get a final volume of 80µl. The samples 
were maintained on ice until the RNA quantification and RT-PCR and were kept for longer 
period at -20°C.  
 
The RNA quantification was done with a NanoDrop spectrophotometer (NanoDrop-1000, 
peqlab). As blank for the measurements were used 2µl of the same RNase-free water 
applied for the RNA elution; to determine the concentration 2µl per sample were used. 
The software from the NanoDrop (ND-1000 v 3.5.2) provided directly the concentration 
data in µg/ml and the ratios between the absorbance at 260nm and 280nm, and between 
260nm and 230nm to determine the purity of the RNA solutions.  
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The RT-PCR from left ventricular myocytes dissociated from hearts during Langendorff 
perfusion and from cultured cardiac fibroblasts was done using a one step kit (Super 
ScriptTM One Step RT-PCR with Platinum® Taq, Invitrogen). PCR products were obtained 
using spanning oligonucleotides as primers. The RT-PCR reactions were made in a final 
volume of 50µl where 25µl were from reaction mix, 1µl from each primer (10µM) and 1µl 
from the enzyme cocktail, and they were carried out in a thermocycler GeneAmp® PCR 
System 9700 (Applied Biosystems). The products were run in 2% agarose gels stained 
with Ethidium Bromide (15µl from a 1% stock solution in a 500ml gel) at 200mV during 
~1.3h. To visualize the products and digitalize pictures from the PCR results a gel imaging 
system (GelDocTM, BioRad) was used. The primers and RT-PCR conditions are 
summarized in Table m2.  As positive control RNA from mouse brain (10µl from a 1ng/µl 
solution) was used and as negative control a reaction replacing the RNA by an equivalent 
volume of a RNase-free water from the total RNA isolation kit plus PCR water was always 
included. 
 
 
4.2.8 Laser Capture Microdissection of mouse cardiomyocytes 
 
One application of the isolated mouse cardiomyocytes was the expression analysis by 
RT-PCR. Because the cardiomyocyte suspension obtained by the digestion of the heart is 
not completely pure (See results, Figure 21, C) the isolation and collection of single CMs 
by Laser Capture Microdissection (LCM) was chosen to obtain a pure population of cells 
for the expression analysis (Emmert-Buck et al., 1996). 
 
After cardiomyocyte isolation and the pre-plating step mentioned previously, the cells 
were pelleted by centrifugation at 40G for 1.5min, then the CMs were resuspended into 
2ml sterile and ice-cold DPBS (Ca2+/Mg2+-free) and the suspension was transferred into a 
new 15ml polypropylene tube. Once more the cells were pelleted by centrifugation 
(40G/1min), resuspended in cold PBS and this last step was done twice to wash the cells. 
Finally the CMs were resuspended in sterile and ice-cold DPBS at a concentration 
between 80-85 cells/µl.  The isolated cardiomyocytes were cytospun on LCM glass slides 
(1mm PEN-membrane covered, Zeiss) pre-treated with UV light for 30min, to increase cell 
attachment, under a cell culture bench to avoid contamination of the slides. 
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Table m2 (A). Primers and conditions used for RT-PCR expression analysis of TRPs.  
Gene Product position
Expected 
product 
size (bp)
TRPC1 PH643 TGC AAA CG TTC TGA GTT ACC Exons 9-11 403
PH644 CGT CAG CAC AAT CAC AAC C
TRPC3 PH647 TAG AGA CAA ATG GCT CCC C Exons 7-8 337
PH648 TTT GAG GAC AAC AGA AGT CAC
TRPC4 KO-42 GCC TCT GCA GAT ATC TCT GGG Exons 6-7 263
KO-06 TCG TGC TGG GCT TTG ACA TTG
TRPC5 PH651 GTA TAA TGG TTC TCG TCC AAG G Exons 6-7 350
PH652 AGA GCG ACT GAA GGG TTT C
TRPC6 PH653 AAA AGT CAC ACT GGG GGA C Exons 6-8 424
PH654 ACC ATA CAG AAC GTA GCC G
TRPM4 IN-48 TCT TCA CAC TGC GCC TGC TG Exons 18-19 207
IN-49 GTC GGT AGA AGA CCC TGC GC
TMEM-2 UK79 CAG CTT TGG GAG GAC AAC G Exons 6-10 397
UK81 GCA GAA CTG GCC ACA AGG
HPRT-1 UW637 GCT CGA GAT GTC ATG AAG G Exons 2-3 225
UW638 AGT TGA GAG ATC ATC TCC ACC
Primers (5'-3')
 
 
Table m2 (B) 
Temperature Time Cycles
50°C 30min 1X
94°C 2min 1X
94°C 15s
56°C 30s
72°C 25s
72°C 7min 1X
8°C hold
40X
RT-PCR conditions
 
(A) Oligonucleotide sequences used for expression analysis of TRPs. All the primers were intron 
expanning. The predicted amplification and the expected product size are mentioned for each 
primer pair. (B) Conditions for the RT-PCR reaction for all the primer combinations. 
 
 
The slides were mounted on pre-cleaned and cold (4°C) cyto-buckets (LT11175753, 
Thermo Electron Corporation), following the manufacture instructions, but with two 
modifications. First, instead of using grease in between the plastic block and the slide, it 
was used a rectangular piece of autoclaved Wathman paper with three holes fitting to the 
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holes of the plastic block. Second, the cells were not placed directly into the three holes of 
the plastic block but into 0.5ml sterile reaction tubes. Only two spaces of the plastic block 
were used to place two 0.5ml tubes because the PEN-membrane from the slides did not 
cover the complete surface of the slide. Inside each tube 150µl of the cardiomyocyte 
suspension were placed and a small hole was made on the tip of the tube with a 23G 1” 
needle (MicrolanceTM, BD). After mounting the bucket with the cells, they were cytospun at 
4°C (Jouan multifunction centrifuge CR3i, Thermo Electron Corporation) using 280G for 
2.5 minutes. The slides were taken out of the buckets and directly fixed with increasing 
Ethanol concentrations (70%, 80%, 90% and 100% on minute each) or later with 
Methanol (100% 1 min). Immediately afterwards every slide was transferred inside a 
single sterile 50ml polypropylene tube to avoid complete drying of the samples and they 
were kept in ice until the isolation of cardiomyocytes.  
 
The collection of the cells was made using a Zeiss P.A.L.M. LCM microscope 
(Zeiss/Microlaser Technologies) with a 20X magnification objective (Plan-Neofluar 0.5 
∞/0.17). The cells were collected on the cap of 0.5ml LCM tubes (AdhesiveCap 500 
opaque, Zeiss) as described by Schütze and Lahr (1998). The setting and controlling of 
the device were made by the incorporated software Palma®Robo Software v1.2.3. Robot 
LPC function was selected to cut and catapult the cells on the cap, the laser focus was set 
between 52 and 54, the laser energy for cutting was between 57 and 59% and the 
catapulting energy (LPC) was set around 83%. Once the setup was prepared, the slide 
was removed from the 50ml tube, placed into the microscope bench and let it dry for 
about 5min before starting. Then, the cap from the LCM tube was cut out from the tube 
and only was manipulated using pre-flamed forceps to avoid RNase contamination. The 
cap was placed facing down on the cap holder and approximated to the slide as much as 
possible, but avoiding any contact to the PEN membrane of the glass slide.  
 
The cells were identified easily because their morphology; only well preserved cells, rod 
shaped and single placed were cut out of the slide. Between 40 and 170 mouse 
ventricular cardiomyocytes were collected on each cap, this number was time dependent. 
I determined to collect as much as possible cells in between 30min per slide, trying to 
reduce the exposure of the preparation. After catapulting the cells on the tube cap they 
were counted using the 4X magnification objective (Achroplan 4X/0.10 ∞/-). The cap was 
carefully removed from the holder and it was used to close the tube that already contained 
150 or 300µl RTL buffer (with 1% β-Mercaptoethanol) from the total RNA purification kit 
(RNeasy Micro Kit, Qiagen). 150µl RTL buffer were used when the cell number was ~50 
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cells, and 300µl when there were ~100 cells. After closing the tube, it was vortexed for 
30s, placed on dry ice and stored at -80°C until the total RNA extraction  
 
Total RNA extraction was made using the RNeasy Micro Kit (Qiagen). The procedure was 
similar except that before starting the isolation a carrier RNA was added (5µl per sample 
of a solution with 4ng/µl) for extraction of RNA from small number of cells. Elution volumes 
were variable (25µl, 46µl, 41µl 2X and 51µl 2X) depending on the amount of starting cells 
to get the maximum RNA from each preparation. The RT-PCR from these isolated 
cardiomyocytes was done also using the one step kit (Super ScriptTM One Step RT-PCR 
with Platinum® Taq, Invitrogen) and 50µl final reaction volume, from which usually 22µl 
were from the RNA solution. The RT-PCR and electrophoresis conditions were the same 
mentioned above and total RNA from brain was used as positive control and the elution 
water as negative control.  
 
 
4.2.9 Characterization of cardiac fibroblast culture by immunocytochemistry 
 
To characterize cultured mouse cardiac fibroblasts four different antibodies were selected 
according to Thum and collaborators (2008). The antibodies used were: rabbit anti-human 
prolyl-4-hydroxylase beta polyclonal (Acris) which is mentioned as fibroblast specific 
marker; mouse monoclonal anti-CD31 (Platelet Endothelial Cell Adhesion Molecule or 
PECAM1) clone P2B1 (abcam) used as endothelial marker; rabbit polyclonal against 
smooth muscle α2-actin or ACTA2 (abcam) for smooth muscle cells; and mouse 
monoclonal anti-α-actinin (ACTN2) clone EA-53 (Sigma) used as cardiomyocyte marker. 
For characterization of the fibroblasts I selected the anti-P4HB rabbit polyclonal instead of 
the monoclonal (P4HB, clone 6-9H6, Acris) used by Thum and coworkers because the 
last one reacts with rat but no mouse fibroblasts. The secondary antibodies used were 
goat IgG anti-mouse conjugated to Alexa Fluor 594 and goat IgG anti-rabbit conjugated to 
Alexa Fluor 488 (Molecular Probes, Invitrogen). As positive control for the selected 
markers freshly isolated mouse cardiomyocytes isolated as described, freshly isolated 
ileum smooth muscle cells (iSMC) from the longitudinal muscle layer isolated by 
collagenase treatment (Tsvilovskyy et al., 2009) and mouse aortic endothelial cells 
(MAEC) prepared in our laboratory as described were used (Suh et al., 1999; Freichel et 
al., 2001). Negative controls consisted of cells processed in the same way as positive 
controls but omitting the primary antibody. 
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All different cell types used (CMs, FBs, MAEC and iSMC) were placed on pre-cleaned 
round coverslips (20 or 25mm diameter, Nr. 0/1). Coverslips were cleaned by incubation 
for 2h in 2N NaOH at RT followed by extensive rinse in d-diH2O; they were stored 
submerged in 70% EtOH and flamed before its use. Cardiac fibroblasts and endothelial 
cells were cultured on glass coverslips and they were used between passage 1 (P1) up to 
passage 3 (P3), but in some case acute isolated FBs were directly plated on glass 
coverslips. Cardiomyocytes were attached to coverslips by cytospin; a similar procedure 
was followed as the one mentioned in the LCM procedure but instead of using glass 
slides, three coverslips were placed between the Wathman paper and the plastic block. 
CMs were resuspended for cytospin in PBS at a concentration of 100CMs/µl and after 
cytospining them (280G for 2.5min at 4°C) they were rinsed with PBS to remove non 
attached cells or cell clumps and finally the coverslips were placed into 6 or 12-well 
polystyrene cell culture plates (Falcon, Becton Dickinson) and kept submerged in PBS at 
4°C until cell fixation. Ileum smooth muscle cells were processed similarly to CMs but they 
were cytospun by centrifuging at 250G/2min from a cell suspension containing 50 cells 
per µl.  
 
The immunostaining procedure was standardized for the positive controls in such way that 
at the end there were only small differences in primary antibody concentrations and the 
incubation times. This allowed the staining in parallel of different cell types and different 
cell markers to reduce the variability between preparations. Before cell fixation the 
samples were rinsed in cold PBS (pH 7.4, sterile and filtered). Cell fixation was done by 
incubation in 4% Paraformaldehyde (PFA) prepared in PBS (pH 7.4) over 10min at 4°C 
and subsequently the cells were washed two times for 5min by submerging them in cold 
PBS. The samples were transferred then into pre-chilled Acetone (-20°C) for exactly 5min 
(step omitted when CD31 was used) and washed after 3 times with cold PBS during 5min 
each time. To block unspecific binding, the samples were incubated for 1h (RT) in 1% 
BSA prepared in PBST (only PBS for CD31) including 0.3M Glycine which reduces the 
background by binding to free aldehyde groups. Between 50-100µl from the primary 
antibody solved in 1% BSA (PBST or only PBS for CD31) were added and the cells were 
incubated at RT, protected from light in a humid chamber. Concentration and incubation 
times used are depicted in Table m3. Three washing steps of 5min each with cold PBS 
were made followed by the incubation with the secondary antibodies (Table m3) at RT 
and protected from light. The secondary antibody mixtures were decanted and three 5min-
washing steps with cold PBS were done. Samples were always protected from light. To 
stain the nuclei the cells were incubated for 5min at RT with DAPI 1.5µg/ml in PBS. Finally 
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the coverslides were mounted on glass slides using as an anti-fade mounting medium 
(Vectashield, Linaris) and were stored at 4°C protected from light until its analysis.  
 
 
Table m3.  Immunocytochemistry conditions used for characterization of cardiac fibroblast.  
 
 
 
 
 
 
 
 
anti-P4HB anti-α-actinin anti-α-SM actin anti-CD31 
positive control fibroblasts cardiomyocytes iSMC MAEC
acetone permeabilization yes yes yes no
blocking 1% BSA in PBST 1% BSA in PBST 1% BSA in PBST 1% BSA in PBS
concentration 1µg/ml (in PBST) 150µg/ml (in PBST) 10µg/ml (in PBST) 10µg/ml (in PBS)
incubation time 1h 2h 2h 2h
secondary antibody (2nd-ab) anti-rabbit AlexaF488 anti-mouse AlexaF 594 anti-rabbit AlexaF488 anti-mouse AlexaF 594
2nd-ab dilution 1:1000 (in PBST) 1:200 (in PBST) 1:200 (in PBST) 1:200 (in PBS)
2nd-ab incubation time 1h 1h 1h 1h
iSMC: ileum smooth muscle cells, MAEC: Mouse aortic endothelial cells, PBS: Phosphate buffered 
saline, PBST: PBS-Tween 20 and Alexa-F: Alexa Fluor. 
 
 
The analysis from stained cells was made using two different microscopes. One setup 
was an inverted TE2000-U microscope (Nikon, Japan) with a X-Cite®120 fluorescence 
illumination system (EXFO, Photonic Solutions Inc., Canada) coupled to a digital camera 
(DS5mc, Nikon). This setup was equipped with a FITC filter and a UV filter used to 
visualize signals from Alexa Fluor-488 conjugated antibodies and from the nuclear 
staining DAPI, respectively. The processing and digitalization from the pictures was made 
using the NIS-Elements software (F 2.30, Nikon). The second setup was an AxioVert 
200M inverted microscope (Zeiss, Germany) equipped with a HXP120 fluorescence lamp 
(Kübler codex, Germany), a digital camera AxioCam MRm (Zeiss), filters for FURA 
(DAPI), GFP (Alexa Fluor-488) and Alexa-594 and the software used was AxioVision 
v4.7.2 (Zeiss). The imaging conditions, like exposition time, used in positive controls were 
the same for the negative controls. 
 
 
4.2.10 Calcium imaging from mouse cultured cardiac fibroblasts 
 
To measure changes in intracellular calcium concentration from isolated mouse cardiac 
fibroblasts the ratiometric calcium indicator FURA-2 for microflurometric analysis was 
used. For measurements an inverted AxioObserver A.1 microscope (Zeiss, Germany) 
equipped with a polychromatic Xenon light source (Polychrome V, TILL Photonics, 
Germany) was utilized. A 20X magnification objective (FLUAR 20X/0.75 ∞/0.17, ref. 
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420150-9900, Zeiss) was used and the recordings were obtained through a digital camera 
AxioCam MRm (Zeiss). Cells were alternately excited at 340 nm and at 380 nm and the 
exposure time varied from 60-400 milliseconds; pairs of frames were recorded every 0.2-5 
seconds. Increase in intracellular calcium concentrations [Ca2+]i led to an increase in the 
emitted fluorescence at 510 nm after 340 nm excitation and decreasing emission after 380 
nm excitation. Changes in [Ca2+]i levels over time were expressed in arbitrary units as 
fluorescence ratio between emission-340/emission-380 (Em340/Em380), calculated from 
regions of interest (ROI) that included complete cells. Settings of the setup and, recording 
and analysis of the data were done with the Physiology module from the AvioVision 
software (v4.8.1, Zeiss). 
 
Mouse adult cardiac fibroblasts were cultured on sterile and round pre-cleaned (see 
section 4.2.9) glass slides (25mm diameter). To increase the density of cells, silicone 
isolators were used for plating. In some experiments cells were serum starved over night. 
The fibroblasts were incubated with 5µM FURA-2-AM (Molecular Probes, Invitrogen, 
Germany) in M199 (10% FCS or without when mentioned) at 37°C for 25-45min. The 
medium was removed, the cells were rinsed with physiological buffer and transferred into 
a stainless steel chamber (Attofluor® A-7816, Molecular Probes) coupled to a vacuum 
sucking system and a perfusion system to be washed with running buffer over 15-30min. 
As physiological solution was selected modified Tyrode’s buffer containing 1.8mM CaCl2, 
after trying other solutions found to be used in the literature like HEPES buffered saline 
(Ostrom et al., 2003) or Ringer solution (Shumilina et al., 2005). In some set of 
experiments of Calcium re-addition the Ca2+-free solution contained 1mM EGTA.  
 
Initial measurements were done at room temperature but during the standardization of the 
protocol it was established to measure at 37°C. To this end a dual automatic temperature 
control system (TC344 Heater Controller, Warner Instrument Corp. Harvard Apparatus 
Company, USA) was used with a heating tube for the perfusion solutions and a heating 
element connected to a home made aluminium support to keep the coverslip’s chamber 
warm. After the de-esterification period (~30min) the recordings were done. First, a one 
minute period was recorded to obtain a basal calcium level; cells were then stimulated 
with different agonists such as Serotonin, Isoproterenol, human ATII (Sigma) or 
Thapsigargin. Agonists were prepared at the desired final concentration in Tyrode’s buffer 
to perfuse the cells constantly with it. In most of the experiments different agonist were 
tested with washing steps in between. The data from the fluorescence ratios were 
exported with AxioVision and mean traces for groups of cells were made with Origin 8 
(OriginLab Corporation, USA). 
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4.2.11 Surface ECG recording  
 
ECG recordings were made under 2% isofluran anesthesia (in O2/N2O gas mixture 1:2). 
The mice were kept laying on their front on a warm plate at 37°C and three steel 
electrodes (29G, MLA1203, ADInstruments) were placed subcutaneously as described by 
Li and coworkers (2004a) but following the lead I configuration (positive electrode in left 
foreleg, negative electrode in right foreleg and ground electrode in left rear leg). The 
electrodes were connected to a BioAmp and a Power Lab/8S (ADInstruments). The ECGs 
were recorded at a rate of 4 KHz using high pass filtering 0.3Hz and low pass filtering 
100Hz. The signal range was determined between 4 to 10mV. The analysis of ECG traces 
was made with the ECG analysis module from ChartPro v5.5.5 and LabChart 6.0 
(ADInstruments). The ECG from each mouse was recorded for about 5 minutes and for 
the analysis a period of 1 minute was taken after the first minute of recording when the 
signal was completely stabilized. For analysis and detection of the ECG waves the option 
“mouse” in the ECG module and the option “rodent T wave” were selected. Additionally, 
an average trace (Figure m4) was made from ten beats and the QT interval correction 
was calculated using the formula QTc=QT/√RRx10 from Mitchell et al. (1998).  
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Figure m4. Surface ECG trace from mouse. Original trace of and ECG recording (left panel) from 
a mouse kept under isofluran anesthesia. On the right is shown an average ECG trace obtained 
from 10 heart beats where the different ECG waves and the Q-T interval limits are depicted. 
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At the end the detection of different waves and intervals was checked manually. Also the 
presence of irregular beatings was checked manually by scrolling through the recording. 
The following parameters and the corresponding units were obtained for each ECG 
measurement: RR Interval (s), Heart Rate (BPM), PR Interval (s), P Duration (s), QRS 
Interval (s), QT Interval (s), QTc (s), JT Interval (s), Tpeak-Tend Interval (s), P Amplitude 
(mV), Q Amplitude (mV), R Amplitude (mV), S Amplitude (mV), ST Height (mV), T 
Amplitude (mV).  
 
 
4.2.12 Organ bath: spontaneously beating isolated right atria 
 
Four atria were placed in the organ bath (5ml, FMI-Föhr Medical Instruments, Germany) 
to measure two atria per genotype simultaneously. To prepare the atrium the heart was 
quickly excised after the injection of 1ml Krebs-Henseleit (KH) into the left ventricle and 
was placed into a plastic Petri dish (Silicone pre-coated) containing KH solution constantly 
gassed (95% O2 and 5% CO2). The heart was gently fixed with a needle through the left 
ventricle with the posterior part of the heart facing up and the adhering fat close to the 
aorta was removed. The right atrium was partially dissected free from the heart by an 
incision close to the coronary vessels positioned parallel to it and by one cut made on the 
inferior vena cava; then, the excess from the superior vena cava was removed. A ~12cm 
thread (7/0 Suprama, Germany) with a small ring (~2mm diameter) at the end and spaced 
for 9.5cm to the knot point was fixed to the tip of the right atrium and the remaining thread 
distal to the ring was cut out (Figure m5, A). The needle fixing the heart was removed; the 
heart was turned down and fixed again through the left ventricle and finally the right atria 
was completely dissected free from the heart by cutting carefully the remaining tissue 
below it. Finally, a second thread was fixed to the remaining part of the inferior vena cava, 
this suture also had a small ring at the end but spaced only by ~3mm from the knot place. 
Special attention was taken when the second thread was closed to avoid closure of the 
atrial opening.  
 
The atria were suspended in the organ bath using two threads, the short one attached to 
the lower hook and the long one to the hook below the transducer. Each isometric 
transducer (TIM-1030, FMI) was coupled to an amplifier (MIO-0501 DC, FMI) connected 
to a Power Lab 8S (ADinstruments) that allowed the digitalization and recording of the 
measurements with the LabChart software (ADInstruments). The organ bath chambers 
were filled with warmed (37°C) and constantly gassed (95% O2 and 5% CO2) KH solution. 
The atria were pre-loaded to 0.4g tension and were let to equilibrate for 1 hour until they 
reached a stable beating rate. This equilibration period included two washing steps in 
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between at minute 30 and 45. Once the beating rate was stable the cumulative 
concentration dose response experiments with different agonists were done. In a series of 
experiments Isoproterenol was applied first in a concentration range from 10pM to 1µM 
(Figure m5, B). After the last dose of isoproterenol three washing steps were made and 
the atria were let to recover to the basal beating rate for one hour with two additional 
washing steps (40 and 50min after last Isoproterenol dose). Then, Acetylcholine (ACh) 
dose response (10nM to 30µM) was carried out. After washing out ACh and getting the 
basal beating rate, a final 10nM Isoproterenol dose to test the atrial response at the end 
was used.  
 
Angiotensin II dose responses (10pM to 10µM) were preceded by three washing steps 
with a recovery period of 20min between each step. After the last ATII dose four additional 
washing steps spaced each by ten minutes with a final recovery of 10-15 minutes were 
done. After this, increasing Phenylephrine concentrations (PE) (1nM to 300µM) were 
applied to test the normal response to this agonist. A final single application of Iso 10nM 
was done after washing out the PE and recovering to the basal beating rate. To analyze 
the data and to extract the values from the recordings the Dose Response module from 
the LabChart software (v7.1.2) was used. The dose response curves were made with a 
mean value of 30s from the beating rate when the maximum and stable response was 
achieved for every concentration.   
 
 
 
tra
ns
du
ce
r
O2/CO2
Is
op
ro
te
re
no
l 1
0 
pM
Is
op
ro
te
re
no
l 1
0 
pM
Is
op
ro
te
re
no
l 1
00
 p
M
Is
op
ro
te
re
no
l 3
00
 p
M
Is
op
ro
te
re
no
l 1
 n
M
Is
op
ro
te
re
no
l 3
 n
M
Is
op
ro
te
re
no
l 1
0 
nM
Is
op
ro
te
re
no
l 3
0 
nM
Is
op
ro
te
re
no
l 1
00
 n
M
Is
op
ro
te
re
no
l 3
00
 n
M
Is
op
ro
te
re
no
l 1
 µ
M
1:35:00 1:40:00 1:45:00 1:50:00 1:55:00 2:00:00 2:05:006 7 8 9 10 11 12 13 14 15 16
B
P
M
600
500
400
300
200
A B
 
 
 
 
 
 
 
 
 
 
 
Figure m5. Mouse right atrial preparation for organ bath experiments. (A) Graphic 
representation and original picture from a mouse right atria hanged in the organ bath to quantify the 
spontaneous atrial beating rate. (B) Original trace from the spontaneous beating of a right atria 
exposed to increasing isoproterenol doses starting from 10pM up to 1µM.   
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4.3 In vitro analysis of platelets 
 
4.3.1 Platelet counting 
 
The manual platelet counting  was made from diluted blood in a 1% Ammonium Oxalate 
solution prepared with d-diH2O sterile and filtered (stored at 4°C) following the method 
described by Harrison and coworkers (2004). Before starting each preparation the 
Ammonium Oxalate solution was centrifuged for 15min at 1500G to remove debris. The 
blood was taken from conscious mice by submandibular bleeding using 18G 11/2” needles 
(MicrolanceTM, BD) and 50 to 70µl blood were collected into Heparin containing sampling 
tubes (SARSTEDT ref. 41.1503.005). To dilute the blood 50µl blood were added into 
950µl 1% Ammonium oxalate solution to have a 1:20 dilution, the suspension was mixed 
for 15min at RT to lyse the erythrocytes and to keep the platelets intact. From the blood 
suspension 10µl were placed into an improved Neubauer counting chamber (BRAND, 
Germany). The chamber was placed into a moist Petri dish for 20min to allow the platelets 
to settle and afterwards the platelets were counted under an inverted Nikon microscope 
(Eclipse TS100) using a 40X magnification objective (LWD 40X/0.55 Ph1 ∞/1.2 WD 2.1, 
Nikon). The cells were counted from the smallest squares on the middle of the chamber 
(25 squares subdivided in 16 squares that are equivalent to 0.1µl) and a zigzag sequence 
between the squares was followed. At the end the number of cells per µl was calculated.  
 
In addition to the manual counting, platelets numbers were obtained with a Coulter 
counter (AcT diff, Beckman Coulter). For this, blood samples were collected into EDTA 
containing sampling tubes (SARSTEDT ref. 41.1503.005). The blood was obtained by 
submandibular bleeding, mixed by repetitive inversion of the tube and kept at RT until the 
measurements. From each sample 12µl blood were taken by the counter. 
 
 
4.3.2 Hematocrit quantification from mouse samples  
 
Blood were taken from conscious mice by submandibular bleeding. Around 50µl blood (~5 
drops) were collected into heparin containing sampling tubes (SARSTEDT ref. 
41.1503.005). The blood was transferred into Hematocrit capillaries (Na-heparin, 7493-11, 
BRAND, Germany), the capillary end, where the blood was inserted, was sealed with 
yellow Plasticine and the tubes were centrifuged for 10 minutes at 13000rpm in a 
Hematocrit centrifuge (Type 2011-Hettich, Germany). At the end the total lengths of the 
sample contained in the tube and the red portion were measured with a ruler, and the 
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proportion in percentage of the red phase was calculated in relation with the total length to 
obtain the hematocrit value.  
 
 
4.3.3 Isolation of mouse platelets and preparation of platelet rich plasma (PRP) and 
washed platelet (WP) suspensions 
 
For both PRP and WP preparations the mice were anesthetized with Avertin given by an 
i.p injection (300-800µl depending on the mouse weight and genotype). After checking the 
absence of sensitivity from the paw sole and tip tail the blood was obtained by 
submandibular bleeding using an 18G 11/2” needle (MicrolanceTM, BD). The resulting 
protocols to prepare PRP and WP were modifications from different published methods 
(Hechler et al., 1998; Fabre et al., 1999; Foster et al., 2001; Nieswandt et al., 2002; 
Cazenave et al., 2004). 
 
Preparation of platelet rich plasma (PRP). To prepare PRP the blood was collected into 
15ml polypropylene tubes containing 10µl of Na-heparin solution (1000U/ml). The blood 
from 4 to 8 mice from the same genotype and gender was pooled and Na-heparin 
(1000U/ml) was added to have a final concentration of 10U/ml heparin. The blood was 
centrifuged for 8min at 260G (RT); the supernatant represented the platelet rich plasma 
(PRP) and was transferred into a new 15ml polypropylene tube. Platelets from the PRP 
were counted from a diluted sample (1:10) made using 5µl PRP and 45µl sterile Sodium 
Chloride (0.9%) solution and placing 10µl into a Neubauer chamber for manual counting. 
The remaining blood was centrifuged once more for 15min at 2200G to obtain the platelet 
poor plasma (PPP) that was moved into another new 15ml tube. From the PPP 200µl 
were saved for the calibration of the aggregometer and the rest was used to dilute the 
PRP to a final concentration of 3x108 platelets/ml. The PRP was kept at 37°C before and 
during the aggregation experiments.  
 
Preparation of washed platelets (WP). To prepare washed platelets blood from 4 to 7 
mice from the same genotype and gender was collected in 15ml polypropylene tubes 
containing 100µl of Acid-Citrate-Dextrose (ACD). Between blood collection from individual 
mice or when the volume reached around 900µl ACD (100µl) was added to have a final 
ratio 1:10 between ACD and blood. After adding ACD the blood was gently mixed; it was 
checked for clumps and the wall of the tubes was cleaned with a cotton bud rinsed with 
ACD. To each blood sample 0.75 volumes from the 1X Platelet’s Buffer (pre-warmed at 
37°C) were added, mixed well and centrifuged at 2300G during 10s per milliliter of final 
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volume. The supernatant, rich in platelets, was transferred carefully and without red cells 
into a new 15ml tube. Prostacyclin (PGI2) was added to the platelet suspension (5µl per 
ml from a 0.1mM solution) and the cells were incubated in a warming bath for 5min at 
37°C. After incubation PGI2 was added once more as before (5µl/ml) to the cell 
suspension and this was centrifuged at 1000G for 5 minutes. The supernatant was 
discarded and the platelet pellet was resuspended in 2ml Platelet’s Buffer where 5µl/ml 
PGI2 (0.1mM) and 2µl/ml heparin (5000U/ml) were included. The suspension was 
incubated one more time at 37°C for 5 minutes; next 5µl/ml PGI2 were added and the 
platelets were pelleted (1000G, 5 minutes). Then the supernatant was discarded, the cells 
were resuspended in 1ml Platelet’s Buffer and were kept at 37°C. To count the cells a 5µl 
aliquot from the cell suspension was diluted in 195µl 0.9% NaCl, from this dilution 10µl 
were placed into a Neubauer chamber to determine the number of platelets. The platelet 
concentration was adjusted with Platelet’s Buffer to 3x108 platelets per milliliter (Walther et 
al., 2003) and 1µl per ml apyrase (0.2 or 0.02U/µl), which hydrolyses ATP and ADP into 
AMP, was added into the cell suspension to have final concentrations of 0.2U/ml or 
0.02U/ml. The apyrase concentration was reduced specially to evaluate the platelet 
aggregation induced by thromboxane analogue U46619. TxA2 and its analogues induce 
ADP release from platelets that amplifies platelet aggregation mediated by the TxA2 
receptor itself. Apyrase in a concentration of 0.2U/ml significantly reduced the U46619-
induced aggregation, even at high concentrations such as 10µM (Figure m6, A). Finally, 
the platelets were incubated to recover for at least 30min at 37°C before starting the 
aggregation experiments. 
 
 
4.3.4 Platelet aggregation: turbidimetric measurements 
 
To evaluate the in vitro platelet aggregation of TRPC-deficient mice I established in our 
group a protocol for turbidimetric measurements using PRP and WP preparations (see 
4.3.3). The principle of the method is described in the Figure m7. The aggregometer used 
was an APACT 4S Plus (Rolf Greiner BioChemica, Germany) which has the option to 
measure 4 samples in parallel at 37°C. It monitors the aggregation, measured by changes 
in the optical density (OD) at 740nm under constant stirring (1000 rpm) from samples 
placed in plastic cuvettes (400068, Micro-Planküvetten with mixer 1.0x4mm, Rolf Greiner 
BioChemica) that included a metallic mixer. In addition, the raw and graphic data from the 
aggregation were visualized and obtained with the APACT software AS-IS v1.21c (Rolf 
Greiner BioChemica). The software calculated the following parameters from each 
aggregation curve that were used for the aggregation analysis: Platelet Shape Change 
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(PSC) given in percentage of aggregation, maximum aggregation expressed in 
percentage of aggregation, area under the aggregation curve given in percentage of 
aggregation, and slope of the aggregation curve defined as the maximum slope during 
aggregation, in percentage of aggregation, over the time in minutes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure m6. Effect of apyrase, fibrinogen or Clopidogrel in washed platelets preparations 
from wild type mice used for in vitro aggregation. (A) Platelet aggregation induced in washed 
platelets by 10µM U46619 in the absence (blue traces) or in the presence of 0.2U/ml (black traces) 
of Apyrase. (B) ADP-induced aggregation in washed platelets requires the presence of fibrinogen. 
Without adding fibrinogen ADP fails to induce aggregation in a concentration of 10µM (blue) or 
20µM (orange); when fibrinogen (70µg/ml) was added 10µM ADP induced aggregation (black). (C) 
Platelets from mice pre-treated with Clopidogrel (o.p. 5mg/kg/day over 2 days) in blue, from mice 
receiving only vehicle (DSMO 1% and NaCl 0.009% in a 5% Saccharose solution) in gray or 
without any pre-treatment in black. The aggregation was induced by 10µM ADP (left panel) or by 
thrombin 0.1U/ml (right panel). There is no change in the aggregation compared between vehicle 
and non pre-treated mice. The arrows indicate the time of the agonist addition. 
 
 
 
Around 20 min before starting the measurements the aggregometer was turned on 
because it was required to be pre-warmed at 37.4°C for automatic calibration of the 
channels (without measuring cuvettes). Every channel was calibrated separately with a 
cuvette containing 200µl of platelet poor plasma (PPP) or 1X Platelet’s Buffer depending if 
the experiments were done with platelet rich plasma or washed platelets, respectively. 
This calibration value was automatically set as equivalent to the maximum possible 
aggregation value (100% aggregation). Subsequently, four samples, two per genotype, 
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consisting each in 190µl platelets suspension were placed inside the measuring spaces 
and the basal value (0% aggregation) was set. Measurements were started with a time lag 
of ~8s between channels and a base line was recorded for 90s without stimulation. After 
the time point of 90s an aliquot of 10µl from the agonist was added to the platelet 
suspension of each channel and the aggregation was recorded up to 800s in case of 
Collagen, Thrombin or the TxA2 analogue U46619 stimulation, and up to 600 for ADP 
stimulation.  
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Figure m7. Turbidimetric aggregometry. The platelet suspension before stimulation (1) presents 
a high optical density (OD) which is set as the baseline level of aggregation (0%). After the addition 
of an agonist the platelets aggregate leading to a reduction in the optical density of the suspension 
(2) until the aggregation is completed (3). The maximum aggregation (100%) reference is given by 
the resuspension buffer in case of WP or by the platelet poor plasma in case of PRP analysis. The 
inset shows the usual way to represent the aggregation curve (Modified from Jarvis, 2004). 
 
 
All agonists were solved in sterile NaCl (0.9%) and were stored below -20°C. Only freshly 
thawed aliquots were used for every day of experiments. ADP-induced aggregation in 
washed platelets was done in the presence of human fibrinogen because, similar to 
experiments performed with washed platelets from humans (Park and Hourani, 1999) and 
mice (Varga-Szabo et al., 2008a), I observed no aggregation by adding ADP in washed 
platelet preparations from mice (Figure m6, B). The final fibrinogen concentration was 
70µg/ml; 4µl from a fibrinogen solution (35mg/ml in 0.9% NaCl, sterile filtered) were added 
to each platelet sample around 4min before starting the aggregation experiments.  
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4.3.5 Platelet aggregation in platelets from mice pre-treated with Clopidogrel 
 
To distinguish the aggregation response mediated by the two different ADP receptors 
expressed in mouse platelets (P2Y1 and P2Y12) Clopidogrel was used to selectively block 
P2Y12 receptors. 24h and 2h before blood collection the mice received Clopidogrel orally 
(o.p.) at a dose of 5mg/kg (Savi et al., 1992) and at a volume of 10µl/g body weight. For 
peroral administration a curved reusable gavage feeding needle (PS/18, No.18061-50; 
F.S.T., Germany) was used. Clopidogrel was solved with DMSO to a concentration of 
50mg/ml (stock solution kept at 4°C) and subsequently solved 1:1 with sterile saline 
(0.9%) solution to a concentration of 25mg/ml, this second dilution was made shortly 
before application to the mice. Saccharose 5% (w/v) solved in tap water was used as 
vehicle. The sweet water was used to avoid rejection and regurgitation of the drug by the 
mice and this was confirmed by the constant observation of the mice during the 15min 
subsequent to drug administration. In the first experiments with Clopidogrel a group of 
vehicle treated mice receiving the same proportion of DMSO and 0.9% NaCl was included 
(Figure m6, C). Because there was no obvious inhibition of platelet aggregation by these 
vehicle substances this vehicle control treatment was omitted later on. Preparation of 
washed platelets from Clopidogrel treated mice for in vitro aggregation experiments were 
performed as described (see 4.3.4).  
 
 
4.3.6 RNA isolation from mouse platelets and RT-PCR 
 
Total platelet RNA was extracted from washed platelet preparations. After a final washing 
step when platelets were resuspended in 1X Platelet’s Buffer and counted, the cells were 
washed again 2 times with sterile and Ca2+/Mg2+ free DPBS. Briefly, the platelets were 
pelleted by centrifugation during 5min at 1000G and the supernatant was discarded, the 
platelets were resuspended into 2ml DPBS and were transferred into a sterile 2ml reaction 
tube where a second washing step with DPBS was performed. Finally, the pellet was 
obtained by centrifuging for 10min at 1200G into a microcentrifuge and it was 
resuspended in 300µl RTL Buffer provided with the RNA isolation kit. Cells were lysed by 
30s shaking with the vortex. The samples were kept on ice if the total RNA isolation was 
made immediately or were kept at -80°C until RNA was extracted.  
 
For extraction of total RNA the RNeasy Micro Kit (Qiagen) was used like for cardiac cells 
(see 4.2.7) and 6x107 to 1x109 platelets were used in each RNA extraction column. RNA 
was eluted two times in 41µl RNase-free water included in the kit. The RT-PCR from the 
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platelets was done also using the one step kit (Super ScriptTM, Invitrogen) in 50µl final 
reaction volume, and between 20 to 60ng total RNA were used per RT-PCR reaction. The 
RT-PCR and electrophoresis conditions were the same mentioned already and total RNA 
from brain was used as positive control and the elution water as negative control.  
 
 
4.3.7 Fluorescence-activated cell sorting (FACS) of mouse platelets  
 
The sorting of mouse platelets was done with P.D Dr. Stephan Philipp from our 
Department and it was made as second Spezialpraktika from the GK 1326 (“Fluorescence 
Activated Cell Sorting (FACS) of mouse platelets for further expression analysis of TRPC 
channels”). This method served to sort platelets for RT-PCR analysis and also to evaluate 
the purity of the washed platelet preparation used for aggregometry and expression 
analysis.  
 
Washed platelets were prepared as described using 2 to 3 mice, but 1X Platelet’s Buffer 
without CaCl2 was used during the platelet isolation. Platelet concentration was adjusted 
to 1x108 platelets per ml and the cells were allowed to recover for 30min at 37°C before 
starting the experiments. An aliquot of 100µl (1x107 platelets) was transferred into a 2ml 
sterile tube and 5µl from a monoclonal FITC-labeled antibody against mouse αIIbβ3 
integrin (CD41/CD61) (Clone Leo.F2, emfret analytics, Germany) and 400µl of Platelet’s 
Buffer containing 1mM CaCl2 were added. The suspension was incubated at RT for 15 
minutes in the dark and after the labeled cells were placed into ice and protected from the 
light until the sorting.  
 
The cell sorting was done using a MoFlo fluorescence-associated cell sorter (Dako 
Cytomation Beckman Coulter, Germany) using a 488nm argon laser beam for excitation. 
After calibration of the sorting machine an aliquot of the non stained platelets was used to 
characterize the cell population using the forward scatter (FSC) and side scatter (SSC). 
Then, the stained platelets were compared to non stained platelets with respect to FSC, 
SSC and to the FITC fluorescence. A right shift of the FITC fluorescence was observed in 
the stained platelet samples. Finally the cells were sorted directly into PCR tubes in 
groups of 50, 200, 500 and 2000 per tube. When one 96-PCR rack was completed, this 
one was placed under a flow bench and the PCR tubes were rapidly closed to prevent 
sample evaporation. The tubes were transferred into dry ice and they were stored at 
minus 80°C. The RT-PCR was done using freshly thawed platelets and a one step kit 
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(Super ScriptTM, Invitrogen) in 25µl final reaction volume. The RT-PCR primers and 
conditions were the same used for cardiac cells (Table m2). 
 
 
4.3.8 Western blot from mouse isolated platelets 
 
For isolation of protein fractions from platelets the blood from 4-6 mice was pooled and 
washed platelets were obtained as described. In addition to the procedure mentioned 
before, platelets were washed two times with sterile warm (37°C) DPBS (Ca2+/Mg2+ free) 
supplemented with Heparin (10U/ml final concentration). To wash the platelets a cell pellet 
was obtained by centrifugation (1000G/5min) and the cells were resuspended in 2ml 
DPBS (5µl/ml from a 0.1mM PGI2 solution were added) the suspension was incubated 
5min at 37°C, PGI2 was added again (5µl/ml) and the cells were pelleted once more and 
resuspended in DPBS in the presence of PGI2 (5µl/ml). Finally, the cells were incubated 5 
minutes (37°C), a 5µl aliquot was taken to count the cells and the DPBS was removed by 
centrifugation. The pellet was kept on ice and the cells were homogenized with RIPA 
Lysis Buffer containing protease inhibitors (added before use); this material was used for 
expression analysis by western blots. Western blots were performed with help from 
Christine Wesely (AG Prof. Flockerzi) and home-made rabbit polyclonal antibodies 
against TRPC1 (unpublished), TRPC3 (unpublished), TRPC4 (Freichel et al., 2001), 
TRPC5 (unpublished), TRPC6 (Tsvilovskyy et al., 2009) and TRPM4 proteins (Mathar et 
al., 2010) were used. 
 
 
4.4 Data analysis  
 
The graphs presented in this work were made with Origin v7.0220 and v8.1.13.88 
(OriginLab Corporation, USA). Inside the graphs error bars represent the Standard Error 
of the Mean (SEM). In case of data presented in tables or numbers inside text, bars or 
graphs the Standard Deviation (SD) was included. Statistical significances were depicted 
as *p<0.05; **p<0.01, ***p<0.001 and ns (not significant). Descriptive statistical values 
such as mean value, median, SEM and SD were calculated with Microsoft Office Excel 
(Office 2003, Microsoft Corporation) or with Origin. Other descriptive statistics like 
frequency count were done only with Origin. Specific data analysis procedures used are 
described under each topic (i.e. cardiac fibrosis).  
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For statistical analysis comparing mean values from two independent group, for example, 
comparison between maximal aggregation from WT and KO, the two samples 
independent Student’s t-test was used. In some cases like comparing the weight before 
and after cardiac hypertrophy induction from the same group, the two-sample paired t-
tests were computed. These tests and the probability values (p or p-value) were obtained 
either with Excel or with Origin and were made after determining if the data from the 
samples followed a normal distribution. The normality was tested with the Shapiro-Wilk 
Normality Test from Origin and assumed normal when the p-value was lower than 0.05. 
 
When comparing three or more group mean values, for example aggregation from 
platelets from Clopidogrel pre-treated mice or cardiac hypertrophy indexes, the one-way 
analysis of variance (ANOVA) was used after testing if the data were normally distributed. 
One-way ANOVA calculations were made in Origin and within the calculation the Levene’s 
test for equal variance was computed because one-way analysis of variance assumes 
that the sample data sets have been drawn from populations that follow a normal 
distribution with constant variance. In addition, the computations for actual power of the 
tests were done to assess the probability of successfully rejecting the null hypothesis (no 
difference between the mean values). When there were significant differences (p<0.05) 
the Bonferroni post hoc mean comparisons were calculated also with Origin.  
 
In addition to the one-way ANOVA when data from cardiac hypertrophy indexes from wild-
type and knockout groups (HW/BW, HW/TL and others) were compared the two-way 
ANOVA (in Origin) was used because strictly some of these experiments followed an 
experimental design with two factors (variables) and each one had two levels. One factor 
was the genotype of the mice subdivided in two levels, WT and KO; the second factor was 
the treatment also with two levels, control treatment (saline) or treatment (Iso or ATII). 
With the Two-way ANOVA was tested if there were significant differences between the 
variables level means within a factor and the interactions between the factors. Also 
computations for Bonferroni post hoc means comparisons and for actual power were 
performed.  
 
When the data did not follow a normal distribution the non-parametric statistic analysis 
Kruskal-Wallis was used to compare the results from the analyzed groups and the 
calculation were done manually. Briefly, all the data were organized from the smaller to 
the higher value and then were ranked with consecutive numbers starting from 1 up to n. 
Next, the rank sum (Ai) for each group (A1, A2, A3…Aith) and the average rank for each 
group (Āi= Ai/ni) were computed. After that it was calculated the sum of squared deviations 
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between each sample group’s average rank and the overall average rank, weighted by the 
sizes of the group. This calculation is a measure of variability between the observations 
and what it is expected if the hypothesis of no treatment effect is true; the equation used 
for this sum was: 
 
  D= n1(Ā1- Ā)2 + n2(Ā2- Ā)2 +… ni(Āi- Ā)2 
 
Where, n1 refers to the number of observations of the ith group and Ā is the average rank 
of all the observations (N= n1+n2+…ni) and was equal to (N+1)/2. The value D was used 
to compute the Kruskal-Wallis test statistic H as follows: 
 
  H= D/(N(N+1)/12) 
 
The null hypothesis of no difference between the mean values of the groups was rejected 
when the calculated H value was higher then the corresponding value with k-1 degrees of 
freedom from critical values for the X2 distribution, where k was the number of treatment 
groups. When there were significant differences between the means from the treatments 
the non-parametric multiple comparisons were done with the Dunn’s test. For each pair of 
comparisons the Q value was calculated:  
 
  Q= (Ā1 - Ā2)/ √((N(N+1)/12) (1/n1 + 1/n2)) 
 
Finally Q values were compared with the critical values of Q for nonparametric multiple 
comparison testing (Glantz, 2005) and the null hypothesis was rejected or accepted.  
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5. Results 
 
5.1 Cardiac hypertrophy in TRPC deficient mice 
 
5.1.1 Characterization of protocols for Isoproterenol- and Angiotensin II-induced 
cardiac hypertrophy in wild type mice 
 
The neurohumorally induced cardiac hypertrophy was selected as method to test the role 
of TRPC channels for cardiac remodeling. Cardiac hypertrophy induction was done by 
chronic infusion of two different substances, the β-adrenergic agonist Isoproterenol (Iso) 
or the AT1 receptor agonist angiotensin II (ATII). Both agonists were delivered into mice 
via micro-osmotic pumps. Isoproterenol was mainly given at a dose of 30mg/kg/day over 7 
days (referred as Iso-30) but in one series of experiments it was tested a dose of 
8.7mg/kg/day over 7 days. ATII was used in two doses, a pressor dose of 3mg/kg/day 
over 14 days (ATII-3) and a lower dose of 0.3mg/kg/day over 14 day (ATII-0.3).  
 
Before it could be quantified whether the development of cardiac hypertrophy might be 
changed in TRPC knockout (KO) mice it was required to establish a reliable cardiac 
hypertrophy induction protocol and all related analysis steps. The protocol was 
established first in wild type (WT) mice from the first generation offspring between 
C57Bl6/N and 129SvJ mice because these mice have a genetic background that could be 
used as control for the TRPC deficient mouse lines available in our laboratory. The main 
readout of the initial experiments of neurohumoral induced hypertrophy in WT mice 
(Figure 1) were hypertrophy indexes such as heart weight/body weight (HW/BW) or heart 
weight/tibia length (HW/TL) ratios (Figure 1, Aa and Ba). The related percentage of 
increase of each index in relation to saline treated control mice were determined (Figure 
1, Ab and Bb). From these data the Iso-induced increase in HW/BW was 20.25 ±8.41% 
(p<0.001), in the ATII-0.3 group the increment was 10.03 ±6.80% (p<0.001) and in the 
ATII-3 the increase was 38.12 ±15.49% (p<0.001). The increments in HW/TL were 26.89 
±9.30% (p<0.001) for the Iso group, 10.98 ±4.96% (p<0.001) for ATII-0.3 and 17.25 
±13.71% (p<0.001) for ATII-3. The variability in HW/BW and HW/TL was higher in the 
ATII-3-treated mice compared to those treated with Iso-30 or only saline as shown in the 
frequency distribution from both indexes (Figure 1, C and D).  
 
Weight from lungs and liver were determined too as well as the corresponding values 
normalized to body weight or tibia length and the water content from both organs. An 
increase in lung weight ratios or in lung water content can be indicatory of left ventricular 
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malfunction that ends into pulmonary congestion. In addition, liver weight ratios or the liver 
water content can be increased when right ventricular function is significantly impaired. 
Lung weight/body weight ratio (LW/BW) was increased in mice treated with ATII-3 (Figure 
1, Ea) which is due to the fact that the ATII-3 dose led to weight loss (Figure 1, I) and not 
to water accumulation in lungs from mice treated with this ATII dose (Figure 1, G). Lung 
weight/tibia length ratio (LW/TL) was increased in Iso-treated mice (Figure 1, Eb). This 
increase was not due to an increment in lung water content caused by Iso-30 (Figure 1, 
G) and it was not evident with the LW/BW index probably because Iso-30 treatment 
produced a significant increase in body weight (Figure 1, I). ATII-3 treatment led to a 
significant increment of liver weight/body weight ratio (LivW/BW) but not of liver 
weight/tibia length ratio (LivW/TL), most likely due to weight loss caused by ATII-3 
treatment instead of changes in right ventricular function (Figure 1, Fa). Liver water 
content was slightly increased only in mice that received the ATII-3 dose (Figure 1, H).  
 
Because the body weight was an important parameter used to normalize organ weights 
and to know the effect of each protocol on it, mice were weighed before and at the end of 
cardiac hypertrophy induction and the change in body weight was calculated (Figure 1, I). 
Saline treatment alone induced minor and not significant increments in body weight after 7 
(2.29 ±4.64%) or 14 days (3.81 ±5.10%) of infusion. In contrast, isoproterenol led to a 
9.84 ±4.70% increase in body weight that was significantly different (p<0.001) to saline 
treated mice, and ATII-3mg led to a significant (p<0.001) decrease in body weight of 13.70 
±6.77%. ATII-0.3mg treated mice showed a similar weight gain (3.97 ±4.06%) as saline 
treated mice.  
 
Tibia length was not affected by any neurohumoral treatment in comparison to saline 
treatment (saline: 17.48 ±0.43mm; Iso-30: 17.45 ±0.50mm; ATII-0.3: 17.50 ±0.21mm, and 
ATII-3: 17.50 ±0.41mm). Therefore, values normalized to body weight reflected more a 
systemic effect of the treatment and those values normalized to tibia length reflected 
changes in a determined organ.  
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(filled bars) hypertrophy induction and the percentage of change in body weight (b) are presented. 
BW: body weight, HW: heart weight, TL: tibia length, LW: lung weight, LivW: Liver weight, n=: 
number of mice. Error bars indicate SEM. *p<0.05, **p<0.01 and ***p<0.001 according to 
Bonferroni comparisons (A-H) or the paired Student’s t-test (I). 
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Figure 1. Neurohumoral-induced cardiac hypertrophy in wild type mice. Cardiac hypertroph
induced by infusion of Isoproterenol (Iso) at a dose of 30mg/kg/day (7 days) or angiotensin II (ATII)
at doses of 3mg/kg/day or 0.3mg/kg/day over 14 days. Cardiac hypertrophy was evaluated using
(A) HW/BW index (a) and corresponding percentage of increase (b); (B) HW/TL (a) an
corresponding percentage of increase (b); frequency distribution of (C) HW/BW and (D) HW/T
indexes. In addition, weight of lungs (E) and liver (F) normalized to BW (a) or TL (b) and the wate
content from both organs (G-H) were evaluated. (I) Body weight (a) before (hatched bars) and after
(B) (D)
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(F) (H)
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Induction of cardiac hypertrophy with neurohumoral agents implies a complex effect on 
different organ systems and its development is mediated by other organs beyond the 
heart itself. In addition to cardiac hypertrophy indexes I measured with Ilka Mathar the 
effects of Iso-30 or ATII-3 on blood pressure from conscious mice because cardiac 
hypertrophy development can be mediated by changes in blood pressure. Wild type mice 
were implanted with telemetric blood pressure transmitters and after 7 days of recovery 
from the transmitter implantation basal mean arterial blood pressure (MAP) was 
continuously recorded during one week. Afterwards, micro-osmotic pumps were implanted 
and MAP was recorded until the end of the infusion. Isoproterenol led to a significant 
increase in MAP after two days of pump implantation (Figure 2, A and C). When the mean 
values before and during isoproterenol infusion were compared (Figure 2, E) no significant 
increment (p=0.13138) in blood pressure was identified by Iso infusion in this time period 
of seven days despite parameters for cardiac size increased significantly (Figure 1, A and 
B). On the other hand, ATII-3mg produced an immediate and significant rise in MAP that 
increased day by day until the end of the infusion on day 14th (Figure 2, B and D); the 
mean elevation of MAP produced by ATII during the complete period of treatment was 
44.9mmHg compared to basal values (Figure 2, E).  
 
To further characterize the hypertrophy protocol and in addition to hypertrophy indexes 
and blood pressure I analyzed the heart rate from both, telemetric blood pressure 
recordings and from ECG recordings at the day 6th of Iso infusion or day 13th of ATII 
infusion. From telemetric recordings we observed that during Iso-30 treatment the heart 
rate was significantly increased by about 143BPM, and during ATII-3 infusion the heart 
rate was also significantly increased by about 37BPM (Figure 2, F). From ECG recordings 
I observed that isoproterenol treated mice had a significantly (p<0.001) higher heart rate 
of 636 ±46BPM (n=41) compared to 486 ±31BPM (n=16) from saline treated mice. ATII-
3mg produced a significant (p<0.01) elevation of heart rate (530 ±58BPM, n=26) 
compared to the saline infused mice (486 ±42BPM, n=20) despite was expected a 
reflectory bradycardia as response to the increment of MAP produced by ATII-3. Possibly, 
this was not observed because the ECG recordings were obtained under anesthesia. 
However, from the telemetric recordings we observed a reflectory bradycardia but only 
during the first two days of ATII-3mg infusion and the subsequent days the heart rate 
increased. ATII-0.3 dose did not affect significantly the heart rate (518 ±58BPM, n=12) 
(p=0.05783). 
 
 
 
 
Results  79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (C)
(B) (D)
-2 0 2 4 6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effects of isoproterenol or ATII on blood pressure during cardiac hypertrophy 
induction. Mean arterial blood pressure (MAP) from conscious wild type mice before and during 
(A) Iso or (B) ATII treatment; day 1 corresponds to time point of osmotic pump implantation. The 
daily percentage of increase in MAP calculated relative to mean value before pump implantation is 
presented for (C) isoproterenol and (D) ATII treatments. Mean values from (E) MAP and (F) heart 
rate (F) before and during the isoproterenol (left panels) or ATII (right panels) treatments are 
shown. Basal mean blood pressure was calculated from measurements during 4 days before 
osmotic pump implantation. Mean MAP during Iso treatment was calculated from all days omitting 
the one were the osmotic pumps were implanted. Mean MAP during ATII infusion was calculated 
from all days of treatment. Iso was infused at a dose of 30mg/kg/day over 7 days and ATII at a 
dose of 3mg/kg/day during 14 days. ATII: angiotensin II, Iso: isoproterenol, n=: number of mice. 
Error bars indicate SEM. *p<0.05, **p<0.01 and ***p<0.001 according to the Student’s t-test for 
paired samples. 
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5.1.2 Neurohumoral-induced cardiac hypertrophy in TRPC3/TRPC6 (-/-)2 mice 
 
Using RNA isolated from mouse cardiac cells I amplified transcripts from TRPC3 and 
TRPC6 (Figure 3, A). In addition, TRPC6 proteins of a size of ~120 kiloDaltons (kDa)  
were detected by western blot analysis (made in collaboration with C. Wesely and Prof. V 
Flockerzi) with an antibody against a C-terminal fragment of TRPC6 (Tsvilovskyy et al., 
2009) in heart preparations from wild type mice but not from TRPC6 deficient mice (Figure 
3, B). 
 
Isoproterenol-induced hypertrophy. Analysis of HW/BW and HW/TL indexes (Figure 3, 
Ca and Cb) revealed a significant isoproterenol effect (p<0.001, two-way ANOVA) but no 
differences due to genotype, which implies no reduction in the isoproterenol-induced 
cardiac hypertrophy in TRPC3/TRPC6 (-/-)2 mice. Analysis of LW/TL and LivW/TL indexes 
and the water content in lungs and liver (Figure 3, D) revealed no difference between wild 
type and TRPC3/TRPC6 (-/-)2 mice. 
 
ATII treatment. In experiments using the ATII-3 dose only 43% of TRPC3/TRPC6 (-/-)2 
mice survived until the end of the treatment whereas 86% of the ATII-treated wild type 
mice survived (Figure 3, E). The wild type survival rate calculated from all the experiments 
that I did during my thesis was 97%. In the surviving mice no difference was found in 
HW/BW or in water content from lungs and liver between genotypes (Figure 3, F). 
Statistical analysis of HW/TL index showed significant differences due to genotype 
(p<0.001) and the values were 8.93 ±0.34mg/mm for WT-saline, 9.91 ±0.53mg/mm for 
WT-ATII-3, 7.43 ±0.33mg/mm for TRPC3/TRPC6 (-/-)2-saline and 8.76 ±0.4mg/mm for 
TRPC3/TRPC6 (-/-)2-ATII-3, the difference between genotypes in this index could be 
explained because of reduced values observed in TRPC3/TRPC6 (-/-)2 mice. However no 
reduction in percentual increases of HW/TL between WT and TRPC3/TRPC6 (-/-)2 mice 
was observed (p<0.24409). Still the number of mice was quite low in this experimental 
series due to the mortality. 
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Figure 3. No reduction in cardiac hypertrophy response in TRPC3/TRPC6 (-/-)2 mice after 
isoproterenol or angiotensin II treatment. (A) TRPC3 and TRPC6 transcripts from cardiac cells 
obtained by Langendorff perfusion. Products were amplified using intron spanning oligonucleotides 
as primers and single step RT-PCR amplification kit. Total RNA from brain (Br) was used as 
positive control and RNA free water was used as negative one. (B) Western blot with anti-TRPC6 
using microsomal membrane protein fractions from WT (+/+) and TRPC6 deficient (-/-) mice. (C) 
HW/BW (a) and HW/TL (b) indexes from WT and TRPC3/TRPC6 (-/-)2 mice after Iso-30 treatment 
(D) LW/TL (a), LivW/TL (b) and water content in lungs or liver (c) after Iso treatment. (E-F) ATII-
induced cardiac hypertrophy in TRPC3/TRPC6 deficient mice. (E) Survival curve of ATII-3 treated 
WT and TRPC3/TRPC6 (-/-)2 mice compared to saline (sal) treated mice of both genotypes. (F) 
HW/BW (a) and water content in lungs and liver (b) after ATII-3 treatment were analyzed. kDa: 
kiloDalton, BW: body weight, HW: heart weight, TL: tibia length, LW: lung weight, LivW: Liver 
weight, n=: number of mice. KO: knockout. Error bars indicate SEM. **p<0.01 and ***p<0.001 and 
ns (not significant) according to Bonferroni comparisons. 
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Because the high mortality triggered by ATII-3mg in TRPC3/TRPC6 (-/-)2 mice I used a 
lower dose of ATII-0.3 to induce cardiac hypertrophy in these mice. No ATII-0.3 treated 
WT or TRPC3/TRPC6 (-/-)2 mice die during the two independent performed experimental 
series. HW/BW and HW/TL indexes were not reduced in TRPC3/TRPC6 (-/-)2 mice 
compared to wild type mice (Figure 4, Aa-b and Ba-b). The percentual increase for both 
indexes was not reduced rather increased in TRPC3/TRPC6 deficient mice (Figure 4, Ac 
and Bc). However the differences in the hypertrophy indexes were not observed between 
saline treated WT and TRPC3/TRPC6 (-/-)2 mice in this study using AT-0.3 (Figure 3C). 
Analysis of LW/TL, LivW/TL and water content in lungs and liver showed no evidence of 
pulmonary or liver congestion in WT or TRPC3/TRPC6 (-/-)2 mice (Figure 4, C). In 
addition, direct measurements of left ventricular function were obtained with a Mikro-Tip 
catheter under Isoflurane anesthesia but no differences were detected in parameters such 
as maximum pressure, change in pressure over time (dP/dt), contractility, exponential 
time constant of relaxation (τ) and pressure time index. Only a lower heart rate was 
observed in ATII treated TRPC3/TRPC6 (-/-)2 mice  compared to wild type (Table 1). 
 
 
 
Table 1. No differences in left ventricular pressure in TRPC3/TRPC6 (-/-)2 mice at the end of 
treatment with a low dose of angiotensin II. 
The following parameters at the end of ATII-0.3 treatment were obtained: heart rate; maximum 
(Max) pressure; maximum change in pressure during systole (Max dP/dt); contractility index 
defined as the quotient of the Max dP/dt divided by the pressure on the time of Max dP/dt; 
exponential time constant of relaxation Tau (τ); and pressure time index or tension time index 
determined as the product between the average ventricular pressure during systole and the systolic 
duration. SD: Standard deviation; p: probability values from the Student’s t-test; n= number of mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype/treatment Heart Rate (BPM)
Max 
Pressure 
(mmHg)
Max dP/dt 
(mmHg/s)
Contractility 
Index (1/s) τ (s)
Pressure 
Time Index 
(mmHg.s)
129B6F1/saline (n=4) Mean 554.79 76.33 3979.34 135.11 0.0134 2.70
SD 13.70 6.20 389.24 6.87 0.0010 0.27
129B6F1/ATII (n=10) Mean 513.51 81.78 3807.6 119.74 0.0149 3.11
SD 39.44 6.08 653.63 6.56 0.0013 0.67
TRPC3/C6 (-/-)2/saline (n=5) Mean 459.36 83.39 4105.6 135.49 0.0142 3,32
SD 61.53 13.27 516.05 28.35 0.0019 0.56
TRPC3/C6 (-/-)2/ATII (n=6) Mean 466.62 94.42 4610.58 126.57 0.0164 3.94
SD 47.34 17.91 1153.81 20.89 0.0040 0.88
Comparison ATII treatments t-test (p) 0.01986 0.36316 0.69833 0.98012 0.46777 0.08426
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Figure 4. No reduction in cardiac hypertrophy response in TRPC3/TRPC6 (-/-)2 mice after 
treatment with a low dose of angiotensin II. After ATII-0.3 treatment TRPC3/TRPC6(-/-)2 mice 
did not show a reduction in the hypertrophic response compared to WT mice analyzed by: (A) 
HW/BW (a and b) and its percentual increase (c); (B) HW/TL (a and b) and its percentual increase 
(c); and (C) LW (a) and LivW (b) both normalized to TL, and water content from both organs (c). 
BW: body weight, HW: heart weight, TL: tibia length, LW: lung weight, LivW: Liver weight, n=: 
number of mice. Error bars indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) 
according to Bonferroni comparisons. 
 
 
5.1.3 Reduced neurohumoral-induced cardiac hypertrophy in TRPC1/TRPC4 (-/-)2 
mice  
 
Northern blot analysis revealed abundant expression of TRPC1 and possibly expression 
of TRPC4 transcripts (Freichel et al., 2004). The expression of TRPC1 and TRPC4 
transcripts was confirmed by RT-PCR using total RNA from cardiac cells (Figure 6, A).  
 
Isoproterenol-induced hypertrophy. Based on the expression data I made a pilot 
experiment to induce cardiac hypertrophy in TRPC1/TRPC4 (-/-)2 mice. Mice were 
subjected to isoproterenol infusion at a dose of 60mg/kg/day during 7 days. Evaluation of 
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HW/BW and HW/TL revealed a significant reduction in cardiac hypertrophy development 
in TRPC1/TRPC4 (-/-)2 mice (Figure 5, A and B), but no differences in LW/TL ratio were 
observed (Figure 5, C).  
 
 
Figure 5. Pilot experiment showed a reduced cardiac hypertrophy development in 
TRPC1/TRPC4 (-/-)2 after isoproterenol treatment. Evaluation of (A) HW/BW, (B) HW/TL and (C) 
LW/TL in WT (black) and TRPC1/TRPC4 (-/-)2 mice (red) after isoproterenol infusion (60mg/kg/day) 
during 7 days. BW: body weight, HW: heart weight, TL: tibia length, LW: lung weight, n=: number of 
mice. Error bars indicate SEM. **p<0.01 and ns according to the Student’s t-test. 
 
 
Isoproterenol treatment. Effects on heart weight. All following experiments of 
isoproterenol induced hypertrophy were done using the Iso-30 dose (30mg/kg/day) 
because this dose is reported by many other groups in the literature and allows better 
comparison afterwards. After Iso-30 treatment there was also an obvious macroscopic 
increase in heart size in the wild type group and this hypertrophic response was also 
reduced in TRPC1/C4 knockout mice (Figure 6, B). Statistical analysis of HW/BW showed 
both, a significant isoproterenol effect (p<0.001) and a significant genotype effect 
(p<0.05). Also the percentual change in HW/BW was significantly reduced (p<0.05) in 
TRPC1/TRPC4 (-/-)2 mice by about 40% (Figure 6, C). No differences in body weight 
between treatments (WT-Iso= 29.78 ±1.94g and TRPC1/TRPC4 (-/-)2-Iso= 29.59 ±2.60g; 
p=0.14808) or in the percentual change in body weight (WT-Iso= 7.67 ±2.92% and 
TRPC1/TRPC4 (-/-)2-Iso= 6.69 ±3.75%; p=0.40199) were observed. Similarly, the HW/TL 
index was reduced significantly by ~27% in TRPC1/TRPC4 (-/-)2 mice (Figure 6, Dc).  
 
Isoproterenol treatment. Effects on lung weight. Analysis of lung weight showed no 
significant differences in LW/BW index (Figure 6, Ea) due to isoproterenol (p=0.08943) or 
due to genotype (p=0.06138). From the analysis done with the LW/TL index (Figure 6, Eb) 
there was a significant effect of isoproterenol (p<0.001) on lung weight in WT that can not 
be attributed to an accumulation of water in the lungs because of the isoproterenol 
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treatment (Figure 6, Ec). In contrast, there was a difference in lung water content between 
genotypes being this value smaller in TRPC1/TRPC4 (-/-)2 mice (Figure 6, Ec).  
 
Isoproterenol treatment. Effects on liver weight. Isoproterenol had no significant effect 
on both LivW/TL (p=0.18008) and in the liver water content (Figure 6, Fb-c). It was 
remarkable that livers from TRPC1/TRPC4 deficient mice were smaller, either from 
absolute weight values or from values normalized to body weight (p<0.001) or to tibia 
length (p<0.001) independent of saline or isoproterenol treatment (Figure 6, Fa and b). 
 
Isoproterenol treatment. Effects on cardiomyocyte size. To asses changes in 
cardiomyocyte size after Iso-30 treatment the cross sectional area from transversally 
sectioned left ventricular cardiomyocytes was quantified (Figure 7, A). Comparison of WT 
and TRPC1/TRPC4 (-/-)2 mice treated either with saline or isoproterenol revealed a 
significant effect due to both, Iso-treatment (p<0.001) and to genotype (p<0.001). Also, a 
significant (p<0.001) reduction of 79% in the Iso-induced increase of cardiomyocyte cross 
sectional area was observed in TRPC1/TRPC4 (-/-)2 mice (Figure 7, B). This difference 
can be appreciated by contrasting the frequency distribution from the cross sectional area 
of wild type (Figure 7, Ca) with the one from TRPC1/TRPC4 deficient mice (Figure 7, Cb), 
or by comparing the relative cumulative frequency from both genotypes that shows a left 
shift in the cell area from the TRPC1/TRPC4 (-/-)2-iso treated group versus the WT-Iso 
treated group (Figure 7, Cc). 
 
Isoproterenol treatment. Effects on cardiac fibrosis. Isoproterenol-induced cardiac 
hypertrophy is not only associated with increment of cardiac mass or cardiomyocyte size, 
but also with changes in other cellular populations and tissue structure of the heart like an 
increase in collagen deposition by fibroblasts. Therefore the collagen content was 
measured in Sirius red stained cross heart sections from WT-saline, WT-Iso, 
TRPC1/TRPC4(-/-)2-saline and TRPC1/TRPC4(-/-)2-Iso treated mice (Figure 7, D). 
Isoproterenol generated a significant (p<0.001) increase of interstitial heart fibrosis in both 
genotypes, however, TRPC1/TRPC4 (-/-)2 mice responded in lesser extent compared with 
wild type mice (Figure 7, E).  
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Figure 6. TRPC1/TRPC4 (-/-)2 mice have reduced isoproterenol-induced cardiac hypertrophy. 
(A) TRPC1 and TRPC4 transcripts from cardiac cells isolated by Langerdorff perfusion. Total RNA 
from brain (Br) was used as positive control and RNA free water from the RNA isolation kit was 
used as negative control (neg). (B-F) Hypertrophy development after Iso-30 treatment. (B) 
Representative hearts from WT and TRPC1/TRPC4 (-/-)2. (C) HW/BW (a and b) and percentage of 
change in HW/BW weight relative to the corresponding saline group (c) from WT and 
TRPC1/TRPC4 (-/-)2 mice. (D) HW/TL (a and b) and percentage of change in HW/TL (c). (E-F) 
Evaluation of pulmonary or liver congestion. (E) LW/BW (a), LW/TL (b) and lung water content. (F) 
LivW/BW (a), LivW/TL (b) and liver water content. BW: body weight, HW: heart weight, TL: tibia 
length, LW: lung weight, LivW: Liver weight, n=: number of mice (pooled from three independent 
experiments). Error bars indicate SEM. **p<0.01, ***p<0.001 and ns (not significant) according to 
Bonferroni comparisons. 
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Figure 7. Isoproterenol-induced increase in cardiomyocyte size and in myocardial fibrosis 
are reduced in TRPC1/TRPC4 (-/-)2 mice. Histopathological analysis of Iso-30-induced cardiac 
hypertrophy. (A) Representative paraffin heart sections (5µm) from the left ventricle stained with 
Hematoxylin-Eosin; representative examples of analyzed cells are marked. (B-C) Statistical 
analysis of cardiomyocyte cross sectional area. (B) Comparison of cell areas normalized to the 
corresponding saline groups; the numbers represent number of mice and the number of cells (in 
parenthesis). (C) Relative frequency distribution (a-b) of the cell areas shown in B from saline and 
isoproterenol treated mice. In c, the relative cumulative frequency from the cross sectional area is 
shown. (D) Representative paraffin sections (5µm) from the left ventricle stained with Sirius red. (E) 
Analysis of cardiac fibrosis measured as the percentage of increase in Sirius red staining 
compared to the corresponding saline control; lower panel shows the dot plot with single values 
from each mouse. n= number of mice. Error bars indicate SEM. *p<0.05, **p<0.01 and ***p<0.001 
according to Bonferroni comparisons. 
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Analysis of cardiac hemodynamic functions. Measurements with the Millar tip catheter 
were carried out under two independent anesthetics, Avertin (2,2,2-tribromoethanol) or 
Isoflurane. Under Avertin, almost all calculated parameters, except for the exponential 
time constant of relaxation (τ), differed significantly in TRPC1/TRPC4 (-/-)2 mice. But, 
under Isoflurane anesthesia there were no differences. A possible explanation for this 
discrepancy is that the heart rate was different between the two genotypes under Avertin 
but not under isoflurane narcosis (Table 2).  
 
 
Table 2. Left ventricle pressure in TRPC1/TRPC4 (-/-)2 mice at the end of isoproterenol 
treatment. 
Hemodynamic Parameters obtained from mice under Avertin or isofluran anesthesia on the 7th day 
of Iso-30 treatment using a Millar catheter. The following parameters were measured: heart rate; 
maximum (Max) ventricular pressure; maximum change in pressure during systole (Max dP/dt); 
contractility index defined as the quotient of the Max dP/dt divided by the pressure on the time of 
Max dP/dt; exponential time constant of relaxation (τ); and pressure time index or tension time 
index determined as the product between the average ventricular pressure during systole and the 
systolic duration. SD: Standard deviation; p: probability values from the Student’s t-test; n= number 
of mice. 
 
 
Angiotensinogen plama levels. I observed that livers from TRPC1/TRPC4 (-/-)2 mice 
were considerably smaller compared to those from wild type mice (Figure 6, Fa-b). This 
observation was corroborated when the liver weight values of saline-treated mice from 
different experiments were analyzed together (Figure 8, inset). Angiotensinogen is 
produced and released into the circulation mainly by the liver and it is a substrate for 
renin, which can be increased by isoproterenol stimulation of the kidney. Therefore, 
angiotensinogen plasma levels were determined in untreated wild type and 
TRPC1/TRPC4 (-/-)2 mice, but they were not different (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
Genotype Heart Rate (BPM)
Max 
Pressure 
(mmHg)
Max dP/dt 
(mmHg/s)
Contractility 
Index (1/s) τ (s)
Pressure 
Time Index 
(mmHg.s)
129B6F1 (n=7) Mean 629.44 99.41 5317.77 144.00 0.012 3.23
Avertin SD 19.87 14.09 1037.02 22.62 0.002 0.058
TRPC1/C4 (-/-)2 (n=8) Mean 583.09 74.77 3698.76 116.58 0.013 2.48
Avertin SD 41.85 9.18 771.75 18.15 0.001 0.34
t-test 0.0193 0.0013 0.0043 0.0218 0.3415 0.0085
129B6F1 (n=9) Mean 533.92 78.46 3631.64 109.91 0.015 2.96
Isofluran SD 49.14 30256 581.84 12.55 0.002 0.23
TRPC1/C4 (-/-)2 (n=5) Mean 513.77 74.60 3290.31 103.31 0.018 3.11
Isofluran SD 48.17 2.99 222.48 13.40 0.002 0.39
t-test 0.4734 0.4937 0.2374 0.3752 0.0805 0.373
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Figure 8. Angiotensinogen plasma levels are not different in TRPC1/TRPC4 (-/-)2 mice 
despite the smaller liver size. Angiotensinogen plasma levels determined by a sandwich ELISA 
from wild type (black) and TRPC1/TRPC4 (-/-)2 (red). The right inset shows liver weight normalized 
to body weight (left bars) or tibia length (right bars). n= number of mice. Error bars indicate SEM. 
***p<0.001 and ns (not significant) according to the Student’s t-test. 
 
 
Regulation or renal renin secretion in TRPC1/TRPC4(-/-)2 mice. β-adrenergic 
stimulation by isoproterenol leads to renin secretion that could affect ATII plasma levels 
and subsequently cardiac hypertrophy development. In collaboration with Prof. Frank 
Schweda from Regensburg we observed in isolated kidneys that the isoproterenol-
induced renin production was not impaired in TRPC1/TRPC4 deficient mice; as well, the 
inhibition of renin secretion by ATII in both wild type and TRPC1/TRPC4(-/-)2 mice was 
similar.  
 
ATII-induced hypertrophy. The decreased hypertrophic response in TRPC1/TRPC4(-/-)2 
mice after isoproterenol treatment could be due to changes upstream or downstream of 
the ATII production. Therefore I induced cardiac hypertrophy in wild type and 
TRPC1/TRPC4 (-/-)2 mice with the ATII.  
 
ATII. Effects on cardiomyocyte size and cardiac fibrosis. The histopathological 
examination of cardiomyocyte cross sectional area from Hematoxylin-eosin stained heart 
sections (Figure 9, A) showed both, a significant ATII effect (p<0.0001) and a significant 
genotype effect (p<0.05). ATII-induced increase in cardiomyocyte area in TRPC1/TRPC4 
deficient mice was 71% less compared with ATII-treated wild type mice (Figure 9, B). 
Additionally, the relative collagen content was quantified from Sirius red stained heart 
sections (Figure 9, C). ATII treatment augmented significantly cardiac fibrosis (p<0.001) 
and the cardiac fibrosis development was significantly reduced in TRPC1/TRPC4 (-/-)2 
mice (Figure 9, D). 
 
 
 
 
 
 
 
 
 WT TRPC1/C4(-/-)2
0
500
1000
1500
2000
2500
3000
2917 ±3782949 ±390
A
ng
io
te
ns
in
og
en
 [n
g/
m
l] 
n=10 n=9
ns
A
ng
io
te
ns
in
og
en
 [n
g/
m
l] 
0
10
20
30
40
50
60
70
80
90
LivW/BW LivW/TL
0
10
20
30
40
50
60
70
80
90
***
LivW
(m
g)/TL(m
m
)Li
vW
(m
g)
/B
W
(g
)
n=19 n=17 n=19 n=17
***
LivW
(m
g)/TL(m
m
)Li
vW
(m
g)
/B
W
(g
)
Results  90 
 
Figure 9. TRPC1/TRPC4 (-/-)2 mice presented reduced angiotensin II-induced cardiac 
hypertrophy. Hypertrophy development after ATII-3 II treatment. (A) Representative paraffin heart 
sections (5µm) from the left ventricle. (B) Cardiomyocyte cross sectional area normalized to the 
corresponding saline group; numbers represent number of mice and number of cells (in 
parenthesis). (C) Representative paraffin sections (5µm) from the left ventricle. (D) Percentage of 
increase in Sirius red staining compared to the corresponding saline control. (E) HW/BW (a) and 
HW/TL (b). (F) LW/TL (a) and LivW/TL (b), and water content in lungs or liver (c). BW: body weight, 
HW: heart weight, TL: tibia length, LW: lung weight, LivW: Liver weight, n=: number of mice. Error 
bars indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to Bonferroni 
comparisons. 
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ATII. Effects on body weight and hypertophy indexes. No significant changes in body 
weight were observed in wild type (3.91 ±6.52%) or TRPC1/TRPC4 (-/-)2 (2.67 ±3.68%) 
mice treated with saline. ATII produced a significant reduction in body weight that was 
similar between both genotypes (WT: -13.47 ±5.23% and TRPC1/TRPC4 (-/-)2: -10.24 
±4.84%). HW/BW was significantly reduced in TRPC1/TRPC4 (-/-)2 mice after ATII 
treatment (Figure 9, Ea). This corresponds to a 28% reduced hypertrophy response in 
TRPC1/TRPC4 (-/-)2 mice. The HW/TL index revealed a significant effect of ATII 
(p<0.001) but no significant difference with respect to genotype (p=0.35432) although the 
average reduction in HW/TL was ~36% in TRPC1/TRPC4 (-/-)2 mice (Figure 9, Eb). 
Analysis of other indexes such as lung weigh/tibia length, liver weight/tibia length and 
water content of lungs or liver showed no differences between WT and TRPC1/TRPC4 
deficient mice and no differences caused by ATII treatment. Only the reduced liver size 
previously observed in TRPC1/TRPC4 (-/-)2 mice was confirmed (Figure 9, F).  
 
Isoproterenol treatment. Effects on heart rate and blood pressure. Heart rate was 
calculated from surface ECG recordings obtained under Isoflurane anesthesia and from 
telemetric blood pressure recordings. Analysis of surface ECG recordings under 
anesthesis at day 6 of isoproterenol infusion showed that HR was significantly increased 
in both wild type and TRPC1/TRPC4 deficient mice (p<0.001). The absolute heart rate 
and its increase were significantly reduced in TRPC1/TRPC4 (-/-)2 mice (Figure 10, A). 
 
HR measurement obtained from telemetric blood pressure recordings from WT and 
TRPC1/TRPC4 (-/-)2 conscious mice under isoproterenol treatment confirmed that the 
increase in HR produced by Iso-treatment is significantly reduced in TRPC1/TRPC4 (-/-)2 
mice (Figure 10, Bc). A similar small elevation in the mean arterial pressure in both 
genotypes was observed (Figure 10, B). Comparison of HW/BW and HW/TL from mice 
with blood pressure transmitters showed that TRPC1/TRPC4 (-/-)2 mice developed less 
cardiac hypertrophy (Figure 10, E and F). The increase in body weight was similar in both 
genotypes (Figure 10, D). There was no evidence of pulmonary or hepatic congestion and 
the reduced liver size in TRPC1/TRPC4 (-/-)2  mice was still evident (Figure 10, G).  
 
ATII treatment. Effects on heart rate.  ATII treatment (3mg/kg/day) produced a 
significant increase in heart rate (Figure 2, F). Therefore, I analyzed heart rate from 
surface EGCs obtained under anesthesia at the end of ATII-3 treatment. In WT mice heart 
rate was significantly increased. However, no significant increase was observed in 
TRPC1/TRPC4 (-/-)2 mice treated with ATII and treated with saline (Figure 10, H). 
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Figure 10. Heart rate and mean arterial pressure during isoproterenol infusion in 
TRPC1/TRPC4 (-/-)2 mice. TRPC1/TRPC4 (-/-)2 mice have reduced isoproterenol-induced 
increase in heart rate but no differences in MAP compared with wild-type control mice. (A) Mean 
values (a) dot plot (b) and percentual increase (c) of heart rate (HR) measured from surface ECG 
recordings on 6th day of Iso-30 treatment. (B, a) Mean arterial blood pressure (MAP) from 
conscious mice before and during isoproterenol treatment and (B, b) daily percentages of increase 
in MAP calculated from the mean value before pump implantation; day 1 corresponds to time point 
of osmotic pump implantation. (C) Daily percentage of increase in heart rate from conscious mice. 
From these mice (D) weight before and after isoproterenol treatment is presented as well as the 
cardiac hypertrophy indexes (E) HW/BW and (F) HW/TL and (G) liver weight normalized to body 
weight or tibia length. (H) Mean values (a) and percentual increase (c) of heart rate (HR) measured 
from surface ECG recordings at the end of ATII treatment. n= number of mice. Error bars indicate 
SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to the Student’s t-test. 
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Heart rate regulation in isolated right atria. To further examine the observed 
differences in regulation of heart rate between wild type and TRPC1/TRPC4 (-/-)2 mice 
during Iso-30 and ATII-3 treatments I analyzed the beating frequency of isolated 
spontaneously beating right atria to evaluate the regulation of the pacemaking activity in 
both genotypes.  I analyzed the effect of the β-adrenergic receptor agonist isoproterenol, 
the AT1 receptor agonist angiotensin II, the muscarinic receptor agonist Acetylcholine 
(Ach), and the α1-adrenergic receptor agonist Phenylephrine on atrial preparations. For all 
agonists cumulative concentration responses were performed and the absolute beating 
rate, the change in beating compared to basal beating rate and the percentual change in 
beating rate were analyzed. Right atria from TRPC1/TRPC4 deficient mice responded to 
the same extent as wild type atria to stimulation with isoproterenol and Acetylcholine 
(Figure 11, A and B). However, the response positive chronotropic response to ATII was 
reduced in atria from TRPC1/TRPC4 (-/-)2 mice in terms of absolute beating rate and 
beating rate normalized to basal level, but not when normalized to the maximal response 
(Figure 11, C). Similarly, the positive chronotropic response to Phenylephrine was 
significantly reduced in TRPC1/TRPC4 deficient atria in all three dose-response analysis 
(Figure 11, D).   
 
5.1.3.1 Isoproterenol-induced cardiac hypertrophy in TRPC1-/- and TRPC4-/- mice 
 
Reduced cardiac hypertrophy development in TRPC1/TRPC4 deficient mice after 
isoproterenol or angiotensin II treatment could be solely due to inactivation either of 
TRPC1 or TRPC4. Therefore I analyzed development of hypertrophy, in single TRPC1-/- 
and TRPC4-/- mice, by treatment with Iso-30 treatment and also ATII-3 (see section 
5.1.3.2). 
 
TRPC1 -/- mice. Iso-30 treatment had a significant effect (p<0.001) on both hypertrophy 
indexes, HW/BW and HW/TL from wild type and TRPC1-/- mice (Figure 12, A-B), but no 
reduction in the cardiac hypertrophy was observed in TRPC1-/- mice (Figure 12, A). 
Interestingly, the HW/TL ratio in TRPC1 deficient mice was increased compared to wild 
type mice (Figure 12, B). The percentual increase in HW/BW from TRPC1-/- mice (23.36 
±9.83%) was also significantly (p<0.05) higher compared to the increase produced in wild 
type mice (14.16 ±8.45%). However, the percentual increment produced in HW/TL from 
wild type mice (27.99 ±9.04%) was not different to the increment produced in TRPC1 
deficient mice (32.66 ±8.80%). There were no effects of isoproterenol treatment or 
differences between genotypes on lung weight/tibia length ratio (Figure 12, C) and on 
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water content in lungs or liver (Figure 12, E). Isoproterenol had no effect on liver 
weight/tibia length ratio (Figure 12, D). 
 
 
Figure 11. Reduced chronotropic response in isolated right atria from TRPC1/TRPC4 (-/-)2 
mice after ATII stimulation but not after Isoproterenol stimulation. Different dose-response 
curves from agonist-induced chronotropic effect on beating isolated right atria from wild type (black) 
and TRPC1/TRPC4 (-/-)2 (red) mice. The tested agonists were (A) isoproterenol, (B) Acetylcholine 
(ACh), (C) angiotensin II (ATII) or (D) Phenylephrine (PE). From each agonist the absolute values 
of beating rate (a panels), the change in beating rate normalized to the basal values (b panels) and 
the percentage of change in beating rate normalized to the maximum response (c panels) are 
shown. n= number of mice. Error bars indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns 
according to the Student’s t-test. 
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TRPC4 -/- mice. The effect of Iso-30 on HW/BW and HW/TL was significant (p<0.001) for 
both wild type and TRPC4-/- mice; comparisons of these two indexes between both 
genotypes showed no differences (Figure 13, A and B). Iso-30 produced a similar 
percentual increase in HW/BW in wild type (16.40 ±5.34%) and in TRPC4-/- mice (14.60 
±6.45%). Percentual increase of HW/TL in wild type (24.81 ±7.23%) and in TRPC4-/- mice 
(22.64 ±6.93%) were also comparable. In both animal groups isoproterenol had a similar 
effect on LW/TL, on LivW/TL and on water content from lungs and liver (Figure 13, C-E).   
 
 
Figure 12. Isoproterenol-induced cardiac hypertrophy is not reduced in TRPC1-/- mice. 
Cardiac hypertrophy induced in wild type and TRPC1 deficient mice by Iso-30 treatment. Cardiac 
hypertrophy indexes (A) HW/BW and (B) HW/TL were analyzed. Additionally, (C) LW/TL, (D) 
LivW/TL and (E) water content in lungs (a) and in liver (b) are included. BW: body weight, HW: 
heart weight, TL: tibia length, LW: lung weight, LivW: Liver weight, n= number of mice. Error bars 
indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to Bonferroni 
comparisons. 
 
 
 
5.1.3.2 Angiotensin II-induced cardiac hypertrophy in TRPC1-/- and TRPC4-/- mice 
 
TRPC1-/- mice. ATII-3 produced a significant increase (p<0.001) of both hypertrophy 
indexes HW/BW and HW/TL in a similar manner in wild type and TRPC1-/- mice (Figure 
14, A and B). No difference caused by ATII treatment or by genotype was observed on the 
LW/TL (Figure 14, C). ATII treatment reduced LivW/TL in both genotypes but had no 
influence on liver or lung water content (Figure 14, D-E).  
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Figure 13. Isoproterenol-induced cardiac hypertrophy is not reduced in TRPC4-/- mice. 
Cardiac hypertrophy induced in wild type and TRPC4 deficient mice by Iso-30 treatment. Cardiac 
hypertrophy indexes (A) HW/BW and (B) HW/TL were analyzed. Additionally, (C) LW/TL, (D) 
LivW/TL and (E) water content in lungs (a) and in liver (b) are included. BW: body weight, HW: 
heart weight, TL: tibia length, LW: lung weight, LivW: Liver weight, n= number of mice. Error bars 
indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to Bonferroni 
comparisons. 
 
 
 
TRPC4-/- mice. In experiments with TRPC4-/- mice ATII-3 treatment produced a 
significant (p<0.001) increase in HW/BW and HW/TL that was similar to the increase in 
wild type mice (Figure 15, A and B). LW/TL, LivW/TL and water content from lungs and 
liver were not different between genotypes (Figure 15, C-E). In this group ATII-3 treatment 
decreased LivW/TL index in TRPC4-/- mice (Figure 15, Eb). This was the only 
experimental case were a significant increase in water content in the liver was observed. 
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Figure 14. Angiotensin II-induced cardiac hypertrophy is not reduced in TRPC1-/- mice. 
Cardiac hypertrophy induced in wild type and TRPC1 deficient mice by ATII-3 treatment. Cardiac 
hypertrophy indexes (A) HW/BW and (B) HW/TL were analyzed. Additionally, (C) LW/TL, (D) 
LivW/TL and (E) water content in lungs (a) and in liver (b) are included. BW: body weight, HW: 
heart weight, TL: tibia length, LW: lung weight, LivW: Liver weight, n= number of mice. Error bars 
indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to Bonferroni 
comparisons. 
 
Figure 15. Angiotensin II-induced cardiac hypertrophy is not reduced in TRPC4-/- mice. 
Cardiac hypertrophy induced in wild type and TRPC4 deficient mice by ATII-3 treatment. Cardiac 
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hypertrophy indexes (A) HW/BW and (B) HW/TL were analyzed. Additionally, (C) LW/TL, (D
LivW/TL and (E) water content in lungs (a) and in liver (b) are included. BW: body weight, HW: 
heart weight, TL: tibia length, LW: lung weight, LivW: Liver weight, n= number of mice. Error bars
indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to Bonferroni
comparisons. 
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5.1.4 TRP expression analysis in isolated adult mouse cardiomyocytes 
 
Analysis of the development of cardiac hypertrophy revealed a reduced Iso- and ATII-
induced increase in collagen content in cardiac tissue sections from TRPC1/TRPC4 (-/-)2 
mice (Figure 7, D and Figure 9, D). Nevertheless, comparison of absolute values of basal 
fibrosis levels in heart sections showed a significantly higher proportion of Sirius red 
stained tissue in TRPC1/TRPC4 (-/-)2 mice compared to WT mice (Figure 16). Also, the 
reduced hypertrophy development and increase of cardiomyocyte cross sectional area 
observed in TRPC1/TRPC4 deficient mice may not only be a result of a direct action of 
isoproterenol or angiotensin II on cardiomyocytes, but could also be mediated by other 
cell types within the heart (see Figure i1). The differences in the content of cardiac 
collagen, which is mainly defined by the function of cardiac fibroblasts, as well as the 
observed cardiomyocyte growth after neurohumoral stimulation, prompted me to study the 
expression of TRPC channels in these cell types.  
 
 
Figure 16. Basal levels of cardiac fibrosis are higher in TRPC1/TRPC4 (-/-)2 mice. Cardiac 
fibrosis quantified from Sirius red stained tissue sections from wild-type and TRPC1/TRPC4 (-/-)2 
mice. (A) Representative paraffin sections (5µm) from the left ventricle stained with Sirius red from 
saline treated mice. (B) Analysis of cardiac fibrosis determined as the percentage of tissue stained 
with Sirius red, mean values (a) and single values from each anylyzed mouse (b) are presented. n= 
number of mice. Error bars indicate SEM. *p<0.05 according to the Student’s t-test. 
 
 
Cardiomyocytes from adult wild type mice were isolated by digestion of hearts in 
Langendorff preparations and separated by centrifugation and differential plating steps. 
The major proportion of these cell suspensions which were used until now for RT-PCR 
analysis as those shown in Figure 17 (A) was cardiomyocytes, but this suspension also 
contained other cell types including endothelial cells, macrophages, smooth muscle cells 
and a large number of cardiac fibroblast, as I observed later when cells were stained for 
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the fibroblast marker P4HB in cardiomyocyte preparations (Figure 19, D). From RNA 
isolated from these cellular preparations termed “Langendorff suspension” I amplified 
transcripts specific for TRPC1, TRPC3, TRPC4 and TRPC6 (Figure 17, Ab). These results 
were reproduced and we also detected transcripts of genes encoding TRPM4, TMEM-2 (a 
gene close to TRP family), L-type voltage-gated calcium auxiliary subunit Cavβ2 (Meissner 
et al., 2011) and the Hypoxanthine Phosphoribosiltransferase-1 (HPRT-1) (see Table 3, in 
the column “Langendorff suspension”). TRPC5 was not included in this analysis because 
it could never be amplified from two independent Langendorff preparations (Table 3), 
which is in line with observations from others that did not detect TRPC5 expression in 
mouse heart by northern blot analysis (Okada et al., 1998). 
 
Figure 17. Expression of TRPs in isolated mouse cardiomyocytes analyzed by RT-PCR.  
Different TRPs transcripts amplified from total RNA obtained from either cell suspensions isolated 
by (A, a) heart digestion according to the Langendorff perfusion system (“Langendorff suspension”) 
or (B, a) from mouse cardiomyocytes (CM) collected by Laser Capture Microdissection (LCM). 
Representative agarose gels showing (A, b) the expression of TRPC1, TRPC3, TRPC6 and 
TRPC4 in RNA from “Langendorff suspension” and gels showing (B, b) the expression in LCM-
collected cardiomyocytes of TRPC1, TRPM4, TMEM-2 and HPRT-1 that was used as control for 
the RNA quality obtained from the LCM-isolated cardiomyocytes. Total RNA from brain was used 
as positive control (Br) and RNA free water from the RNA isolation kit was used as negative control 
(neg). bp: base pair.  
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To circumvent contamination by other cell types and to obtain a pure cardiomyocyte 
fraction out of the cell population obtained after Langendorff digestion of the heart for RT-
PCR analysis, I decided to selectively isolate cardiomyocytes by Laser Capture 
Microdissection (LCM). With this procedure, single cardiomyocytes were collected on a 
special glass slide (Figure 17, Ba) for RNA isolation. From this material I amplified 
transcripts of TRPC1, TRPM4, TMEM-2  and HPRT-1 (Figure 17, Bb) and I amplified only 
once TRPC3 from five experiments and once TRPC4 from ten experiments. TRPC6 
transcrips were never amplified (Table 3, in the column  “LCM-Cardiomyocytes”).  
 
 
Table 3. Summary of TRP expression analysis in mouse cardiomyocytes and cultured 
cardiac fibroblasts by RT-PCR. 
 
The expression of distinct TRPs was analyzed using RNA from three different sources (1) cell 
suspensions isolated by Langendorff heart preparation, (2) cardiomyocytes isolated by Laser 
Capture Microdissection (LCM), and (3) from cultured cardiac fibroblasts. In the table are included 
the number of cell preparations (# Cell preps) equivalent to independent mice, the number of 
independent RNA isolations (# RNA preps), the number of independent RT-PCR experiments (# 
PCRs) and the amplification results expressed as the number of positive amplifications related to 
the number of RT-PCR reactions carried out (positive amplifications/reactions). Results from 
amplification of transcripts of TRPM4, TMEM-2, Cavβ2 subunit and HPRT-1 (Hypoxanthine 
Phosphoribosiltransferaseare also given. nt: not tested and *: weak bands, observed only once. 
 
In addition to the expression analysis described above we carried out a systematic 
procedure using cardiomyocytes isolated by LCM. Four independent cell preparations, 
corresponding to four mice were prepared and around 300 cardiomyocytes per 
preparation were collected to obtain four separate RNA preparations. RT-PCR 
experiments were performed with each RNA preparation and the result are summarized in 
Figure 18, where only transcripts from TRPC1, TRPM4 and TMEM2 were detected, which 
is in correspondence with the analysis described above. However, TRPC3, TRPC4 and 
TRPC6 transcripts were not detected in any of the four independent LCM preparations of 
 
gene # Cell preps
# RNA 
preps # PCRs
positive 
amplification/ 
reactions
# Cell 
preps
# RNA 
preps # PCRs
positive 
amplification/ 
reactions
# Cell 
preps
# RNA 
preps # PCRs
positive 
amplification/ 
reactions
TRPC1 6 6 5 10/10 4 7 9 7/9 3 3 4 4/4
TRPC3 5 5 4 5/7 4 5 5 1*/5 3 3 4 4/4
TRPC4 5 5 5 7/10 5 10 10 1*/10 3 3 5 8/8
TRPC5 2 2 2 0/2 1 1 1 0/1 3 3 3 3/3
TRPC6 5 5 3 5/5 5 12 14 0/14 3 3 3 3/3
TRPM4 1 1 1 1/1 3 3 3 3/3 1 1 1 1/1
TMEM-2 4 4 1 4/4 3 4 4 4/4 nt nt nt nt
Cavβ2 nt nt nt nt 1 1 1 1/1 1 1 1 1/1
HPRT-1 6 6 3 6/6 5 8 8 8/8 3 3 3 3/3
    Cultured cardiac fibroblasts    Langendorff suspension    LCM-cardiomyocytes
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cardiomyocytes. TRPC5 was not included in this analysis because it could never be 
amplified from the initial cell suspensions obtained by Langendorff preparations. 
 
 
 
Figure 18. Systematic RT-PCR expression analysis of TRPs in LCM-isolated mouse 
cardiomyocytes. Transcripts from different TRPs amplified from total RNA obtained from mouse 
cardiomyocytes (CM) collected by Laser Capture Microdissection (LCM). Representative agarose 
gels (1- 4) after RT-PCR amplification showing the expression TRPC1, TRPM4, TRPC3, TRPC4, 
TRPC6 and TMEM-2 transcripts in total RNA from LCM-isolated cardiomyocytes. Each gel 
corresponds to an independent experiment and to an independent mouse. On the bottom the 
amplification results are summarized. Positive amplifications are coded with a plus symbol (+) and 
negative amplifications with a minus symbol (-). Total RNA from brain was used as positive control 
(Br) and PCR water was used as negative control (neg). bp: base pair, nt: not tested. 
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5.1.5 Isolation, culture and characterization of adult mouse cardiac fibroblasts 
 
In order to study the expression and functional contribution of cardiac fibroblasts in the 
development of cardiac hypertrophy mediated by TRPC channels, it was required to 
establish a method to isolate cardiac fibroblasts and to characterize the obtained cell 
population by immunostaining using markers for different cardiac cell types. 
 
5.1.5.1 Characterization of cardiac fibroblast culture by immunocytochemistry 
 
There are only a few reports about culturing primary cardiac fibroblasts. Most of them are 
from rats (Colston et al., 2002; Ostrom et al., 2003; Olson et al., 2008) and only a few 
from mice (Jaffré et al., 2009). Based on information from the reported methods I 
established a protocol to culture fibroblasts from mouse heart. To isolate these cells 
hearts were perfused according to the Langendorff preparation, but were digested more 
rigorously than for cardiomyocyte isolation. From these preparations most of the 
cardiomyocytes were separated by centrifugation steps and the remaining cells were 
subjected to differential plating to get a population mostly composed of fibroblasts. An 
example of cultured cells from different time points after plaiting is shown in Figure 19 (A). 
Once a reproducible culture protocol was determined and it was observed that the cells 
had a typical reported cardiac fibroblasts morphology (Wang et al., 2003; Haudek et al., 
2006; Landeen et al., 2007), samples from different preparations between the first and 
third passage were used to demonstrate the expression profile of markers of different 
cardiac cell types by Immunocytochemistry (ICC ethods.
 
To characterize the cultured fibroblasts four markers were used according to Thum and 
collaborators (2008): 1) P4HB (Prolyl-4-hydroxylase) as marker for fibroblasts; 2) CD-31 
(or PECAM-1) used as endothelial marker; 3) α-smooth muscle 2-actin (or ACTA2) for 
identification of smooth muscle cells or myofibroblasts, and 4) α-actinin (ACTN2) used as 
cardiomyocyte marker. A representative staining using these markers to characterize 
cultured cardiac fibroblasts is shown in Figure 19 (B). The cultured cells were positive for 
PH4B and negative for α-actinin, α2-actin and for CD-31. In a few cells an un-specific 
staining close to the nucleus was observed. Also markers were tested with positive 
controls using established isolation procedures. Freshly isolated cardiomyocytes were 
only positive for α-actinin. Positive controls for α-smooth muscle actin and for CD-31 were 
freshly isolated ileum smooth muscle cells (Tsvilovskyy et al., 2009) and cultured mouse 
aortic endothelial cells (Freichel et al., 2001), respectively. 
 
) m   
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Figure 19. Characterization of cultured mouse cardiac fibroblasts. (A) Phase contrast 
photographs of cultured cardiac fibroblasts at different time points of culture. The inset shows two 
selected cells from the first hours after plating. (B) Representative immunocytochemical staining of 
cultured cardiac fibroblasts (Passage 1) and cardiomyocytes with DAPI (blue) and antibodies 
against α-actinin (red), α-smooth muscle actin (α-SM actin, green), prolyl 4-hydroxylase (P4HB, 
green) and CD31 (red). Isolated mouse ileum smooth muscle cells (iSMC) and mouse aortic 
endothelial cells (MAEC) were used as positive controls for α-SM actin and CD31 respectively. 
Similar staining patterns were obtained in at least one preparation from the second and third 
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passages. (C) A representative example of negative controls without the first antibody is included 
for the secondary antibody Alexa fluor-488 (green). (D) Positive cells for P4HB (green) found in 
preparations of freshly isolated cardiomyocytes are shown with red arrows. Higher magnification 
microphotographs from these cells stained with anti-P4HB (green) and nuclear staining DAPI (blue) 
are included. Red scale bars in B and C and corresponds to 20µm. 
 
 
As negative control all cell types were processed similarly but the primary antibody was 
omitted, as shown for cardiac fibroblasts and the secondary antibody Alexa Fluor-488 
(Figure 19, C). To quantify the number of P4HB positive cells in the cardiac fibroblasts 
culture the number of positive cells for P4HB was determined in comparison with the 
number of nuclei (DAPI staining) in at least three independent cell preparations between 
the first and third passage. From these quantifications about 95% of the cells were P4HB 
stained. 
 
 
5.1.5.2 TRP expression analysis in adult mouse cardiac fibroblasts 
 
Using cultured cardiac fibroblasts characterized by ICC we made a systematic expression 
analysis of TRPCs by RT-PCR. Cells were harvested between the first and third passage 
when they were confluent. From different preparations corresponding to independent mice 
we amplified transcripts from TRPC1, TRPC3, TRPC4, and also from TRPC5 and TRPC6 
(Figure 20) that were not detected in any preparation of isolated cardiomyocytes. Beyond 
these genes, we could also detect transcripts from TRPM4 and the control gene HPRT-1. 
The results summari  3 (under “Cultured cardiac fibroblasts” title). 
 
 
 
Figure 20. TRPC expression in cultured adult mouse cardiac fibroblasts. Transcripts from 
different TRPCs amplified from total RNA obtained from cultured mouse cardiac fibroblasts (CF) as 
those shown in the left picture. On the right, a representative agarose gel after RT-PCR 
amplification showing the expression of TRPC1, TRPC3, TRPC4, TRPC5 and TRPC6 in RNA from 
cultured fibroblasts. Total RNA from brain was used as positive control (Br) and RNA free water 
from the RNA isolation kit was used as negative control (neg). bp: base pair.  
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5.1.5.3 Calcium microflurometry from mouse cardiac fibroblasts 
 
The reduced isoproterenol- and angiotensin II-induced cardiac hypertrophy development 
in TRPC1/TRPC4 (-/-)2 mice might be due to impaired secretion of hypertrophy inducing 
factors from cardiac fibroblasts after Iso or ATII stimulation (Jaffré et al., 2009). Since 
these stimuli are known to increase the intracellular Ca2+ concentration in cardiac 
fibroblasts I started Ca2+ microflurometic analyses from cardiac fibroblasts lacking TRPC1 
and TRPC4 proteins, which are able to form cation channels in other cell types (Freichel 
et al., 2001; Liu et al., 2007). Different agonists including isoproterenol, angiotensin II or 
serotonin were applied. There is not much information in the literature about calcium 
measurements in muse cardiac fibroblasts; therefore, it was required to settle a 
reproducible protocol using our cultured fibroblasts.  
 
First attempts to detect changes in [Ca2+]i by agonist stimulation at room temperature were 
not successful. When the measurements were performed at 37°C by heating the perfusion 
solutions with a temperature control system the response rate improved significantly. An 
example comparing some of the firsts experiments performed at room temperature or with 
a pre-warmed physiological solution (~37°C) using isoproterenol as stimulus is shown in 
Figure 21 (A).   
 
Several agonists like isoproterenol, serotonin and angiotensin that are related with cardiac 
hypertrophy development and secretion of hypertrophy inducing factors from cardiac 
fibroblasts were tested. I obtained fast responses after stimulation with all three agonists, 
but the responses were heterogeneous in terms of magnitude and also because not all 
cells responded to all agonist (Figure 23, B).  Also, differences in response depending on 
the confluence state of the cells, time after splitting and serum deprivation (as mentioned 
in the literature) were observed (data not shown). 
 
Due to the observed high variability in the responses, I decided to apply a more common 
protocol used to test calcium entry triggered by depletion of intracellular Ca2+ stores with 
Thapsigargin stimulation and analyzed changes in fluorescence in fibroblasts from wild 
type and TRPC1/TRPC4 deficient mice. Fibroblasts in calcium free solution were 
stimulated with 1µM Thapsigargin that produced a fast increase in the fluorescence 
FURA-2 ratio comparable between both genotypes (Figure 21, C and D, middle panels).  
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Figure 21. First Ca2+ imaging experiments with cultured adult mouse cardiac fibroblasts.  
Changes in intracellular calcium concentration in cultured cardiac fibroblasts loaded with Fura-2 
(5µM) were expressed as changes in the fluorescence ratio (Em340/Em380). (A) First 
measurements where isoproterenol was applied at room temperature (a) or at (b) 37˚C; each panel 
corresponds to different set of experiments and arrows indicate the time of isoproterenol addition. 
(B) Agonist induced increase in [Ca2+]i concentration. Upper left a picture from fibroblasts that were 
stimulated with serotonin (ser), isoproterenol (iso) and angiotensin II (ATII) and on the right the 
corresponding original trace from the fluorescence ratio. As can be observed, the responses were 
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variable and not all cells were responded to all agonists. For example serotonin and isoproterenol 
evoked a change in fluorescence ratio but in case of cell 2 the response was observed only after 
stimulation with serotonin and not after isoproterenol. On the lower panels are depicted examples 
of evoked-Ca2+ transients by stimulation with iso (a), ser (b) and ATII (c) from the upper cells. (C-D) 
Calcium re-addition protocol where Thapsigargin (1µM) was applied in Ca2+-free (1mM EGTA) 
external solution to deplete the stores and then 1.8mM external Ca2+ was added as indicated. Left 
pictures show representative pictures from the cells used for the experiments. (C) Cells with the 
typical fibroblast morphology in culture highly confluent. (D) Larger cells with a myofibroblast 
morphology. The middle panels show changes in fluorescence ratios from these two types of 
analyzed cells and the right insets correspond to the two steps of Ca2+ addition showed in the 
middle panels. Black traces are from WT cells and red traces from TRPC1/TRPC4 (-/-)2 cells. n= 
number of cells from two independent preparations from passage 1. 
 
 
After recovering to the base line, calcium (1.8mM) was re-added by changing to a calcium 
containing solution, and a second increase in the fluorescence ratio was observed 
corresponding to calcium entry; after some minutes the calcium was removed and re-
added to monitor once more the calcium entry. 
 
From two independent series I observed that TRPC1/TRPC4 knockout cells presented a 
reduced increase in the fluorescence ratio in the two calcium re-addition phases (Figure 
21, C). The difference was observed in highly confluent cells with a characteristic 
fibroblasts morphology (Figure 21, A, left panel) but not in those cell popupations that 
were less confluent and showed a myofibroblast-like morphology (Figure 21, D). 
Morphological differences related with the density of the cells have been already observed 
in corneal fibroblasts from rabbit (Masur et al., 1996). In the future this morphological 
difference will be further analyzed by staining the α-smooth muscle to evaluate whether 
the cells shown in Figure 21 (D) are myofibroblasts. Changes of intracellular Ca2+ 
concentration after stimulation with physiological agonists in cells of different states of 
differentiation will be analyzed in both genotypes. Additional experiments are required to 
characterize the observed phenotype after Thapsigargin addition, as well as the impact of 
changes in the intracellular calcium concentration for the secretion of hypertrophy 
inducing factors in TRPC1/TRPC4 (-/-)2 mice.  
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5.2 Platelet aggregation in TRPC deficient mice  
 
To investigate whether TRPC proteins are relevant for platelet aggregation I performed in 
vitro aggregation experiments with mouse platelets from different TRPC single and 
compound knockout mouse lines using several platelet activating agonists (Table 4). 
Additionally, the expression of different TRPs in mouse platelets has been analyzed.  
 
 
Table 4. Overview of platelet aggregometry screening with TRPC deficient mouse lines.  
 
Mouse model
ADP Thrombin Collagen U46619
TRPC1 -/- ♀ X X X X
♂ X ▬ ▬ ▬
TRPC3 -/- ♀ ▬ X ▬ ▬
♂ ▬ X X ▬
TRPC5 -/- ♀ ▬ ▬ ▬ ▬
♂ X X X X
TRPC6 -/- ♀ X X X X
♂ X X X X
TRPC1/C4 (-/-)2 ♀ ▬ X X ▬
♂ ▬ ▬ ▬ ▬
TRPC1/C6 (-/-)2 ♀ X X X X
♂ X X X X
TRPC4/C6 (-/-)2 ♀ X X X X
♂ X X X X
TRPC3/C6 (-/-)2 ♀ X X X X
♂ X X X X
TRPC1/C4/C6 (-/-)3 ♀ X X X X
♂ ▬ ▬ ▬ ▬
TRPC1/C3/C6 (-/-)3 ♀ X X X X
♂ ▬ ▬ ▬ ▬
Agonist tested
In the table is listed which of the four agonists (ADP, thrombin, collagen or TxA2 analogue U46619) 
were tested in different TRPC deficient mouse lines. The systematic screening was performed with 
platelets isolated either from male or female mice. Platelets from mouse lines that presented 
significant differences for a determined agonist are highlighted in blue; — indicates that the 
condition has been not tested yet. 
 
 
As one of the initial steps in the analysis of platelet function we determined platelet 
numbers in male mice using whole blood from some mouse lines mentioned in Table 4, as 
well as from three of the wild type mouse lines used in our group. Platelet counts in 
129SvJ mice were significantly lower in comparison with C57BL/6N mice or with mice first 
generation (F1) offspring from these two mouse lines (Figure 22, A). Platelet counts were 
comparable to corresponding controls in TRPC6, TRPC3/TRPC6, TRPC1/TRPC4 and 
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TRPC4/TRPC6 deficient male mice (Figure 22, B-E). In addition, I counted manually 
platelets from wild type and TRPC4/TRPC6 (-/-)2 male and female mice and there were 
also no differences between wild type and TRPC4/TRPC6 (-/-)2 mice. Only differences in 
platelet counts due to the gender were observed. Platelet counts between WT male and 
female mice were significantly different (p<0.001) as well as counts between 
TRPC4/TRPC6 (-/-)2 male and female mice (p<0.001). These platelet counts expressed 
as 103 platelets/µl were 1235 ±315 and 1221±144 for WT (n=11) and TRPC4/TRPC6 (-/-)2 
(n=11) male mice, respectively; and they were 944.5±153 and 872 ±189 for WT (n=10) 
and TRPC4/TRPC6 (-/-)2 (n=10) female mice, respectively.  
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Figure 22. Whole blood platelet counts are not altered in different TRPC deficient mouse 
lines. Platelet counts from (A) wild type male mice from three mouse lines, and platelet counts 
from (B) TRPC6-/-, (C) TRPC3/TRPC6(-/-)2, (D) TRPC1/TRPC4(-/-)2 and (E) TRPC4/TRPC6(-/-)2 
male mice were determined with a Coulter counter AcT diff (Beckman) and compared to 
appropriate wild type controls. In addition, values for Error bars indicate SEM. ***p<0.001 and ns 
(not significant) according to the Student’s t-test. 
 
 
5.2.1 TRP expression analysis in isolated mouse platelets 
 
For analysis of TRPC protein expression in isolated mouse platelets we used antibodies 
directed against TRPC1 (unpublished) TRPC3 (unpublished), TRPC4 (Freichel et al., 
2001), TRPC5 (unpublished), TRPC6 (Tsvilovskyy et al., 2009) and TRPM4 proteins 
(Mathar et al., 2010) that has been generated by Prof. V. Flockerzi and coworkers. Using 
the antibody ab861 against a C-terminal fragment of the murine TRPC6, proteins of 
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~120kDa in platelet protein preparations from wild type mice but not from TRPC6 -/- mice 
were detected (Figure 23, A). So far, using antibodies directed against TRPC1, TRPC3, 
and TRPC4 the observed protein patterns detected by western blot analysis did not differ 
between protein preparations from wild type and the corresponding knockout controls 
(data not shown). We did not detected TRPC5 proteins in mouse platelets with antibodies 
against TRPC5 that detected TRPC5 proteins in brain preparations from wild type mice 
but not from TRPC5-/- mice (data not shown). With the antibody Ak578 directed against 
the amino-terminal end of mouse TRPM4, proteins of ~138kDa in platelet protein 
preparations from wild type mice but not from TRPM4-/- mice were detected (Figure 23, 
B). In addition, using RT-PCR analysis, I amplified transcripts from TRPC1 and TRPC6 
using total RNA isolated from wild type mouse platelets (Figure 23, C). Moreover, I also 
amplified transcripts from TRPM4, TMEM-2, and the housekeeping genes, HPRT-1 and 
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase). With our protocol that produced 
amplification products with RNA from other tissues no transcripts from TRPC3, TRPC4 or 
TRPC5 were detected so far (Table 5).  
 
 
 (C) TRPC6TRPC1
1     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Expression analysis of TRPs in mouse platelets. (A) Western blot with the antibody 
861 against TRPC6 proteins using platelet protein fractions from wild type (line 3) and TRPC6 
deficient mice (line 4). (B) Western blot with the antibody Ak578 against TRPM4 proteins using 
platelet protein fractions from wild type (line 3) and TRPM4 deficient mice (line 4). (A-B) Lung 
protein preparations from wild type (lines 1) and from corresponding TRP-deficient mice (lines 2) 
were used as control. (C) Detection of transcripts of TRPC1 and TRPC6 in isolated platelets. Total 
RNA from brain was used as positive control (Br) and RNA free water from the RNA isolation kit 
was used as negative control (neg). kDa: kiloDalton, bp: Base pair. 
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Table 5. Summary of TRP expression analysis in mouse platelets by RT-PCR. 
 
 
 
 
 
 
gene # Cell preparations
# RNA 
preparations
FACS 
preparations # PCRs
positive 
amplification/reactions
TRPC1 5 4 1 6 7/12
TRPC3 6 5 1 4 0/8
TRPC4 3 2 1 3 0/6
TRPC5 1 nt. 1 1 0/2
TRPC6 4 3 1 5 10/10
TRPM4 1 nt. 1 2 4/7
TMEM-2 2 1 1 2 4/4
HPRT-1 2 2 nt. 2 2/2
GAPDH 1 1 nt. 1 1/1
             Platelets               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The expression of different TRPs was analyzed in isolated mouse platelets. In the table the number 
of cell preparations equivalent to independent mice, the number of independent RNA isolations, the 
number of independent RT-PCR experiments (# PCRs) and the amplification results expressed as 
the number of positive amplifications related to the number of RT-PCR reactions carried out 
(positive amplifications/reactions) are mentioned. Preparations from sorted platelets by FACS were 
used directly for RT-PCR without RNA extraction. Amplifications of transcripts of a TRP relative 
TMEM-2, of HPRT-1 (Hypoxanthine Phosphoribosiltransferase) and of GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) were used as positive control for RNA integrity. #: number, nt: not 
tested. 
 
 
 
5.2.2 Turbidimetric aggregometry and characterization of the platelet preparation 
 
For analyzing of the role of TRPC proteins for platelet aggregation I decided for the 
turbidimetric method or optical aggregometry as an in vitro assay of platelet function. 
Because platelet expression analysis and aggregation experiments were made using 
isolated washed platelets, we determined the purity of the preparation by flow cytometry. 
The size and complexity of the cells in the platelet suspension were characterized using 
the forward scatter (FSC) and side scatter (SSC) (Figure 24, A). The analyzed platelet 
population was more than 99.5% homogeneous (See values of region 35 in upper right 
table from Figure 24, A) and this homogeneity was observed in two independent platelet 
preparations. To corroborate that the cells were indeed platelets, we incubated platelets 
with an antibody against mouse αIIbβ3 integrin (CD41/CD61) FITC-labeled used as 
specific platelet marker. We characterized the stained sample by FSC and SSC and the 
observed pattern was identical to the one from the non-stained sample with more than 
99.5% homogeneity (Figure 24, Ab).  
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When the samples were analyzed by fluorescence intensity, there was a right switch into 
the fluorescence signal in comparison with the non stained platelet sample (compare 
Figure 24, Ba and Bb). It was determined that >99.9% of the cells expressed the αIIbβ3 
integrin (Figure 24, see values from regions 12 and 14 for stained platelets in B) indicating 
the high purity of the preparation. This observation was confirmed in two independent 
preparations. Additionally, we sorted stained platelets in groups of 50, 200, 500 and 2000 
platelets in single PCR reaction tubes and after freezing the samples I made RT-PCR 
directly with these platelets. From these samples I amplified transcripts from TRPC1, 
TRPC6, TRPM4 and TMEM-2 (Table 5).  
 
Because calcium in an important component of platelet function and its extracellular 
presence is needed to obtain platelet aggregation due to its requirement for fibrinogen 
binding and for maintaining the platelet signaling by its influx into platelets, I did 
aggregometry experiments with platelets from wild type mice in the presence and in the 
absence of extracellular calcium. When washed platelets from wild type were stimulated 
with agonists like ADP, thromboxane A2 receptor agonist (U46619), thrombin or collagen 
in the presence of 2mM extracellular Ca2+, a rapid aggregation response was observed 
with all four agonist. When the same stimuli were used with platelets in a calcium free 
solution containing 2mM EGTA (Weber et al., 1999), no aggregation was observed and 
only an increase in the optical density of the suspension, corresponding to the called 
platelet shape change (PSC), was evident for stimulation with ADP, U46619 or collagen 
(Figure 24, C).  
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Figure 24. Washed platelet preparation is 99.9% pure and Ca2+ is required for platelet 
aggregation. (A) Flow cytometric analysis of mouse isolated platelets. Unstained platelet’s sample 
(a) and platelets incubated with FITC-conjugated anti integrin αIIbβ3 (b) were analyzed by side 
scatter (SSC; y axis) and forward scatter (FSC; x axis). Platelets were identified in region 1 (R1, 
lower left quadrant). (B) Single color flow cytometric analysis of mouse isolated platelets. 
Unstained platelets (a) and platelets incubated with FITC-conjugated anti-integrin αIIbβ3 (b) were 
gated by FSC/SSC characteristics and the fluorescence was analyzed. The platelet population 
incubated with the anti-integrin αIIbβ3 shows a right shift in the fluorescence, compare region 2 (R2) 
between right and left panels. Data tables on the right contain number of analyzed platelets and 
percentage of events for each region. (C) Representative original traces from aggregation 
experiments performed in washed platelets from wild type (WT) male mice. Aggregation was 
induced by application (arrow) of ADP, Thromboxane A2 receptor agonist analogue U46619, 
thrombin or collagen. Aggregation from platelets of WT mice in the presence of 2mM Ca2+ (black 
traces) or with 2mM EGTA (blue traces) are given.  
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5.2.3 ADP-, Thromboxane A2 analogue U46619-, Thrombin- and Collagen-induced 
aggregation in platelets from wild type mice 
 
Four different agonists were used for the analysis of platelet aggregation to cover a variety 
of activation mechanisms and cascades involved in platelet activation: ADP, 
Thromboxane A2 analogue U46619, thrombin or Collagen, agonists that stimulate 
P2Y1/P2Y12, TP, PAR4 and GPVI receptors, respectively. I analyzed four parameters from 
aggregation traces: 1) the platelet shape change (PSC) that corresponds to the fast 
negative inflection in the aggregation curve observed after agonist addition; 2) the 
maximum aggregation that is defined as the maximum percentage value reached during 
aggregation; 3) the area under the aggregation curve, defined as the integral of the 
aggregation curve over the time period corresponding to the aggregation phase; and 4) 
the maximum slope of the aggregation curve, defined in percentage of aggregation per 
minute.  
 
For the aggregation assays I used platelets from male or female mice because it has been 
reported that platelets from female mice are more sensitive to agonists than platelets from 
male mice (Leng et al., 2004). A comparison between agonist-induced platelet 
aggregation in platelets from wild type female and male mice was made (Figures 25 and 
26). ADP produced a significantly higher maximal aggregation in female platelets at 3µM 
and 10µM compared to platelets from male mice, also the area under the aggregation 
curve was significantly higher for 30µM in female platelets. No differences in PSC or in the 
aggregation slope between both genders were detected (Figure 25, A). After stimulation 
with U46619 only the PSC at two concentrations in platelets from female mice was 
increased (Figure 25, B).  
 
Thrombin stimulation induced a small but significantly augmented maximal aggregation 
and aggregation area at a concentration of 1U/ml in platelets from female mice; 
interestingly, in these platelets the aggregation slope at 0.1U/ml thrombin was higher, but 
smaller at 3U/ml compared to platelets from males (Figure 26, A). Collagen induced in 
platelets from females a significantly increased maximal aggregation and aggregation 
area at a concentration of 10µg/ml; however, no difference was observed in PSC or in the 
maximal slope (Figure 26, B).  
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ADP (male and female platelets)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. In vitro platelet aggregation in male and female wild type platelets induced by 
ADP or by U46619. Concentration-response curves from platelets stimulated with: (A) ADP or (B) 
Thromboxane A2 analogue U46619 where maximal aggregation (a), area under the aggregation 
curve (b), platelet shape change (PSC, c) and maximal slope during aggregation (d) were 
analyzed. Numbers of measurements per ADP concentration for males were: 0.01µM=12, 
0.03µM=14, 0.1µM=26, 0.3µM=38, 1µM=42, 3µM=30, 10µM=24 and 30µM=25, and for females 
were: 0.01µM=22, 0.03µM=24, 0.1µM=31, 0.3µM=51, 1µM=62, 3µM=45, 10µM=46 and 30µM=28. 
Numbers of measurements per U46619 concentration for males were: 0.01µM=10, 0.03µM=8, 
0.1µM=13, 0.3µM=15, 1µM=44, 3µM=17 and 10µM=10, and for females were: 0.01µM=16, 
0.03µM=18, 0.1µM=21, 0.3µM=27, 1µM=78, 3µM=35 and 10µM=22. Error bars indicate SEM.  
*p<0.05, **p<0.01 and ***p<0.001 according to the Student’s t-test. 
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Figure 26. In vitro platelet aggregation in male and female wild type platelets induced by 
thrombin or by collagen. Concentration-response curves from platelets stimulated with: (A) 
Thrombin or (B) collagen where maximal aggregation (a), area under the aggregation curve (b), 
platelet shape change (PSC, c) and maximal slope during aggregation (d) were analyzed. 
Numbers of measurements per thrombin concentration for males were: 0.01U/ml=9, 0.03U/ml=10, 
0.1U/ml=21, 0.3U/ml=20, 1U/ml=14 and 3U/ml=17, and for females: 0.01U/ml=15, 0.03U/ml=14, 
0.1U/ml=36, 0.3U/ml=22, 1U/ml=18 and 3U/ml=19. Numbers of measurements per collagen 
concentration for males were: 0.1µg/ml=8, 0.3µg/ml=8, 1µg/ml=21, 3µg/ml=20, 10µg/ml=23 and 
30µg/ml=17, and for females were: 0.1µg/ml=9, 0.3µg/ml=19, 1µg/ml=29, 3µg/ml=31, 10µg/ml=32 
and 30µg/ml=22. Error bars indicate SEM. *p<0.05, **p<0.01 and ***p<0.001 according to the 
Student’s t-test. 
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5.2.4 Screening of TRPC deficient platelets by turbidimetric aggregometry 
 
It has been reported that different TRPCs are expressed in platelets and we were able to 
detect the expression of TRPC1 and TRPC6. Although, so far the expression analysis, as 
first step in studying the role of TRPCs in platelets, is hampered due to lack of appropriate 
antibodies and to restricted mRNA content in platelets. In addition, there are still no 
specific agonists or antagonist for these channels available. Therefore, I compared 
agonist-induced aggregation in platelets from different single and compound TRPC 
deficient mouse lines. A summarized description of my observations from aggregation 
experiments is contained in Tables 6 and Table 7 for results from female and male mice, 
respectively.  
 
TRPC6 -/- mice. Based on our expression analysis I focused on studying platelets 
obtained from TRPC6 deficient female or male mice bred with two different genetic 
backgrounds (C57BL/6N or the F1 offspring of C57BL/6Nx129SvJ intercrosses). No 
difference in maximal aggregation using different concentrations of ADP, Thrombin, 
Collagen or U46619 between platelets from wild type and TRPC6-/- mice was observed 
(Tables 6A and 7A); a detailed description of these results is presented below under 
section 5.2.4.1.  
 
TRPC1 -/- mice. Aggregation in washed platelets from TRPC1-/- mice induced by 
thrombin, collagen or U46619 showed no difference in the maximal aggregation between 
wild type and TRPC1 deficient platelets from female mice (Table 6A). In experiments 
performed with platelet rich plasma (PRP) the ADP-induced maximal aggregation was 
similar between platelets from wild type and TRPC1-/- mice (Table 6A). 
 
TRPC3 -/- mice. Other groups reported the expression of TRPC3 in platelets (see Table 
i4). I analyzed platelet aggregation in platelets from TRPC3 deficient mice. Maximal 
aggregation after thrombin or ADP stimulation was similar between platelets from wild 
type and TRPC3-/- female mice at the tested concentrations (Table 6A). Using platelets 
from TRPC3-/- male mice no differences in aggregation were detected at one collagen 
concentration (Table 7A); however, the thrombin-induced aggregation was slightly but 
significantly reduced at the concentrations of 0.3/Uml (-14%) and 1U/ml (-11%) in platelets 
from TRPC3-/- male mice (Table 7A).  
 
TRPC5 -/- mice. Also the expression of TRPC5 in platelets has been reported (see Table 
i4). In experiments comparing platelet aggregation between wild type (F1) and TRPC5 
deficient platelets no difference was observed in the maximal aggregation after thrombin, 
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collagen or U46619 stimulation. The ADP induced aggregation was significantly reduced 
in platelets from TRPC5-/- male mice when compared to the response from F1 mice 
(Table 7A). For TRPC5-/- mice of a mixed genetic background litter-matched controls from 
heterozygous breedings were available. In two experimental series using these mice I 
observed no difference in aggregation induced by ADP, thrombin, collagen and U46619 
(Table 7A). Then, the observed difference in the ADP response between TRPC5-/- and F1 
mice could be explained by differences in the genetic background and not due to the 
TRPC5 deletion.  
 
TRPC compound knock out mice. It has been proposed that TRPC channels can form 
heteromeric channel complexes. The loss of one channel or channel subunit could be 
compensated by others; for that reason I performed experiments with platelets from 
TRPC1/TRPC6 and TRPC3/TRPC6 compound deficient mice. Both mouse lines were 
generated by intercrossing between corresponding single TRPC deficient mouse lines. 
TRPC1/TRPC6 and TRPC3/TRPC6 mice were fertile and show no obvious sign of 
disease. The most striking finding from these experiments was an impaired ADP-induced 
platelet response in platelets from both genotypes (Table 6B) and was extensively 
analyzed in platelets from TRPC1/TRPC6 and TRPC3/TRPC6 female (Table 6B) and 
male (Table 7B) mice. These results are described in detail under sections 5.2.4.2 and 
5.2.4.3, respectively. 
 
TRPC1/TRPC4/TRPC6 (-/-)3 mice. TRPC1/TRPC4/TRPC6 deficient mice were fertile and 
show no obvious sign of disease. Platelets from TRPC1/TRPC4/TRPC6 deficient female 
mice showed no differences in aggregation after stimulation with several collagen doses 
(Table 6B). But, platelets from these mice had a reduced response after stimulation with 
different ADP concentrations, and a significant (p<0.01) reduction of about 43% in the 
maximal aggregation after stimulation with 1µM U46619 and a significant (p<0.05) 
reduction of 34% in maximal aggregation induced by 0.1U/ml thrombin were observed 
(Table 6B).  
 
TRPC4 deficiency in platelets. Since TRPC4 was reported in platelets (see Table i4) I 
also analyzed TRPC4/TRPC6 deficient mice. No difference in thrombin- induced 
aggregation was observed in platelets from TRPC4/TRPC6 (-/-)2 mice (Tables 6B and 
7B). After stimulation with 1µM U46619 was observed a 23% reduction in maximal 
aggregation only in platelets from TRPC4/TRPC6 deficient male mice (Table 7B). ADP-
induced aggregation was tested in PRP preparations but revealed no difference in 
aggregation of platelets from TRPC4/TRPC6 (-/-)2 male mice (Table 7B). An small 
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impairment in platelet aggregation in platelets from TRPC4/TRPC6 (-/-)2 female mice was 
observed (Table 6B). Finally, regarding platelets from TRPC1/TRPC4 (-/-)2 mice no 
differences after collagen or thrombin stimulation were observed in one experimental 
series (Table 6B) and this corresponded to the observations mentioned for 
TRPC1/TRPC4/TRPC6 (-/-)3 platelets (Table 6B). 
 
 
Table 6A. Summary of platelet aggregometry results from different single TRPC deficient 
mouse lines analyzed in platelets from female mice. 
 TRP
#prep #exp µM Obs. #prep #exp µM Obs. #prep #exp U/ml Obs. #prep #exp µg/ml Obs. #prep #exp µM Obs.
TRPC1 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ 1x 2 0.01 no ≠ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
1x 2 5 no ≠ ▬ ▬ 0.03 ▬ 2x 4 0.03 no ≠ 1x 2 0.3 no ≠ ▬ ▬ 0.03 ▬
1x 2 10 no ≠ ▬ ▬ 0.1 ▬ 2x 4 0.1 i.r. 1x 3 1 no ≠ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ ▬ ▬ 0.3 ▬ 3x 4 0.3 no ≠ 2x 3 3 no ≠ ▬ ▬ 0.3 ▬
▬ ▬ 1.0 ▬ 1x 2 1 no ≠ 2x 4 10 i.r. 1x 1 0.5 no ≠
▬ ▬ 3.0 ▬ 1x 2 3 no ≠ 1x 2 30 no ≠ ▬ ▬ 1 ▬
▬ ▬ 10 ▬ 1x 2 50 no ≠ 2x 2 2 no ≠
▬ ▬ 30 ▬ ▬ 3 ▬
▬ ▬ 10 ▬
TRPC3 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
1x 1 5 no ≠ ▬ ▬ 0.03 ▬ ▬ ▬ 0.03 ▬ ▬ ▬ 0.3 ▬ ▬ ▬ 0.03 ▬
1x 2 10 no ≠ ▬ ▬ 0.1 ▬ 1x 1 0.1 no ≠ ▬ ▬ 1 ▬ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ ▬ ▬ 0.3 ▬ 1x 4 0.15 no ≠ ▬ ▬ 3 ▬ ▬ ▬ 0.3 ▬
▬ ▬ 1.0 ▬ ▬ ▬ 0.2 ▬ ▬ ▬ 10 ▬ ▬ ▬ 1 ▬
▬ ▬ 3.0 ▬ ▬ ▬ 0.3 ▬ ▬ ▬ 30 ▬ ▬ ▬ 3 ▬
▬ ▬ 10 ▬ 1x 4 1 no ≠ ▬ ▬ 50 ▬ ▬ ▬ 10 ▬
▬ ▬ 30 ▬ ▬ ▬ 3 ▬
TRPC6-C57 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ 1x 3 0.01 no ≠ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
▬ ▬ 5 ▬ ▬ ▬ 0.03 ▬ 2x 4 0.03 no ≠ 1x 2 0.3 no ≠ ▬ ▬ 0.03 ▬
▬ ▬ 10 ▬ ▬ ▬ 0.1 ▬ 1x 3 0.1 no ≠ ▬ ▬ 1 ▬ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ 1x 3 0.3 no ≠ 2x 6 0.3 no ≠ 2x 4 3 no ≠ 1x 2 0.3 no ≠
1x 3 1.0 no ≠ ▬ ▬ 1 ▬ 2x 4 10 no ≠ 2x 6 1 no ≠
1x 3 3.0 no ≠ 1x 3 3 no ≠ 2x 4 30 no ≠ 2x 7 3 no ≠
1x 3 10 no ≠ ▬ ▬ 50 ▬ 1x 2 10 no ≠
1x 4 30 no ≠
TRPC6-F1 ▬ ▬ 1 ▬ 3x 8 0.01 no ≠ 1x 2 0.01 no ≠ 2x 7 0.1 no ≠ 1x 2 0.01 no ≠
▬ ▬ 5 ▬ 3x 9 0.03 no ≠ 1x 2 0.03 no ≠ 3x 9 0.3 no ≠ 1x 2 0.03 no ≠
▬ ▬ 10 ▬ 4x 11 0.1 no ≠ 4x 7 0.1 no ≠ 3x 9 1 no ≠ 2x 4 0.1 no ≠
▬ ▬ 50 ▬ 4x 15 0.3 no ≠ 1x 3 0.15 no ≠ 3x 7 3 no ≠ 2x 4 0.3 no ≠
4x 13 1.0 no ≠ 4x 9 0.3 no ≠ 4x 9 10 no ≠ 4x 10 1 no ≠
4x 10 3.0 no ≠ 3x 9 1 no ≠ 2x 4 30 no ≠ 3x 10 3 no ≠
3x 9 10 no ≠ 2x 7 3 no ≠ ▬ ▬ 50 ▬ 3x 6 10 no ≠
2x 4 30 no ≠
Aggregation from female mice
ADP (PRP)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
▬
ADP (WP) Thrombin (WP) Collagen (WP) U46619 (WP)
Platelets from single deficient mouse lines were analyzed after stimulation with ADP, thrombin, 
collagen or the Thromboxane A2 receptor agonist U46619 in platelet rich plasma (PRP) or washed 
platelets (WP) as indicated. For each agonist concentration the number of independent 
preparations (#prep) and the number of experiments (#exp) are given. Differences in maximal 
aggregation are mentioned in the observation (Obs.) columns. The suffixes –F1 or –C57 refers to 
the background of the mouse line, either from a mixed background (129SvJ x C57BL6N) or from a 
single C57BL6N background, respectively. no≠: not significantly different, ≠: different (*p<0.05; 
**p<0.01, and ***p<0.001 according to the Student’s t-test), ≠?: possible difference, but reduced 
number of data to perform proper statistical analysis, and i.r.: inconsistent results. 
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Table 6B. Summary of platelet aggregometry results from different compound TRPC 
deficient mouse lines analyzed in platelets from female mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRP
#prep #exp µM Obs. #prep #exp µM Obs. #prep #exp U/ml Obs. #prep #exp µg/ml Obs. #prep #exp µM Obs.
TRPC3/C6 ▬ ▬ 1 ▬ 3x 6 0.01 no ≠ 2x 5 0.01 no ≠ 1x 2 0.1 no ≠ 3x 7 0.01 no ≠
▬ ▬ 5 ▬ 3x 6 0.03 no ≠ 2x 4 0.03 no ≠ 2x 4 0.3 no ≠ 3x 7 0.03 no ≠
▬ ▬ 10 ▬ 4x 8 0.1 no ≠ 4x 9 0.1 ≠* 2x 4 1 no ≠ 3x 6 0.1 no ≠
▬ ▬ 50 ▬ 6x 18 0.3 no ≠ 1x 2 0.15 i.r. 3x 6 3 no ≠ 3x 6 0.3 no ≠
6x 25 1.0 ≠ *** 3x 7 0.3 no ≠ 3x 5 10 no ≠ 8x 38 1 ≠ ***
5x 12 3.0 ≠ ** 2x 4 1 no ≠ 2x 4 30 no ≠ 4x 11 3 ≠ *
4x 10 10 ≠ * 2x 6 3 no ≠ ▬ ▬ 50 ▬ 1x 2 5 no ≠
4x 9 30 no ≠ 3x 6 10 no ≠
TRPC4/C6 1x 1 0.01 no ≠ ▬ ▬ 0.01 ▬ ▬ ▬ 0.01 ▬ 3x 5 0.1 no ≠ 1x 1 0.25 no ≠
1x 1 0.5 no ≠ ▬ ▬ 0.03 ▬ ▬ ▬ 0.03 ▬ 2x 6 0.3 no ≠ 2x 3 0.5 no ≠
3x 6 1 no ≠ ▬ ▬ 0.1 ▬ ▬ ▬ 0.1 ▬ 3x 6 1 no ≠ 1x 1 0.75 no ≠
2x 4 3 no ≠ ▬ ▬ 0.3 ▬ 1x 2 0.3 no ≠ 4x 10 3 ≠ * 1x 2 2 no ≠
5x 10 5 no ≠ ▬ ▬ 1.0 ▬ 1x 3 1 no ≠ 6x 12 10 no ≠ ▬ ▬ 0.01 ▬
4x 10 10 ≠ ?** ▬ ▬ 3.0 ▬ ▬ ▬ 3 ▬ 4x 8 30 no ≠ ▬ ▬ 0.03 ▬
2x 4 20 no ≠ 1x 1 10 ▬ ▬ ▬ 50 ▬ ▬ ▬ 0.1 ▬
1x 2 50 no ≠ ▬ ▬ 30 ▬ 1x 2 0.3 no ≠
1x 2 100 no ≠ 2x 4 1 no ≠
1x 2 3 no ≠
1x 2 10 no ≠
TRPC1/C6 ▬ ▬ 1 ▬ 3x 7 0.01 no ≠ 3x 6 0.01 no ≠ 2x 4 0.1 no ≠ 2x 4 0.01 no ≠
▬ ▬ 5 ▬ 4x 9 0.03 no ≠ 3x 6 0.03 no ≠ 3x 6 0.3 no ≠ 3x 6 0.03 no ≠
▬ ▬ 10 ▬ 5x 11 0.1 no ≠ 4x 10 0.1 no ≠ 4x 10 1 no ≠ 3x 6 0.1 no ≠
▬ ▬ 50 ▬ 8x 16 0.3 ≠ *** 3x 6 0.3 no ≠ 4x 8 3 no ≠ 3x 6 0.3 no ≠
7x 16 1.0 ≠ *** 3x 6 1 no ≠ 4x 9 10 no ≠ 7x 17 1 ≠ **
6x 12 3.0 ≠ *** 3x 8 3 no ≠ 4x 8 30 no ≠ 3x 6 3 no ≠
5x 13 10 no ≠ 50 3x 6 10 no ≠
4x 9 30 no ≠
TRPC1/C3/C6 ▬ ▬ 1 ▬ 2x 4 0.01 no ≠ ▬ ▬ 0.01 ▬ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
▬ ▬ 5 ▬ 3x 5 0.03 no ≠ ▬ ▬ 0.03 ▬ ▬ ▬ 0.3 ▬ ▬ ▬ 0.03 ▬
▬ ▬ 10 ▬ 3x 9 0.1 no ≠ 2x 4 0.1 ≠ ? ▬ ▬ 1 ▬ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ 3x 10 0.3 ≠ *** 1x 2 0.3 no ≠ ▬ ▬ 3 ▬ 1x 2 0.3 no ≠
3x 8 1.0 ≠ * 1x 2 1 no ≠ 2x 4 10 ≠ ? 3x 15 1 ≠ *
3x 6 3.0 no ≠ ▬ ▬ 3 ▬ 1x 2 30 no ≠ 2x 5 3 ≠ ?
3x 6 10 ≠ ? ▬ ▬ 50 ▬ 1x 2 10 no ≠
2x 5 30 ≠?
TRPC1/C4/C6 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.1 ▬ 1x 2 0.01 no ≠
▬ ▬ 5 ▬ ▬ ▬ 0.03 ▬ 1x 2 0.03 no ≠ 1x 2 0.3 no ≠ 1x 2 0.03 no ≠
▬ ▬ 10 ▬ ▬ ▬ 0.1 ▬ 3x 9 0.1 ≠ * 1x 4 1 no ≠ 1x 2 0.1 no ≠
▬ ▬ 50 ▬ 1x 2 0.3 no ≠ 1x 2 0.15 no ≠ 2x 4 3 no ≠ 2x 4 0.3 no ≠
2x 8 1.0 ≠ *** 1x 4 0.3 no ≠ 3(4)x 7 10 no ≠ 4x 13 1 ≠ ***
2x 6 3.0 ≠ *** 1x 2 1 no ≠ 1(2)x 6 30 no ≠ 6x 16 3 no ≠
2x 6 10 ≠ * 1x 2 3 no ≠ 50 ▬ 1x 2 10 no ≠
1x 1 30 ▬
TRPC1/C4 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
▬ ▬ 5 ▬ ▬ ▬ 0.03 ▬ ▬ ▬ 0.03 ▬ ▬ ▬ 0.3 ▬ ▬ ▬ 0.03 ▬
▬ ▬ 10 ▬ ▬ ▬ 0.1 ▬ 1x 2 0.1 no ≠ 1x 2 1 no ≠ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ ▬ ▬ 0.3 ▬ 1x 2 0.3 no ≠ 1x 3 3 no ≠ ▬ ▬ 0.3 ▬
▬ ▬ 1.0 ▬ 1x 2 1 no ≠ 1x 2 10 no ≠ ▬ ▬ 1 ▬
▬ ▬ 3.0 ▬ 1x 2 3 no ≠ 1x 2 30 no ≠ ▬ ▬ 3 ▬
▬ ▬ 10 ▬ ▬ ▬ 50 ▬ ▬ ▬ 10 ▬
▬ ▬ 30 ▬
ADP (PRP)
Aggregation from female mice
U46619 (WP)Collagen (WP)Thrombin (WP)ADP (WP)
Platelets from compound deficient mouse lines were analyzed after stimulation with ADP, thrombin, 
collagen or the Thromboxane A2 receptor agonist U46619 in platelet rich plasma (PRP) or washed 
platelets (WP) as indicated. For each agonist concentration the number of independent 
preparations (#prep) and the number of experiments (#exp) are given. Differences in maximal 
aggregation are mentioned in the observation (Obs.) columns. no≠: not significantly different, ≠: 
different (*p<0.05; **p<0.01, and ***p<0.001 according to the Student’s t-test), ≠?: possible 
difference, but reduced number of data to perform proper statistical analysis, and i.r.: inconsistent 
results. 
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Table 7A. Summary of platelet aggregometry results from different single TRPC deficient 
mouse lines analyzed in platelets from male mice. 
 TRP
#prep #exp µM Obs. #prep #exp µM Obs. #prep #exp U/ml Obs. #prep #exp µg/ml Obs. #prep #exp µM Obs.
TRPC3 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ 1x 2 0.01 no ≠ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
▬ ▬ 5 ▬ ▬ ▬ 0.03 ▬ 1x 2 0.03 no ≠ ▬ ▬ 0.3 ▬ ▬ ▬ 0.03 ▬
▬ ▬ 10 ▬ ▬ ▬ 0.1 ▬ 2x 4 0.1 no ≠ ▬ ▬ 1 ▬ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ ▬ ▬ 0.3 ▬ ▬ ▬ 0.15 ▬ ▬ ▬ 3 ▬ ▬ ▬ 0.3 ▬
▬ ▬ 1.0 ▬ 1x 4 0.2 no ≠ ▬ ▬ 10 ▬ ▬ ▬ 1 ▬
▬ ▬ 3.0 ▬ 2x 4 0.3 ≠ ** 2x 5 30 no ≠ ▬ ▬ 3 ▬
▬ ▬ 10 ▬ 3x 8 1 ≠ *** ▬ ▬ 50 ▬ ▬ ▬ 10 ▬
▬ ▬ 30 ▬ 2x 6 3 no ≠
TRPC5 ▬ ▬ 1 ▬ 1x 2 0.01 no ≠ ▬ ▬ 0.01 ▬ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
 litter-matched ▬ ▬ 5 ▬ 1x 4 0.03 no ≠ ▬ ▬ 0.03 ▬ ▬ ▬ 0.3 ▬ ▬ ▬ 0.03 ▬
▬ ▬ 10 ▬ 2x 6 0.1 no ≠ 2x 4 0.1 no ≠ ▬ ▬ 1 ▬ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ 2x 7 0.3 no ≠ 1x 2 0.3 no ≠ 1x 5 3 no ≠ 1x 4 0.3 no ≠
2x 8 1.0 no ≠ 1x 4 1 no ≠ 2x 7 10 no ≠ 2x 9 1 no ≠
2x 7 3.0 no ≠ ▬ ▬ 3 ▬ 1x 2 30 no ≠ 1x 2 3 no ≠
1x 3 10 no ≠ ▬ ▬ 50 ▬ ▬ ▬ 10 ▬
1x 4 30 no ≠
TRPC5 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
▬ ▬ 5 ▬ ▬ ▬ 0.03 ▬ ▬ ▬ 0.03 ▬ ▬ ▬ 0.3 ▬ ▬ ▬ 0.03 ▬
▬ ▬ 10 ▬ 1x 2 0.1 no ≠ 1x 4 0.1 no ≠ 1x 4 1 no ≠ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ 1x 3 0.3 ≠ *** 1x 2 0.3 no ≠ 1x 2 3 no ≠ ▬ ▬ 0.3 ▬
1x 4 1.0 ≠* ▬ ▬ 1 ▬ 1x 2 10 no ≠ 1x 2 1 no ≠
1x 3 3.0 ≠ * ▬ ▬ 3 ▬ 1x 2 30 no ≠ 1x 2 3 no ≠
1x 2 10 no ≠ ▬ ▬ 50 ▬ ▬ ▬ 10 ▬
1x 2 30 no ≠
TRPC6-C57 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ 3x 9 0.01 no ≠ 4x 11 0.1 no ≠ 2x 4 0.01 no ≠
▬ ▬ 5 ▬ ▬ ▬ 0.03 ▬ 4x 10 0.03 no ≠ 2x 7 0.3 no ≠ 1x 2 0.03 no ≠
▬ ▬ 10 ▬ 1x 2 0.1 no ≠ 7x 15 0.1 no ≠ 5x 9 1 no ≠ 1x 3 0.1 no ≠
▬ ▬ 50 ▬ 1x 2 0.3 no ≠ 3x 6 0.15 no ≠ 5x 14 3 no ≠ 2x 6 0.3 no ≠
2x 9 1.0 no ≠ 5x 10 0.3 no ≠ 7x 13 10 no ≠ 5x 15 1 no ≠
2x 5 3.0 no ≠ 8x 16 1 no ≠ 6x 10 30 no ≠ 4x 13 3 no ≠
2x 6 10 no ≠ 3x 8 3 no ≠ 50 ▬ 3x 6 10 no ≠
2x 9 30 no ≠
TRPC6-F1 ▬ ▬ 1 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.01 ▬ ▬ ▬ 0.1 ▬ ▬ ▬ 0.01 ▬
▬ ▬ 5 ▬ ▬ ▬ 0.03 ▬ 1x 3 0.03 no ≠ 2x 4 0.3 no ≠ ▬ ▬ 0.03 ▬
▬ ▬ 10 ▬ 1x 4 0.1 no ≠ 3x 11 0.1 no ≠ 1x 3 1 no ≠ ▬ ▬ 0.1 ▬
▬ ▬ 50 ▬ 1x 4 0.3 i.r. 1x 2 0.15 no ≠ 4x 8 3 no ≠ 4x 7 0.3 no ≠
1x 4 1.0 no ≠ 3x 9 0.3 no ≠ 3x 11 10 no ≠ 4x 15 1 no ≠
1x 4 3.0 no ≠ 1x 2 1 no ≠ 1x 2 30 no ≠ 3x 7 3 no ≠
1x 4 10 no ≠ ▬ ▬ 3 ▬ ▬ ▬ 50 ▬ 1x 2 5 i.r.
▬ ▬ 30 ▬ ▬ 10 ▬
Aggregation from male mice
ADP (PRP)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ▬
ADP (WP) Thrombin (WP) Collagen (WP) U46619 (WP)
Platelets from single deficient mouse lines were analyzed after stimulation with ADP, thrombin, 
collagen or the Thromboxane A2 receptor agonist U46619 in platelet rich plasma (PRP) or washed 
platelets (WP) as indicated. For each agonist concentration the number of independent 
preparations (#prep) and the number of experiments (#exp) are given. Differences in maximal 
aggregation are mentioned in the observation (Obs.) columns. The suffixes –F1 or –C57 refers to 
the background of the mouse line, either from a mixed background (129SvJ x C57BL6N) or from a 
single C57BL6N background, respectively. no≠: not significantly different, ≠: different (*p<0.05; 
**p<0.01, and ***p<0.001 according to the Student’s t-test), ≠?: possible difference, but reduced 
number of data to perform proper statistical analysis, and i.r.: inconsistent results. 
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Table 7B. Summary of platelet aggregometry results from different compound TRPC 
deficient mouse lines analyzed in platelets from male mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRP
#prep #exp µM Obs. #prep #exp µM Obs. #prep #exp U/ml Obs. #prep #exp µg/ml Obs. #prep #exp µM Obs.
TRPC3/C6 1 ▬ 3x 7 0.01 no ≠ 4x 9 0.01 no ≠ 3x 5 0.1 no ≠ 2x 4 0.01 no ≠
5 ▬ 3x 7 0.03 no ≠ 5x 10 0.03 no ≠ 3x 6 0.3 no ≠ 2x 4 0.03 no ≠
10 ▬ 5x 10 0.1 no ≠ 9x 25 0.1 ≠** 4x 9 1 no ≠ 2x 6 0.1 no ≠
50 ▬ 5x 13 0.3 ≠** 5x 12 0.15 ≠ * 6x 13 3 no ≠ 4x 6 0.3 no ≠
5x 15 1.0 no ≠ 8x 17 0.3 no ≠ 7x 13 10 no ≠ 8x 19 1 ≠ *
5x 10 3.0 no ≠ 7x 16 1 ≠ * 5x 13 30 no ≠ 4x 9 3 ≠ *
5x 10 10 no ≠ 5x 14 3 no ≠ ▬ ▬ 50 ▬ 3x 6 10 no ≠
5x 11 30 ≠** 
TRPC4/C6 ▬ ▬ 0.01 ▬ ▬ ▬ 0.01 ▬ 1x 2 0.01 no ≠ 1x 2 0.1 ▬ ▬ ▬ 0.01 ▬
▬ ▬ 0.5 ▬ ▬ ▬ 0.03 ▬ 1x 2 0.03 no ≠ 1x 2 0.3 ▬ ▬ ▬ 0.03 ▬
2x 3 1 no ≠ ▬ ▬ 0.1 ▬ 1x 2 0.1 no ≠ 2x 6 1 ▬ 1x 1 0.1 ▬
1x 1 3 no ≠ ▬ ▬ 0.3 ▬ 1x 2 0.15 no ≠ 3x 5 3 ≠ ** 1x 3 0.3 no ≠
1x 2 5 no ≠ ▬ ▬ 1.0 ▬ 2x 5 0.3 no ≠ 2x 5 10 ≠ * 1x 3 1 ≠ ?
3x 7 10 no ≠ ▬ ▬ 3.0 ▬ 2x 5 1 no ≠ 2x 5 30 ≠ * 1x 2 3 no ≠
▬ ▬ 20 ▬ ▬ ▬ 10 ▬ 2x 3 3 no ≠ ▬ ▬ 50 ▬ ▬ ▬ 10 ▬
▬ ▬ 50 ▬ ▬ ▬ 30 ▬
▬ ▬ 100 ▬
TRPC1/C6 ▬ ▬ 1 ▬ 2x 4 0.01 no ≠ 2x 4 0.01 no ≠ 1x 3 0.1 no ≠ 2x 4 0.01 no ≠
▬ ▬ 5 ▬ 2x 4 0.03 no ≠ 2x 4 0.03 no ≠ 1x 3 0.3 no ≠ 2x 4 0.03 no ≠
▬ ▬ 10 ▬ 4x 10 0.1 no ≠ 2x 4 0.1 no ≠ 2x 4 1 no ≠ 2x 4 0.1 no ≠
▬ ▬ 50 ▬ 6x 14 0.3 ≠ ** 2x 4 0.3 no ≠ 3x 6 3 no ≠ 2x 4 0.3 no ≠
6x 14 1.0 no ≠ 2x 5 1 no ≠ 3x 6 10 no ≠ 5x 15 1 ≠ **
4x 12 3.0 no ≠ 2x 5 3 no ≠ 2x 4 30 no ≠ 3x 7 3 no ≠
3x 6 10 no ≠ ▬ ▬ 50 ▬ 2x 4 10 no ≠
3x 11 30 no ≠
Aggregation from male mice
ADP (PRP) ADP (WP) Thrombin (WP) Collagen (WP) U46619 (WP)
Platelets from compound deficient mouse lines were analyzed after stimulation with ADP, thrombin, 
collagen or the Thromboxane A2 receptor agonist U46619 in platelet rich plasma (PRP) or washed 
platelets (WP) as indicated. For each agonist concentration the number of independent 
preparations (#prep) and the number of experiments (#exp) are given. Differences in maximal 
aggregation are mentioned in the observation (Obs.) columns. no≠: not significantly different, ≠: 
different (*p<0.05; **p<0.01, and ***p<0.001 according to the Student’s t-test), ≠?: possible 
difference, but reduced number of data to perform proper statistical analysis. 
 
 
5.2.4.1 Agonist-induced in vitro platelet aggregation in TRPC6-/- platelets 
 
The experiments below are pooled from at least 3 independent experimental series and 
obtained with platelets from female TRPC6-/- mice and F1 controls. Similar results were 
obtained in platelets from male mice as well as from mice of both genders bred under 
C57BL6/N background (see summary of all experiments in Tables 6A and 7A).  
 
ADP-induced aggregation in platelets from TRPC6-/- mice was not impaired at all tested 
concentrations (Figure 27, A). Aggregation analyzed by maximal aggregation, area of the 
aggregation curve, PSC or aggregation curve slope in all ADP concentrations was 
comparable between wild type and TRPC6-/- platelets (Figure 27, A). The Thromboxane 
A2 analogue U46619 produced also similar aggregation responses (Figure 27, B). Neither 
thrombin- (Figure 28, A) nor collagen-induced (Figure 28, B) aggregation in platelets from 
TRPC6 deficient mice presented impaired responses.  
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Figure 27. ADP- and U46619-induced platelet aggregation in washed platelets from wild type 
and TRPC6 -/- mice. Representative original aggregation curves of ADP-induced aggregation in 
wild type (black) and TRPC6-/- platelets where ADP application is indicated by an arrow (A, upper 
panels). Concentration-response curves from platelets stimulated with: (A) ADP or (B) 
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Thromboxane A2 analogue U46619 where maximal aggregation (a), area under the aggregation 
curve (b), platelet shape change (PSC, c) and maximal slope during aggregation (d) were 
analyzed. Numbers of measurements per ADP concentration for wild type were: 0.01µM=6, 
0.03µM=7, 0.1µM=10, 0.3µM=10, 1µM=8, 3µm=8, 10µM=6, 30µM=4, and for TRPC6-/- were: 
0.01µM=8, 0.03µM=9, 0.1µM=11, 0.3µM=15, 1µM=13, 3µm=10, 10µM=9, 30µM=4. Numbers of 
measurements per U46619 concentration for wild type were: 0.01µM=2, 0.03µM=2, 0.1µM=4, 
0.3µM=4, 1µM=8, 3µM=7, 10µM=6, and for TRPC6-/- were: 0.01µM=2, 0.03µM=2, 0.1µM=4, 
0.3µM=4, 1µM=10, 3µM=10, 10µM=6. Error bars indicate SEM. 
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Figure 28. Thrombin- and collagen-induced platelet aggregation in washed platelets from 
wild type and TRPC6 -/- mice. Concentration-response curves from wild type (WT) and TRPC6-/- 
platelets stimulated with: (A) thrombin or (B) collagen where maximal aggregation (a), area under 
the aggregation curve (b), platelet shape change (PSC, c) and maximal slope during aggregation 
(d) were analyzed. Numbers of measurements per thrombin concentration for wild type were: 
0.01U/ml=2, 0.03U/ml=2, 0.1U/ml=5, 0.3U/ml=6, 1U/ml=4, 3U/ml=4, and for TRPC6-/- were: 
0.01U/ml=2, 0.03U/ml=2, 0.1U/ml=7, 0.3U/ml=6, 1U/ml=6, 3U/ml=7. Numbers of measurements 
per collagen concentration for wild type were: 0.1µg/ml=2, 0.3µg/ml=4, 1µg/ml=8, 3µg/ml=4, 
10µg/ml=6, 30µg/ml=4, and for TRPC6-/- were: 0.1µg/ml=5, 0.3µg/ml=7, 1µg/ml=6, 3µg/ml=4, 
10µg/ml=6, 30µg/ml=4. Error bars indicate SEM. 
 
 
 
 
5.2.4.2 Agonist-induced in vitro platelet aggregation in TRPC1/TRPC6 (-/-)2 platelets 
 
In platelets from TRPC1/TRPC6 (-/-)2 female mice a right shift in ADP dose response of 
both the maximal aggregation and the area under the aggregation curve was observed 
(Figure 29, Aa-b). Also, ADP-induced aggregation was slower in TRPC1/TRPC6 (-/-)2 
platelets as measured by the slope of the aggregation curve (Figure 29, Ad). No 
differences were observed in platelet shape change (Figure 29, Ac). Similar results were 
obtained in platelets from male mice. After 0.3µM ADP stimulation the maximal 
aggregation, the aggregation area, the slope of the aggregation curve, and also the PSC 
were significantly reduced in TRPC1/TRPC6 (-/-)2 platelets (Figure 29, B). 
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Figure 29. ADP-induced platelet aggregation in washed platelets from wild type and 
TRPC1/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC1/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
ADP-induced aggregation in wild type and TRPC1/TRPC6 (-/-)2 platelets where ADP application is 
indicated by an arrow (A, upper panels). Concentration-response curves where maximal 
aggregation (a), area under the aggregation curve (b), platelet shape change (PSC, c) and 
maximal slope during aggregation (d) were analyzed. Numbers of measurements per ADP 
concentration for wild type females were: 0.01µM=8, 0.03µM=9, 0.1µM=13, 0.3µM=23, 1µM=20, 
3µm=15, 10µM=18, 30µM=11; for TRPC1/TRPC6 (-/-)2 females were: 0.01µM=7, 0.03µM=9, 
0.1µM=11, 0.3µM=16, 1µM=16, 3µm=12, 10µM=13, 30µM=9; for wild type males were: 0.01µM=5, 
0.03µM=6, 0.1µM=9, 0.3µM=19, 1µM=22, 3µm=13, 10µM=9, 30µM=9; and for TRPC1/TRPC6(-/-)2 
males were: 0.01µM=4, 0.03µM=4, 0.1µM=10, 0.3µM=14, 1µM=14, 3µm=12, 10µM=6, 30µM=11. 
Error bars indicate SEM. *p<0.05, **p<0.01 and ***p<0.001 according to the Student’s t-test. 
 
 
Induction of platelet aggregation with 1µM U46619 revealed a prominent reduction in 
platelets from TRPC1/TRPC6 (-/-)2 mice of both genders. The maximal aggregation was 
significantly reduced by 33% in platelets from TRPC1/TRPC6 (-/-)2 female mice by 31% in 
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males (Figure 30, Aa and Ba). The area under aggregation curve and the slope of the 
aggregation curve were also significantly reduced in platelets from TRPC1/TRPC6 (-/-)2 
mice at 1µM U46619 (Figure 30, A and B). PSC was only different at 3µM only in platelets 
from male mice (Figure 30, Ac and Bc). 
 
Thrombin experiments with TRPC1/TRPC6 (-/-)2 platelets from female or male mice 
showed no difference at any tested concentration in maximal aggregation, area under 
aggregation curve and PSC (Figure 31, Aa-c and Ba-c). Only the slope of the aggregation 
curve was significantly diminished at 0.1U/ml thrombin in platelets from with 
TRPC1/TRPC6 (-/-)2 male mice, and it was reduced at three concentrations in platelets 
from with TRPC1/TRPC6 (-/-)2 female mice (Figure 31, Ad and Bd). 
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Figure 30. U46619-induced platelet aggregation in washed platelets from wild type and 
TRPC1/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC1/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
U46619-induced aggregation in wild type and TRPC1/TRPC6 (-/-)2 platelets where U46619 
application is indicated by an arrow (A, upper panels). At 1µM U46619 not all four traces from 
TRPC1/TRPC6 deficient platelets are visible because there was no aggregation in some of them. 
Concentration-response curves where maximal aggregation (a), area under the aggregation curve 
(b), platelet shape change (PSC, c) and maximal slope during aggregation (d) were analyzed. 
Numbers of measurements per U46619 concentration for wild type females were: 0.01µM=4, 
0.03µM=7, 0.1µM=8, 0.3µM=10, 1µM=22, 3µm=7, 10µM=6; for TRPC1/TRPC6 (-/-)2 females were: 
0.01µM=4, 0.03µM=6, 0.1µM=6, 0.3µM=6, 1µM=17, 3µm=6, 10µM=6; for wild type males were: 
0.01µM=6, 0.03µM=4, 0.1µM=4, 0.3µM=4, 1µM=18, 3µm=8, 10µM=4; and for TRPC1/TRPC6(-/-)2 
males were: 0.01µM=4, 0.03µM=4, 0.1µM=4, 0.3µM=4, 1µM=15, 3µm=7, 10µM=4. Error bars 
indicate SEM. **p<0.01 and ***p<0.001 according to the Student’s t-test. 
 
 
Collagen-induced platelet aggregation evaluated by maximum aggregation, area under 
aggregation curve, PSC and aggregation curve slope was unchanged in platelets from 
TRPC1/TRPC6 deficient mice (Figure 32).  
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Figure 31. Thrombin-induced platelet aggregation in washed platelets from wild type and 
TRPC1/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC1/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
thrombin-induced aggregation in wild type and TRPC1/TRPC6 (-/-)2 platelets where thrombin 
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application is indicated by an arrow (A, upper panels). Concentration-response curves where 
maximal aggregation (a), area under the aggregation curve (b), platelet shape change (PSC, c) 
and maximal slope during aggregation (d) were analyzed. Numbers of measurements per thrombin 
concentration for wild type females were: 0.01U/ml=9, 0.03U/ml=6, 0.1U/ml=12, 0.3U/ml=6, 
1U/ml=7, 3U/ml=9; for TRPC1/TRPC6 (-/-)2 females were: 0.01U/ml=6, 0.03U/ml=6, 0.1U/ml=10, 
0.3U/ml=6, 1U/ml=6, 3U/ml=8; for wild type males were: 0.01U/ml=4, 0.03U/ml=5, 0.1U/ml=3, 
0.3U/ml=6, 1U/ml=4, 3U/ml=6; and for TRPC1/TRPC6(-/-)2 males were: 0.01U/ml=4, 0.03U/ml=4, 
0.1U/ml=2, 0.3U/ml=4, 1U/ml=5, 3U/ml=5. Error bars indicate SEM. *p<0.05 and **p<0.01 
according to the Student’s t-test. 
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Figure 32. Collagen-induced platelet aggregation in washed platelets from wild type and 
TRPC1/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC1/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
collagen-induced aggregation in wild type and TRPC1/TRPC6 (-/-)2 platelets where collagen 
application is indicated by an arrow (A, upper panels). Concentration-response curves where 
maximal aggregation (a), area under the aggregation curve (b), platelet shape change (PSC, c) 
and maximal slope during aggregation (d) were analyzed. Numbers of measurements per collagen 
concentration for wild type females were: 0.1µg/ml=4, 0.3µg/ml=6, 1µg/ml=11, 3µg/ml=11, 
10µg/ml=9, 30µg/ml=8; for TRPC1/TRPC6 (-/-)2 females were: 0.1µg/ml=4, 0.3µg/ml=6, 
1µg/ml=10, 3µg/ml=8, 10µg/ml=9, 30µg/ml=8; for wild type males were: 0.1µg/ml=2, 0.3µg/ml=2, 
1µg/ml=6, 3µg/ml=8, 10µg/ml=8, 30µg/ml=4; and for TRPC1/TRPC6(-/-)2 males were: 0.1µg/ml=3, 
0.3µg/ml=3, 1µg/ml=4, 3µg/ml=6, 10µg/ml=6, 30µg/ml=4. Error bars indicate SEM. ns (not 
significant) according to the Student’s t-test. 
 
 
5.2.4.3 Agonist-induced in vitro platelet aggregation in TRPC3/TRPC6 (-/-)2 platelets 
 
The analysis of platelets from TRPC3/TRPC6 (-/-)2 mice was of particular interest because 
it has been reported that TRPC3 expression is upregulated in TRPC6-/- mice which leads 
to a functional compensation of that of TRPC6 proteins (Dietrich et al., 2005). ADP-
induced platelet aggregation response was diminished in platelets from TRPC3/TRPC6 
deficient female and male mice. Analysis of maximal aggregation, area under the 
aggregation curve and slope of the aggregation curve showed a right shift in the dose-
responses from TRPC3/TRPC6 (-/-)2 platelets and the differences were significant for 
several ADP doses (Figure 33). Also, PSC was significantly reduced in platelets from 
TRPC3/TRPC6 (-/-)2 mice at various ADP concentrations (Figure 33, Ac and Bc). 
 
U46619-induced platelet aggregation in platelets from TRPC3/TRPC6 (-/-)2 mice was also 
impaired. At a concentration of 1µM U46619 maximal aggregation was significantly 
reduced by 36% and 7% in platelets from female and male TRPC3/TRPC6 (-/-)2 mice, 
respectively, and a significant reduction was also observed at 3µM U46619 (Figure 34, Aa 
and Ba). The aggregation area and the slope of the aggregation curve were also reduced 
in platelets from TRPC3/TRPC6 (-/-)2 female mice (Figure 34, A). 
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Figure 33. ADP-induced platelet aggregation in washed platelets from wild type and 
TRPC3/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC3/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
ADP-induced aggregation in wild type and TRPC3/TRPC6 (-/-)2 platelets where ADP application is 
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indicated by an arrow (A, upper panels). Concentration-response curves where maximal 
aggregation (a), area under the aggregation curve (b), platelet shape change (PSC, c) and 
maximal slope during aggregation (d) were analyzed. Numbers of measurements per ADP 
concentration for wild type females were: 0.01µM=8, 0.03µM=8, 0.1µM=8, 0.3µM=16, 1µM=23, 
3µm=12, 10µM=11, 30µM=10; for TRPC3/TRPC6 (-/-)2 females were: 0.01µM=6, 0.03µM=6, 
0.1µM=8, 0.3µM=18, 1µM=25, 3µm=12, 10µM=10, 30µM=9; for wild type males were: 0.01µM=7, 
0.03µM=8, 0.1µM=11, 0.3µM=13, 1µM=15, 3µm=10, 10µM=12, 30µM= 13; and for 
TRPC3/TRPC6(-/-)2 males were: 0.01µM=7, 0.03µM=7, 0.1µM=10, 0.3µM=13, 1µM=15, 3µm=10, 
10µM=10, 30µM=11. Error bars indicate SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (significant) 
according to the Student’s t-test. 
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Figure 34. U46619-induced platelet aggregation in washed platelets from wild type and 
TRPC3/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC3/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
U46619-induced aggregation in wild type and TRPC3/TRPC6 (-/-)2 platelets where U46619 
application is indicated by an arrow (A, upper panels). Concentration-response curves where 
maximal aggregation (a), area under the aggregation curve (b), platelet shape change (PSC, c) 
and maximal slope during aggregation (d) were analyzed. Numbers of measurements per U46619 
concentration for wild type females were: 0.01µM=8, 0.03µM=7, 0.1µM=7, 0.3µM=7, 1µM=29, 
3µm=9, 10µM=6; for TRPC3/TRPC6 (-/-)2 females were: 0.01µM=7, 0.03µM=7, 0.1µM=6, 
0.3µM=6, 1µM=38, 3µm=11, 10µM=6; for wild type males were: 0.01µM=4, 0.03µM=4, 0.1µM=6, 
0.3µM=6, 1µM=14, 3µm=6, 10µM=6; and for TRPC3/TRPC6(-/-)2 males were: 0.01µM=4, 
0.03µM=4, 0.1µM=6, 0.3µM=6, 1µM=13, 3µm=6, 10µM=6, Error bars indicate SEM. *p<0.05, 
**p<0.01 and ***p<0.001 according to the Student’s t-test. 
 
 
The maximal aggregation induced by thrombin was diminished by ~34% in 
TRPC3/TRPC6 (-/-)2 platelets at a concentration of 0.1U/ml thrombin (Figure 35, Aa and 
Ba). In platelets from TRPC3/TRPC6 (-/-)2 female mice the aggregation area at 0.1U/ml 
thrombin and the slope of the aggregation curve at several thrombin concentrations were 
significantly reduced (Figure 35, A). Similar results were seen in platelets from male mice 
(see Table 7B). PSC was not different between genotypes (Figure 35, Ac and Bb). The 
difference observed in thrombin aggregation was reduced when apyrase concentration 
was increased ten fold. Apyrase hydrolyses ATP and ADP into AMP; therefore part of the 
difference in thrombin aggregation could be explained an impaired ADP-induced 
aggregation produced by the secreted ADP during thrombin stimulation (Figure 35, Ba 
and Bc). 
 
Collagen-induced platelet aggregation was not essentially impaired in TRPC3/TRPC6 
deficient platelets of females (Figure 36, A) and males (Figure 36, B). 
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Figure 35. Thrombin-induced platelet aggregation in washed platelets from wild type and 
TRPC3/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC3/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
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thrombin-induced aggregation in wild type and TRPC3/TRPC6 (-/-)2 platelets where thrombin 
application is indicated by an arrow (A, upper panels). In A concentration-response curves where 
maximal aggregation (a), area under the aggregation curve (b), platelet shape change (PSC, c) 
and maximal slope during aggregation (d) were analyzed. In B are shown maximal aggregation (a 
and c) and PSC (b and d) for experiments in the presence of 0.02U/ml (upper panels) or 0.2U/ml 
(lower panels) apyrase. Numbers of measurements per thrombin concentration for wild type 
females were: 0.01U/ml=4, 0.03U/ml=4, 0.1U/ml=12, 0.3U/ml=4, 1U/ml=2, 3U/ml=4; for 
TRPC3/TRPC6(-/-)2 females were: 0.01U/ml=5, 0.03U/ml=4, 0.1U/ml=9, 0.3U/ml=4, 1U/ml=2, 
3U/ml=4; for wild type males (a and b) were: 0.01U/ml=5, 0.03U/ml=5, 0.1U/ml=12, 0.3U/ml=6, 
1U/ml=6, 3U/ml=9; for TRPC3/TRPC6(-/-)2 males (a and b) were: 0.01U/ml=4, 0.03U/ml=4, 
0.1U/ml=12, 0.3U/ml=6, 1U/ml=6, 3U/ml=7; for wild type males (c and d) were: 0.01U/ml=6 , 
0.03U/ml=6, 0.1U/ml=12, 0.15U/ml=15, 0.3U/ml=10, 1U/ml=10, 3U/ml=8; and for TRPC3/TRPC6(-
/-)2 males (c and d) were: 0.01U/ml=5, 0.03U/ml=6, 0.1U/ml=14, 0.15U/ml=12, 0.3U/ml=11, 
1U/ml=10, 3U/ml=7. Error bars indicate SEM. *p<0.05 and **p<0.01 according to the Student’s t-
test. 
 
 
 
 Collagen (♀)
ag
gr
eg
at
io
n
%
time (10min) time (10min) time (10min) time (10min)
100
50
0
[3 µg/ml] [10 µg/ml] [30 µg/ml][1 µg/ml]
100
50
0
100
50
0
100
50
0
(A)
c d
a b
0.1 1 10 100
0
20
40
60
80
100
*
Collagen [µg/µm]
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRPC3/C6 (-/-)2
WT 
M
ax
im
al
 a
gg
re
ga
tio
n
[%
]
M
ax
im
al
 a
gg
re
ga
tio
n
[%
]
0.1 1 10 100
-45
-40
-35
-30
-25
-20
-15
-10
-5
0
Collagen [µg/µm]
PS
C
 [%
]
PS
C
 [%
]
0.1 1 10 100
*
Collagen [µg/µm]
Ar
ea
>0
 [ 
%
]
Ar
ea
>0
 [ 
%
]
0.1 1 10 100
0
10
20
30
40
50
60
70
80
90
100
110
120
130
Collagen [µg/µm]
Ag
gr
eg
at
io
n 
sl
op
e
[%
ag
g/
m
in
]
Ag
gr
eg
at
io
n 
sl
op
e
[%
ag
g/
m
in
]
 
Results  137  
 
Collagen (♂)(B)
a b
0.1 1 10 100
-45
-40
-35
-30
-25
-20
-15
-10
-5
0
PS
C
 [%
]
Collagen [µg/µm]
PS
C
 [%
]
0.1 1 10 100
0
20
40
60
80
100
*
Collagen [µg/µm]
M
ax
im
al
 a
gg
re
ga
tio
n
[%
]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Collagen-induced platelet aggregation in washed platelets from wild type and 
TRPC3/C6 (-/-)2 mice. Platelet aggregation was compared between wild type and TRPC3/TRPC6 
(-/-)2 platelets from (A) female and (B) male mice. Representative original aggregation curves of 
collagen-induced aggregation in wild type and TRPC3/TRPC6 (-/-)2 platelets where collagen 
application is indicated by an arrow (A, upper panels). In A concentration-response curves where 
maximal aggregation (a), area under the aggregation curve (b), platelet shape change (PSC, c) 
and maximal slope during aggregation (d) were analyzed. Numbers of measurements per collagen 
concentration for wild type females were: 0.1µg/ml=2, 0.3µg/ml=4, 1µg/ml=4, 3µg/ml=8, 10µg/ml=6, 
30µg/ml=4; for TRPC3/TRPC6 (-/-)2 females were: 0.1µg/ml=2, 0.3µg/ml=4, 1µg/ml=4, 3µg/ml=6, 
10µg/ml=5, 30µg/ml=4; for wild type males (a and b) were: 0.1µg/ml=4, 0.3µg/ml=4, 1µg/ml=4, 
3µg/ml=4, 10µg/ml=4, 30µg/ml=7; for TRPC3/TRPC6(-/-)2 males (a and b) were: 0.1µg/ml=4, 
0.3µg/ml=4, 1µg/ml=4, 3µg/ml=4, 10µg/ml=6, 30µg/ml=7; for wild type males (c and d) were: 
0.1µg/ml=4, 0.3µg/ml=2, 1µg/ml=4, 3µg/ml=12, 10µg/ml=11, 30µg/ml=8; and for TRPC3/TRPC6(-/-
)2 males (c and d) were: 0.1µg/ml=1, 0.3µg/ml=2, 1µg/ml=5, 3µg/ml=9, 10µg/ml=7, 30µg/ml=6. 
Error bars indicate SEM. *p<0.05 according to the Student’s t-test. 
 
 
 
5.2.4.4 Comparison of ADP-induced in vitro platelet aggregation in TRPC1/TRPC6 
and TRPC3/TRPC6 deficient platelets 
 
In figures 37 and 38 the ADP-induced aggregation responses from TRPC1/TRPC6 (-/-)2 
and TRPC3/TRPC6 (-/-)2 mice was a mixed background are compared. In this comparison 
the results from wild type mice used as control for both genotypes were pooled. 
 
Female mice. Platelets from females from both mouse lines had similar maximal 
aggregation responses, but reduced in comparison to wild type platelets after stimulation 
with ADP in a concentration range from 0.3µM to 3µM for both genotypes, and up to 30µM 
for TRPC3/TRPC6 (-/-)2 platelets. The percentual reduction of maximal aggregation were 
between 7 to 76% depending on the dose (Figure 37, A). The slope of the aggregation 
area was not different between platelets from TRPC1/TRPC6 and TRPC3/TRPC6 
deficient female mice, but it was significantly reduced when compared to wild type mice in 
a broad range of ADP concentrations (Figure 37, D). In contrast, the reduction in the 
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aggregation area was more prominent in platelets from TRPC3/TRPC6 (-/-)2 female mice 
than in platelets from TRPC1/TRPC6 (-/-)2 females, for example at 1µM ADP where the 
reduction was 57% and 22%, respectively (Figure 37, B).  
 
Male mice. In platelets from TRPC1/TRPC6 (-/-)2 and TRPC3/TRPC6 (-/-)2 male mice the 
reduction in the aggregation response was also observed (Figure 38), but it was less 
prominent than in platelets from females. Maximal aggregation, area under aggregation 
curve and slope of the aggregation curve were significantly reduced in TRPC1/TRPC6 
and TRPC3/TRPC6 deficient platelets at various ADP concentrations (Figure 38, A,B and 
D). PSC was significantly reduced only in TRPC3/TRPC6 (-/-)2 platelets. 
 
 
TRPC1/TRPC3/TRPC6 (-/-)3 mice. TRPC1/TRPC3/TRPC6 (-/-)3 mice were also fertile 
and show no obvious sign of disease. These mice were produced specially to asses 
whether the deletion of TRPC1, TRPC3 and TRPC6 together would produces more 
prominent differences than those observed in platelets from TRPC1/TRPC6 (-/-)2 and 
TRPC3/TRPC6 (-/-)2 mice. After stimulation with various collagen or thrombin 
concentrations no difference in aggregation was observed in platelets from 
TRPC1/TRPC3/TRPC6 (-/-)3 mice. In contrast, the ADP response, as well as the response 
to 1µM U46619 were reduced (Table 6B). However, the ADP- and U46619-induced 
aggregation responses in platelets from TRPC1/TRPC3/TRPC6 (-/-)3 mice were around 
the same extent as those in TRPC1/TRPC6 (-/-)2 and TRPC3/TRPC6 (-/-)2 mice.  
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Figure 37. Comparison of ADP-induced platelet aggregation in TRPC1/C6 (-/-)2  and 
TRPC3/C6 (-/-)2 platelets from female mice. Concentration-response curves where (A) maximal 
aggregation, (B) area under the aggregation curve, (C) platelet shape change (PSC) and (D) 
maximal slope during aggregation were analyzed. Bar graphs from the maximal aggregation (A, 
right) and from the area under the aggregation curve (B, right) include the percentage of reduction 
in comparison with the wild type response. Numbers of measurements per ADP concentration for 
wild type mice were: 0.01µM=22, 0.03µM=24, 0.1µM=31, 0.3µM=51, 1µM=62, 3µM=45, 10µM=46, 
30µM=28; for TRPC1/TRPC6 (-/-)2 mice were: 0.01µM=7, 0.03µM=9, 0.1µM=11, 0.3µM=16, 
1µM=16, 3µm=12, 10µM=13, 30µM=9; and for TRPC3/TRPC6 (-/-)2 mice were: 0.01µM=6, 
0.03µM=6, 0.1µM=8, 0.3µM=18, 1µM=25, 3µm=12, 10µM=10, 30µM=9. Error bars indicate SEM. 
*p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to the Student’s t-test from 
comparisons against WT values. 
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Figure 38. Comparison of ADP-induced platelet aggregation in TRPC1/C6 (-/-)2  and 
TRPC3/C6 (-/-)2 platelets from male mice. Concentration-response curves where (A) maximal 
aggregation, (B) area under the aggregation curve, (C) platelet shape change (PSC) and (D) 
maximal slope during aggregation were analyzed. Bar graphs from the maximal aggregation (A, 
right) and from the area under the aggregation curve (B, right) include the percentage of reduction 
in comparison with the wild type response. Numbers of measurements per ADP concentration for 
wild type mice were: 0.01µM=12, 0.03µM=14, 0.1µM=26, 0.3µM=38, 1µM=42, 3µM=30, 10µM=24 , 
30µM=25; for TRPC1/TRPC6 (-/-)2 mice were: 0.01µM=4, 0.03µM=4, 0.1µM=10, 0.3µM=14, 
1µM=14, 3µm=12, 10µM=4, 30µM=11; and for TRPC3/TRPC6 (-/-)2 mice were: 0.01µM=7, 
0.03µM=7, 0.1µM=10, 0.3µM=13, 1µM=15, 3µm=10, 10µM=10, 30µM=11. Error bars indicate 
SEM. *p<0.05, **p<0.01, ***p<0.001 and ns (not significant) according to the Student’s t-test from 
comparisons against WT values. 
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5.2.5 In vitro aggregation in platelets from Clopidogrel pre-treated mice 
 
ADP activates in mouse platelets two differently coupled receptors, P2Y1 and P2Y12 
receptors coupled to Gαq and Gαi proteins, respectively. To distinguish between the ADP-
induced responses mediated by these receptors I did experiments with platelets from mice 
pre-treated with Clopidogrel (5mg/kg/day, orally over 2 days). Clopidogrel is a pro-drug 
and its active metabolite is an irreversible PY12 antagonist. With its use we evaluated the 
ADP pathway leading to activation of the P2Y1-Gαq-PLC pathway which leads to elevation 
of intracellular Ca2+ concentration in platelets and might involve TRPC channels.  
 
 
5.2.5.1 Effect of Clopidogrel in aggregation of platelets from wild type mice 
 
Before performing comparative analysis between wild type and knockout mice using 
Clopidogrel, I compared the in vitro aggregation in platelets isolated from wild type female 
mice treated with vehicle solution or Clopidogrel. Platelets from vehicle pre-treated mice 
aggregated normally after ADP stimulation (Figure 39); therefore the vehicle control could 
be omitted in further experiments. ADP-induced aggregation in platelets from Clopidogrel 
treated mice was significantly reduced in a broad range of ADP concentrations (Figure 39) 
and the maximal aggregation was reduced between 67% up to 97%. Clopidogrel also 
reduced maximal aggregation induced by 10µg/ml collagen or by 1µM U46619, in 22% 
(89 ±2 % vs. 70 ±8%; n=3-5) and 21% (85 ±3% vs. 67 ±%; n=3-5), respectively, indicating 
that TxA2- and collagen-induced aggregation are partially mediated by ADP release. 
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Figure 39. ADP-induced aggregation in platelets from Clopidogrel pre-treated wild type 
female mice. ADP-induced platelet aggregation was compared between platelets from wild type 
mice pre-treated either with vehicle (in black) or with Clopidogrel (in blue). (A) Original traces of 
platelet aggregation where ADP application is indicated by an arrow. Statistical analysis from (B) 
maximal aggregation and (C) area under the aggregation curve. Mice (n=5) received Clopidogrel 
orally at a dose of 5mg/kg/day over 2 days. n=number of aggregation curves. Error bars indicate 
SEM. ***p<0.001 according to the Student’s t-test. 
 
Results  142  
5.2.5.2 Aggregation in TRPC1/TRPC6 (-/-)2 and TRPC3/TRPC6 (-/-)2 platelets from 
Clopidogrel pre-treated mice  
 
The differences in ADP-induced platelet aggregation in both TRPC1/TRPC6 (-/-)2 and 
TRPC3/TRPC6 (-/-)2 female mice became much more prominent in mice that received 
Clopidogrel (Figures 40) compared to untreated mice (Figures 37 and 38). A similar result 
was obtained when ADP-induced aggregation from TRPC3/TRPC6 (-/-)2 male mice 
treated with Clopidogrel (Figure 41) or untreated (Figure 33B) was compared. 
 
Female mice. In comparison to wild type platelets the maximal aggregation was reduced 
between 34% to 82% in TRPC1/TRPC6 deficient platelets, and reduced between 44% 
and 78% in TRPC3/TRPC6 deficient platelets (Figure 40, A). The aggregation area after 
ADP stimulation was reduced between 60% to 98% in TRPC1/TRPC6 (-/-)2, and between 
72% to 100% in TRPC3/TRPC6 (-/-)2 platelets (Figure 40, B). Comparisons of maximal 
aggregation only between TRPC1/TRPC6 (-/-)2 and TRPC3/TRPC6 (-/-)2 platelets 
revealed a significant (p<0.05) difference at 30µM ADP. Similar differences were 
observed in area under the aggregation curve (Figure 40, A and B). PSC was only 
changed at 0.3µM ADP in TRPC1/TRPC6 deficient platelets (Figure 40, C). Maximal 
aggregation slope was reduced in platelets from both TRPC deficient platelet groups to 
similar extent contrasted with wild type (Figure 40, D).  
 
Male mice. Platelets from TRPC3/TRPC6 (-/-)2 Clopidogrel pre-treated male mice 
presented a robust impaired in vitro aggregation for a wide range of ADP concentrations 
(0.3µM-100µM). Results from two pooled independent series showed that platelets from 
TRPC3/TRPC6 (-/-)2 male mice presented significantly reduced maximal aggregation, 
reduced area under the aggregation curve and reduced slope of the aggregation curve 
(Figure 41, A, B and D). In these experiments no differences were detected in PSC 
between wild type and TRPC3/TRPC6 deficient platelets (Figure 41, C). 
 
In addition to ADP I tested other agonists that induce ADP release with platelets from 
mice treated with Clopidogrel. U46619-induced platelet aggregation was impaired in 
TRPC1/TRPC6 (-/-)2 and TRPC3/TRPC6 (-/-)2 platelets not only at 1µM U46619, as 
already observed (Figures 30 and 34), but additionally at 3µM in TRPC3/TRPC6 (-/-)2 
platelets (Table 8). This implies that the reduced U46619-induced aggregation in 
TRPC3/TRPC6 (-/-)2 mice is at least in part due to changes in ADP-induced aggregation 
response.  
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 ADP induced aggregation in clopidogrel pre-treated mice (♀)
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Figure 40. Platelet aggregation in washed platelets from Clopidogrel pre-treated TRPC1/C6 
and TRPC3/C6 deficient female mice. ADP concentration-response curves where (A) maximal 
aggregation, (B) area under the aggregation curve, (C) platelet shape change (PSC) and (D) 
maximal slope during aggregation were analyzed. Bar graphs from the maximal aggregation (A, 
right) and from the area under the aggregation curve (B, right) for selected ADP concentrations 
include the percentage of reduction in comparison with the wild type response. Numbers of 
measurements per ADP concentration for wild type mice were: 0.3µM=10, 1µM=14, 3µM=17, 
10µM=21, 30µM=15, 100µM=12; for TRPC1/TRPC6 (-/-)2 mice were: 0.3µM=6, 1µM=6, 3µm=7, 
10µM=12, 30µM=7, 100µM=4; and for TRPC3/TRPC6 (-/-)2 mice were: 0.3µM=5, 1µM=9, 3µm=11, 
10µM=14, 30µM=8, 100µM=8. Error bars indicate SEM. * <0.05, **<0.01 and ***p<0.001 according 
to the Student’s t-test. Mice received Clopidogrel orally in a dose of 5mg/kg/day over 2 days. Data 
pooled from two independent series. 
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 ADP induced aggregation in clopidogrel pre-treated mice (♂)
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Figure 41. Platelet aggregation in washed platelets from Clopidogrel pre-treated TRPC3/C6 
deficient male mice. ADP concentration-response curves where (A) maximal aggregation, (B) 
area under the aggregation curve, (C) platelet shape change (PSC) and (D) maximal slope during 
aggregation were analyzed. Bar graphs from the maximal aggregation (A, right) and from the area 
under the aggregation curve (B, right) for selected ADP concentrations include the percentage of 
reduction in comparison with the wild type response. Numbers of measurements per ADP 
concentration for wild type mice were: 0.3µM=9, 1µM=7, 3µM=8, 10µM=10, 30µM=8, 100µM=10; 
and for TRPC3/TRPC6 (-/-)2 mice were: 0.3µM=9, 1µM=8, 3µm=8, 10µM=9, 30µM=8, 100µM=10. 
Error bars indicate SEM. * <0.05, **<0.01, ***p<0.001 and ns (not significant) according to the 
Student’s t-test. Mice received Clopidogrel orally in a dose of 5mg/kg/day over 2 days. Data pooled 
from two independent series. 
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After stimulation with thrombin (0.1U/ml) no differences were observed in platelets from 
TRPC3/TRPC6 (-/-)2 female mice. However, in platelet from TRPC3/TRPC6 deficient male 
mice the thrombin response was significantly reduced (Table 8), but not in a higher extent 
than in platelets from TRPC3/TRPC6 (-/-)2 mice that did not received Clopidogrel (Figure 
35). No differences in maximal aggregation were observed after 0.3U/ml thrombin in any 
group of Clopidogrel pre-treated mice (Table 8).  
 
Platelet aggregation induced by 10µg/ml collagen was reduced in similar extent in 
platelets from wild type, TRPC1/TRPC6 (-/-)2 and TRPC3/TRPC6 (-/-)2 female mice. In 
males wild type and TRPC3/TRPC6 (-/-)2 male mice no reduction in collagen-induced 
aggregation was observed by Clopidogrel treatment (Table 8). These observations 
suggest that the efficacy of the inhibitory action of Clopidogrel on aggregation is lower in 
male mice or that higher doses are required in males.  
 
 
 
Table 8. Platelet aggregation in washed platelets from Clopidogrel pre-treated TRPC1/C6 
and TRPC3/C6 deficient mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
U46619 
[1µM]
U46619 
[3µM]
Thrombin 
[0.1U/ml]
Thrombin 
[0.3U/ml]
Collagen 
[10µg/ml]
Max. agg. [%] n= Max. agg. [%] n= Max. agg. [%] n= Max. agg. [%] n= Max. agg. [%] n=
Females
Wild type 13.4 ± 13 11 71.2 ± 9.5 10 27.6 ± 22 92.7 ± 4.0 8 53.6 ± 35 11
TRPC1/TRPC6 (-/-)2 2.7 ± 1.9 * 9 62.3 ± 0.3 4 — 95.1 ± 3.8 4 55.6 ± 21 5
TRPC3/TRPC6 (-/-)2 2.4 ± 1.1 4 49.2 ± 13 *** 8 22.3 ± 17 94.2 ± 3.4 5 53.8 ± 34 4
Males
Wild type 86.1 ± 7.2 10 91.3 ± 6.3 6 89.6 ± 16 9 99.3 ± 11 6 92.1 ± 2.9 4
TRPC3/TRPC6 (-/-)2 2.11 ± 1.2*** 8 78.9 ± 5.6* 4 59.7 ± 9.3** 4 96.8 ± 3.0 4 94.9 ± 2.6 3
Values of maximal platelet aggregation (Max. agg.) after stimulation with different agonist are 
presented. Mice received Clopidogrel orally in a dose of 5mg/kg/day over 2 days. Error (±) 
indicates SD. Number of experiments (n=) are indicated. *p<0.05, **p<0.01 and ***p<0.001 
according to the Student’s t-test against the corresponding wild type control.  
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6. Discussion 
 
6.1 Role of TRPC-channels in cardiac hypertrophy: Analysis of TRPC-deficient 
mice 
 
To analyze whether TRPC proteins are causally involved in the development of cardiac 
hypertrophy induced by neurohumoral mechanisms that contribute to comparable 
pathologies in humans I established in our group a protocol for isoproterenol- and ATII-
induced cardiac hypertrophy. This protocol allowed us to have a reproducible hypertrophy 
induction in TRPC-deficient mouse lines and the corresponding wild type controls of a 
mixed 129SvJ/C57Bl6 genetic background.  
 
Iso and ATII-induced cardiac hypertrophy protocols produced different cardiac and 
systemic effects in wild type mice. With our protocol Iso and ATII infusion produced in 
wild type mice a significant increment of heart weight. In terms of HW/BW the ATII-3 dose 
produced the higher values, followed by Iso-30 and ATII-0.3. In terms of HW/TL Iso-30 
produced higher hypertrophy values compared to both ATII doses. The systemic 
application of Iso or ATII not only affects the heart but also other organ systems that may 
influence cardiac growth and function. With the ATII-0.3 dose no significant changes in 
body weight were observed. However, after Iso-30 treatment the mice gained significantly 
weight and this phenomenon has been already reported in mice treated with Iso during 
one or two weeks and it was associated with gain of brown fat and muscle, and higher 
food intake (Kudej et al., 1997; Friddle et al. 2000). On the contrary, the ATII-3 dose 
produced in wild type mice a reduction in body weight and this body weight reduction 
during ATII treatment has been reported by others using a similar model (Tozakidou et al., 
2010). 
 
The HW/BW index is a measure related more to the systemic effect of the treatment 
because their values are also determined by the changes in body weight that can be 
produced during hypertrophy induction. Assuming that tibia length is not changed by a 
one- or two-week treatment HW/TL index gives more specific information about changes 
in cardiac mass. Therefore, the observed increase in body weight after Iso-30 and the 
decrease in body weight after ATII-3 explain the small increase in HW/BW value in mice 
after Iso-30 compared to the HW/BW value from mice treated with ATII-3. No differences 
in tibia length among any group were observed; therefore, from comparison of the HW/TL 
index the cardiac hypertrophy induced by Iso-30 produced a larger increase in cardiac 
mass compared to the ATII-3 and ATII0.3 treatment. I observed a 25% increment in 
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HW/TL by Iso-30 in wild type mice which is comparable with other studies using the same 
dose (Keys et al., 2002; Maass et al., 2004; Wang et al., 2005; Jafreé et al., 2009). With 
the ATII-3 treatment we obtained similar increase in HW/BW as Tokudome and coworkers 
(2008), but a 50% higher increase in HW/BW than Song and coworkers (2006); HW/TL 
was not reported in these studies. The ATII-0.3 dose produced an increase of HW/TL 
around 11% whereas Pillai and coworkers (2006) reported an increase of 20% with the 
same treatment.  
 
Overall, the variability of the increase in hypertrophy indexes is quite high in the literature 
which could be also be due to genetic variability of the mouse lines used in different 
studies. For instance there are reports showing that after the same ATII treatment C57Bl/6 
and not BALBc wild type mice presented increased HW/BW (Francois et al., 2004). 
Therefore, this was the main reason to characterize the neurohumoral-induced cardiac 
hypertrophy with the appropriate wild type line that serves as control for the TRPC-
deficient mouse lines that are available.  
 
The effects of Iso-30 and ATII-3 on cardiomyocyte size and cardiac fibrosis were also 
analyzed in wild type mice (see Figures 7 and 9). Iso-30 produced a bigger increase of the 
myocytes cross sectional area compared to ATII-3. In contrast, ATII-3 increased the 
collagen content more than Iso-30 in wild type hearts, which was expected as ATII is one 
of the main stimuli that trigger cardiac fibrosis (Brown et al., 2005). The development of 
fibrosis with Iso-30 has been reported (Wang et al., 2005), as well as with several ATII 
doses (see section 3.2.2). With Iso-30 we observed 61% increase in cardiomyocyte size 
and similar results were reported by Iaccarino and coworkers (1999) who used the same 
Iso dose and reported a 67% increase. The ATII-3 dose produced increments in 
cardiomyocyte size of about 50%. This value is much higher than values reported in mice 
between 15 and 30% with other ATII protocols and mentioned in section 3.2.2, but the 
differences could be explained by the use of different doses or mice with different genetic 
background.   
 
One important systemic effect of our neurohumoral-induced cardiac hypertrophy protocols 
evaluated by us was the effect on blood pressure. From telemetric blood pressure 
recording in conscious mice Iso-30 did not change MAP significantly. This agrees with 
other reports where Iso 30mg/kg/day (5 day) did not change MAP at the end of the 
treatment compared to base line (Monassier et al., 2008). In contrast, ATII-3 treatment led 
to a profound increment in MAP of 45mmHg which is in the range between 37 and 
46mmHg reported with ATII doses of 1.44 mg/kg/day (Crowley et al., 2006) and 
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4.6mg/kg/day(Tozakidou et al., 2010), respectively, and measured with a telemetric 
system in conscious mice.  
 
It is a striking observation that even with the notable effect of ATII on blood pressure the 
increase in cardiac weight produced by ATII is smaller when compared with the increase 
in cardiac mass produced by isoproterenol, which has a very small effect on blood 
pressure. From this result it can be concluded that the blood pressure is only a minor 
determinant in our hypertrophy models. In addition, ATII-induced hypertrophy seems to be 
independent of blood pressure per se since in mice some doses of ATII can increased 
cardiac mass without affecting blood pressure (Brancaccio et al., 2003); and, the ATII-
induced cardiac mass increase in mice was prevented by a Serotonin receptor 5-HT2BR 
antagonist independently of the hypertension produced by ATII (Monassier et al., 2008).  
 
I also analyzed the effect of both Iso-30 and ATII-3 on heart rate from telemetric and from 
ECG recordings. Both treatments produced a significant elevation of heart rate that was 
almost four times higher with the Iso-30 dose compared to the ATII-3. The effect of Iso-30 
corresponds to the sympathetic cardiac activation through β-adrenergic receptors in the 
heart with the corresponding positive chronotropic effect. This effect and a similar 
increment were reported in mice using the Iso-30 dose (Jaffré et al., 2009).  
 
ATII had also a positively chronotropic effect. This was unexpected taking into account the 
blood pressure increase produced by ATII-3 which could lead to a reflex bradycardia (Xue 
et al., 2003). It has also been reported that ATII in mice produced no changes of heart 
rate (Kuriso et al., 2003;) or can lower the heart rate (Larkin et al., 2004; Kinoshita et al., 
2010); but these measurements were done under anesthesia which can alter 
cardiovascular parameters in mice (Janssen et al., 2004). From telemetric recordings it 
was reported that ATII (1.2mg/kg/day) lowered heart rate in female but not in male mice 
(Xue et al., 2005). In conclusion, chronic ATII application effect on heart rate is variable 
and depends on doses, measurement conditions and on the mouse lines. 
 
An additional characteristic of our hypertrophy protocols was the absence of edema 
evidence after the infusion of either isoproterenol or both ATII doses in lungs and liver 
which can occurs when there is heart failure (Heineke and Molkentin, 2006). In contrast to 
aortic constriction protocols no deterioration of cardiac output was observed from 
measurements with Millar catheter. From this it can be concluded that our Iso and ATII 
protocols induce cardiac remodeling without heart failure.  
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TRPC3 and TRPC6 proteins are not necessary for the development of cardiac 
hypertrophy induced by Iso or ATII in mice. We showed the expression of TRPC6 
proteins in heart from wild type but not from TRPC6-/- mice giving strong evidence of the 
specificity of our antibody and the abundance of TRPC6 proteins in the heart. Testing of 
antibody specificity is very important since we have been analyzing the expression of 
other TRPC proteins in murine heart, like TRPC3, and so far with our antibodies we 
detected the same protein patterns in heart preparations from wild type and corresponding 
TRPC-deficient mice. By RT-PCR analysis using freshly isolated cardiac cells from 
Langendorff preparations and cultured cardiac fibroblasts we amplified transcripts from 
both TRPC3 and TRPC6 channels. However, from isolated cardiomyocytes by LCM we 
could not consistently detect TRPC3 or TRPC6 transcripts. In agreement with our 
expression analysis it has been published that TRPC3 and TRPC6 channels are 
expressed in the murine heart (Table i1). Nevertheless, any of the reported protein 
expression analysis of TRPC3 and TRPC6 proteins showed unequivocally the expression 
of these proteins in cardiomyocytes, and moreover, no validation of antibody specificity 
using cells or tissue from TRPC3 or TRPC6 deficient mice was presented. Therefore it 
can not be ruled out that the observed expression results from non cardiomyocytes. 
 
Because there are no specific agonists or antagonists for individual TRPC proteins and to 
test the causative role of these proteins in cardiac hypertrophy I evaluated this concept by 
analyzing the development of cardiac hypertrophy in mouse lines lacking TRPC3 and 
TRPC6. Interestingly, the deletion of TRPC6 leads to a compensatory up-regulation of 
TRPC3 in some cells (Dietrich et al., 2005; Weissmann et al., 2006) and these proteins 
could form heteromultimeric units (Hofmann et al., 2002). In contrast to the initial 
hypothesis, the isoproterenol- and the angiotensin II-induced hypertrophic responses 
tended to be rather increased in compound TRPC3/TRPC6 (-/-)2 mice, but certainly were 
not reduced. Furthermore, ATII-3 dose produced an increased mortality in TRPC3/TRPC6 
deficient mice compared to WT mice. We can not exclude that this effect is linked with 
hypertrophy development or other cardiac dysfunction. However, my experiments pointed 
the possibility that it is more related to the deficiency of TRPC3 and not TRPC6 because 
no TRPC6-/- mice died during ATII infusion, but some TRPC3 deficient mice did it during 
the ATII treatment (data not shown). In the ATII experiments using single TRPC3 or 
TRPC6 deficient there was also no evidence of ameliorated hypertrophy response, 
similarly as in one isoproterenol-induced hypertrophy experiment with TRPC3-/- mice. 
Due to the impact of the ATII-3 dose on the survival of TRPC3/TRPC6 (-/-)2 mice I 
evaluated the cardiac hypertrophy in these mice using a lower ATII dose and again no 
hypertrophy reduction was observed. On the contrary, the percentual increase in 
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hypertrophy indexes was significantly higher in TRPC3/TRPC6 (-/-)2 mice, but without 
obvious differences in cardiac contractility between genotypes at the end of ATII 
treatment.  
 
There is evidence from in vitro and transgenic overexpressing models pointing TRPC3 
and TRPC6 proteins as positive mediators of cardiomyocyte hypertrophy. Nevertheless, 
the postulated function of these proteins might not necessarily be reflected in the in vivo 
situation. Using in vivo models it was shown recently that specific cardiomyocyte over 
expression of either TRPC3 or TRPC6 in mice leads to an increase of cardiomyocyte size, 
cardiac mass and heart failure (Kuwahara et al. 2006; Nakayama et al. 2006), and the 
crossing between the TRPC3 transgenic mice with a cardiomyocyte specific transgenic 
PMCA4b mice produced a rescue effect on the hypertrophic phenotype (Wu et al., 2009), 
suggesting that increased cation entry in cardiomyocytes via TRPC3 and TRPC6 
channels causes cardiac hypertrophy (Kuwahara et al. 2006; Nakayama et al. 2006). On 
the other hand, mice with specific cardiomyocyte overexpression of dnTRPC3 or 
dnTRPC6 showed reduced pathologic cardiac hypertrophy (Wu et al., 2010b). However, 
from our data we found no evidence that TRPC3 and TRPC6 channels are positive 
regulators of the neurohumoral induced hypertrophy. I used TRPC deficient mice and 
analyzed the systemic effect of its deletion in the cardiac hypertrophy development, an so 
far, the in vivo published observations about TRPC3 or TRPC6 are based on mouse 
models with cardiomyocyte specific overexpression of the expression of these two 
proteins. This strategy could be difficult to interpret since it was shown that the sole over-
expression of GFP under an α-MHC promoter can lead in some mouse lines to dilated 
cardiomyopathy (Huang et al., 2000) and the hypertrophic response is a result of the 
interaction among several cell types and organs. Not only differences in cardiac 
hypertrophy induction models used by others or mouse lines may explain the different 
findings. It has to be taken into account that TRPC3 and TRPC6 channels are expressed 
in other cardiac cells like fibroblasts (see Figure 20 and Table i3) that can regulate the 
cardiac hypertrophy development in a different manner. For example, is has been shown 
that TRPC6 channels are negative regulators of the myofibroblast formation, being then 
TRPC6 a suppressor of the fibrotic response in cardiac fibroblasts (Nishida et al., 2007). 
These cells types can regulate the cardiomyocyte hypertrophy through secretion of 
growing factors and the collagen deposition during pathological conditions (Souders et al., 
2009).  
 
Concomitant inactivation of TRPC1 and TRPC4 proteins ameliorates the 
development of cardiac hypertrophy induced by Iso or ATII in mice. In addition to 
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TRPC3 and TRPC6 we also found expression of TRPC1 and TRPC4 transcripts in 
cardiac cells, which is in agreement with results our group made by northern blot analysis 
with mouse heart (Freichel et al., 2004) and from reported observations (Table i1). Also, I 
was able to detected specific TRPC1 but not TRPC4 transcripts in isolated adult 
cardiomyocytes, and I detect transcripts from both TRPC1 and TRPC4 in cultured cardiac 
fibroblasts, which can explain partially the different expression pattern between heart and 
cardiomyocytes. A complementary explanation is that in the heart there are other cell 
types including smooth muscle cells, endothelial cells, macrophages and cardiac mast 
cells among others, that indeed express different TRPCs. The expression of TRPC1 
proteins in mouse heart was shown by others with an antibody against TRPC1 that 
detected this protein in heart preparations from wild type mice but not from TRPC1-/- mice 
(Seth et al., 2009). We could not detect TRPC4 expression in purified cardiomyocytes. 
This differs from the TRPC4 protein expression reported in purified adult mouse 
cardiomyocytes (Nakayama et al., 2006); however, the specificity of the used anti-TRPC4 
antibody has not been proven yet and the purity of the used preparation was not assed. 
There could be also limitations regarding in our detection method by RT-PCR regarding 
limited amounts of mRNA due to the number of cells that might be still low to detect 
transcripts of low abundance. 
 
Based on our initial expression analysis in mouse heart I studied mouse lines deficient for 
TRPC1, TRPC4, and TRPC1/TRPC4 (-/-)2. I found clear evidence that in TRPC1/TRPC4 
deficient mice the neurohumoral-induced cardiac hypertrophy generated either by 
isoproterenol or ATII infusion is significantly reduced. This reduced response required the 
deletion of both TRPC1 and TRPC4 proteins because no diminished hypertrophic 
responses in TRPC1-/- and TRPC4-/- mice were observed after isoproterenol and ATII 
treatments. One plausible option could explain that the phenotype was evident only in 
TRPC1/TRPC4 (-/-)2 mice and not in single deficient mice. If both TRPC1 and TRPC4 
proteins have overlapping functions regarding the mechanisms of heart hypertrophy 
development, then the deletion of one protein may be is compensated by other (Dietrich et 
al., 2005). There is evidence that TRPC1 and TRPC4 proteins interact in heterologous 
and native systems (Hofmann et al., 2002; Goel et al., 2002) and could have overlapping 
functions (Sours-Brothers et al., 2009). But this can not be generalized and would depend 
on the cell type and type of stimulation.   
 
After Iso-induced hypertrophy TRPC1/TRPC4 (-/-)2 mice showed a significant reduction in 
both cardiac hypertrophy indexes and the corresponding percentual increments. In these 
experiments LW/TL from both genotypes was increased, but this was not associated to 
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edema in the lungs. In addition, no differences caused by isoproterenol treatment on liver 
weight or its water content were detected. Additionally, no differences were observed in 
left ventricular function parameters from WT and TRPC1/TRPC4 deficient mice at the end 
of the isoproterenol treatment. We can conclude that in these mice the hypertrophy was 
produced without obvious evidence of heart failure. Not only hypertrophy indexes like 
HW/BW in TRPC1/TRPC4 deficient mice were reduced after Iso treatment, also the 
cardiomyocyte cross sectional area and the increment in interstitial fibrosis were smaller in 
TRPC1/TRPC4 (-/-)2 mice. This is an indication of the participation of both TRPCs in 
cardiomyocyte growth and fibroblast collagen formation produced by systemic 
isoproterenol application; although, the mechanisms behind this differences remain to be 
elucidated. 
 
Basal angiotensinogen levels are not different in TRPC1/TRPC4 (-/-)2 mice. Beyond a 
direct effect of isoproterenol on the heart, there are other systemic effects that can be 
involved in the Iso-induced cardiac hypertrophy. Isoproterenol can activate the kidney 
renin-angiotensin-Aldosterone system (RAAS), by stimulating the renin production and 
finally the concomitant increase of ATII levels, either in plasma (Leenen et al., 2001) or 
also local ATII production in the heart (Nagano et al., 1992). Since we observed that 
TRPC1/TRPC4 deficient mice had smaller livers, and the liver is the main source of 
angiotensinogen which is the substrate for ATI synthesis, one possibility was that 
TRPC1/TRPC4 (-/-)2 mice had reduced circulating angiotensinogen that could end in 
reduced ATII levels during isoproterenol infusion and in a reduced hypertrophy 
development. However, this is unlikely because the angiotensinogen levels between wild 
type and TRPC1/TRPC4 (-/-)2 mice were not different.  
 
Renin secretion in TRPC1/TRPC4 (-/-)2 mice is not altered. In collaboration with Prof. 
Frank Schweda (Regensburg) we observed that the isoproterenol-induced renin secretion 
and the ATII inhibition of the renin secretion in isolated kidneys from wild type and 
TRPC1/TRPC4 deficient mice were comparable, ruling out an impaired renal renin 
secretion under isoproterenol stimulation. From these experiments I conclude that the 
reduced response of TRPC1/TRPC4 in the Iso-induced experiments is not due to 
differences in renin secretion stimulated by Iso or due to differences in basal plasma 
levels of angiotensinogen. Still it is required to measure circulating and cardiac 
components of the RAAS under isoproterenol infusion to analyze their contribution to the 
hypertrophy development in TRPC1/TRPC4 (-/-)2 mice.  
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The reduced hypertrophic response in TRPC1/TRPC4 (-/-)2 could be due to and 
impaired response to ATII. There is evidence pointing the importance of systemic and 
local RAAS during the Iso-induced hypertrophy. There are contradictory results regarding 
the role of ATII during Iso-induced hypertrophy. In rats, the isoproterenol-induced cardiac 
hypertrophy was not prevented by both the AT1R-blocker Losartan and the ACE inhibitor 
Quinapril (Leenen et al., 2001). In contrast, in a similar model isoproterenol-induced 
hypertrophy was prevented by the ACE inhibitor Trandolapril but not by bilateral 
nephrectomy (Nagano et al., 1992), suggesting that sympathetic activity is one of the 
regulators of the cardiac RAAS and hypertrophic response. Mice deficient for the AT1A-R 
were not able to develop cardiac hypertrophy after 11 days of isoproterenol infusion 
(Zhang et al., 2007). In addition, the AT1-R antagonist Olmesartan prevented the 
isoproterenol-induced cardiac hypertrophy in mice (Zhang et al., 2007).  
 
To test if the reduced hypertrophy observed in TRPC1/TRPC4 (-/-)2 mice after 
isoproterenol treatment was mediated by ATII, I induced cardiac hypertrophy in these 
mice by ATII infusion. After ATII treatment, the hypertrophy indexes, that are more 
variable with this protocol, as well as the cardiomyocyte size and the fibrosis increment 
were reduced in TRPC1/TRPC4 (-/-)2 mice in a similar proportion compared to the 
reduction registered after isoproterenol treatment. In addition, no evidence of cardiac 
congestion in wild type and TRPC1/TRPC4 (-/-)2 mice was detected in these experiments. 
From these results we can affirm that as well to the isoproterenol-induced hypertrophy, 
also the ATII hypertrophy response was reduced in TRPC1/TRPC4 knockout mice. It is 
conceivable that Iso- and ATII-induced hypertrophy share mechanisms that could be 
linked to the regulation of cardiomyocyte growth and fibrosis development. However, 
impaired pathways mediated through the kidney could also explain the reduced 
hypertrophy development in TRPC1/TRPC4 (-/-)2 mice because angiotensin II-induced 
hypertrophy was abolished completely in mice deficient for the AT1A-R in the kidneys 
independently of the presence of the receptors in the rest of the body (Crowley et al., 
2006). 
 
Reduced Iso-induced hypertrophy in TRPC1/TRPC4 (-/-)2 mice is not explained by 
change in blood pressure. Isoproterenol has many other systemic including stimulation 
of Renin secretion and ATII production. It could also produce changes in blood pressure 
either by direct stimulation of β-receptors on the vessels causing vasodilatation or by 
secondary effects due to changes on heart rate. From analysis of wild type mice the 
isoproterenol effects on blood pressure were minor and it is unlikely that the small 
changes in blood pressure during isoproterenol infusion do significantly contribute to the 
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observed cardiac hypertrophy. However, because it was observed in our group that 
TRPC1/TRPC4 (-/-)2 mice have reduced basal MAP (Mathar, 2010) and this could 
contribute to the differences observed in the Iso-induced hypertrophy, we measured blood 
pressure in TRPC1/TRPC4 deficient mice during the isoproterenol infusion but no 
differences were found in MAP before and during isoproterenol treatment. One 
explanation why the reduced basal MAP was not observed anymore in TRPC1/TRPC4 
deficient mice is a difference in environmental conditions including housing. Unchanged 
blood pressure levels between wild type and TRPC1/TRPC4 (-/-)2 mice were confirmed in 
three independent series. From these mice the Iso-induced hypertrophy was also 
diminished, discarding an obvious effect of the implantation of osmotic minipumps 
together with the blood pressure on the hypertrophy development. Taken together this 
results, it can be ruled out that differences in blood pressure regulation between wild type 
and TRPC1/TRPC4 (-/-)2 during isoproterenol infusion can explain the reduced 
hypertrophy response of TRPC1/TRPC4 deficient mice. 
 
The reduced hypertrophic response of TRPC1/TRPC4 (-/-)2 mice could be related to 
diminished effects of ATII on heart rate. Isoproterenol also has a positive chronotropic 
effect on the heart. The heart rate during isoproterenol infusion measured from 
independent experimental groups and with two different methods, ECG recordings and 
telemetric recordings, showed a consistent reduced response in TRPC1/TRPC4 (-/-)2 
mice. In order to clarify this effect of isoproterenol on heart rate we did the experiments 
using isolated right atria, and isoproterenol or Acetylcholine at different concentrations 
produced comparable positive and negative chronotropic effects respectively, on atria 
from wild type and from TRPC1/TRPC4 (-/-)2 mice. The isoproterenol effects have been 
reported in isolated mouse atrial preparations by others, but with smaller increases in a 
similar range of concentration, possibly due to differences in mouse lines (Vandecasteele 
et al., 1999). On the other hand, the absolute values and the increase in beating 
frequency after stimulation by different ATII concentrations were smaller in 
TRPC1/TRPC4 deficient mice. Therefore it can be speculated that the observed reduction 
of the isoproterenol-induced heart rate increase could be a secondary effect of an 
impaired response to the stimulation of the heart by ATII produced during isoproterenol 
infusion. This is also in agreement with the observation that during ATII infusion the 
increment in heart rate observed in wild type mice was not detected in TRPC1/TRPC4 
deficient mice. It is plausible that part of the increment in heart rate triggered by 
isoproterenol is caused by direct stimulation ATII direct on the heart since in mice the AT1-
R antagonist Valsartan was able to decrease the isoproterenol-induced change in heart 
rate, but not changes in systolic blood pressure (Barki-Harrington et al., 2003). Moreover, 
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in mice the AT1-R antagonist Olmesartan prevented the isoproterenol-induced cardiac 
hypertrophy (Zhang et al., 2007).  
 
ATII receptors are coupled to Gq proteins which have signaling cascades that are 
proposed to activate TRPC channels (Clapham, 2003; Venkatachalam and Montell, 
2007). Additional evidence to impaired Gq signaling in TRPC1/TRPC4 deficient mice is 
that the positive chronotropic response to Phenylephrine in isolated atria was also 
reduced, and Phenylephrine acts through α1-adrenergic receptors which are also coupled 
to Gq proteins (Wettschureck and Offermanns, 2005). Therefore, it is possible that part of 
the mechanisms behind the reduced hypertrophy response of TRPC1/TRPC4 (-/-)2 mice 
involves differences in heart rate regulation and ATII stimulation of the heart independent 
of blood pressure. Heart rate could be an important component of the diminished 
observed hypertrophy in TRPC1/TRPC4 deficient mice, since sustained changes in 
beating frequency can alter basal calcium levels and trigger hypertrophic responses (Tavi 
et al., 2004). 
 
We ruled out that single deletion of TRPC1 or TRPC4 were responsible for the diminished 
hypertrophy responses observed after isoproterenol or ATII treatments, because from 
various independent experimental series we were not able to observed reduced 
responses in the hypertrophy indexes between wild type and TRPC1-/- or TRPC4-/- mice. 
Our results regarding TRPC1-/- mice are contradictory with recent observations using 
TRPC1 deficient mice but with a 129Sv genetic background. It was shown that TRPC1-/- 
mice have a minor increment of cardiac mass induced by TAC and also that they have 
about 58% ameliorated HW/BW increase after infusion of ATII at a dose of 1.44mg/kg/day 
during 28 days (Seth et al., 2009). It is difficult to explain this results compared with ours, 
some explanations could be differences in protocols, like the ATII concentration and 
duration, or the genetic background of the mice, but beyond this there are no more 
obvious differences that explain that other group reported that TRPC1 deficient mice have 
reduced heart hypertrophy and we were not able to detect reductions by two different 
protocols in different experimental groups. In this study it is also intriguingly that only 
TRPC1 is responsible for the reduced response, although TRPC3, TRPC4 and TRPC6 
were shown to be expressed in the heart and they could be involved in hypertrophy 
development. Regarding TRPC4, recently it was published that mice expressing a 
dominant negative TRPC4 with an α-MHC promoter had less cardiac hypertrophy after 
aortic banding. Likewise very similar effects on hypertrophy were obtained also with 
overexpression of two other dominant-negative TRPC isoforms (Wu et al., 2010b). This 
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approach strongly relies on the specificity of the overexpressed protein which is difficult to 
demonstrate.  
 
The expression pattern of TRPCs in the heart pointed a role on non-cardiomyocytes 
in TRPC1/TRPC4 mediated hypertrophy. The Iso- and ATII induced fibrotic increase in 
TRPC1/TRPC4 (-/-)2 mice was reduced, but from comparison of control groups we 
observed that TRPC1/TRPC4 deficient mice had slightly significant increased basal 
fibrosis levels. For this reason and in order to identify cardiac cell types involved in the 
reduced cardiac hypertrophy observed in TRPC1/TRPC4 (-/-)2 mice, the expression of 
different TRPC channels was analyzed in mouse heart, cardiac cells isolated from 
Langendorff preparations, isolated mouse cardiomyocytes by LCM and cultured cardiac 
fibroblasts, and some findings were discussed above. From heart Langendorff 
preparations we amplified transcripts from TRPC1, TRPC3, TRPC4 and TRPC6, but not 
transcripts from TRPC5 in agreement with northern blot expression analysis of TRPC5 in 
mouse heart reported by others (Okada et al., 1998). In isolated cardiomyocytes we were 
only able to detect TRPC1 transcripts. On the other hand, transcripts from TRPC1, 
TRPC3, TRPC4, TRPC5 and TRPC6 were obtained from cultured mouse cardiac 
fibroblasts. The differences in the expression pattern between cell pellets from 
Langendorff preparations and isolated cardiomyocytes can be explained by the presence 
of other cells different than cardiomyocytes on the Langendorff preparations. Indeed, I 
showed the presence of positive cells for a fibroblast marker (P4HB) in this kind of 
preparations (Figure 19, D). Other possible explanation is that the amount of RNA from 
LCM-cardiomyocytes was not sufficient to detect low abundance transcripts. Although, I 
tried with independent preparations and different cell numbers and the results were 
consistent, and the method worked to detect several other transcripts, for example 
TRPM4 or TMEM-2. It can also be possible that there are differences in the expression 
between species. We consider that the isolation of cardiomyocyte previous to selection of 
the cells by LCM is sufficient strategy to obtain a pure population for cell specific 
expression analysis. From the literature describing TRPC expression analysis in the heart, 
most of the data came from complete heart preparations or enriched cell pellets. Only the 
expression of TRPC1 proteins in the heart using hearts from TRPC1-/- mice was shown 
so far (Seth et al., 2009) as we showed for TRPC6 proteins. So far, no specific TRPC 
expression in adult wild type cardiomyocytes has been reported. Immunocytochemistry 
experiments with adult mouse ventricular cardiomyocytes (Kuwahara et al., 2006) or 
mouse sinoatrial cells (Ju et al., 2007) using antibodies which have not been rigorously 
tested for their specificity were reported.  
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TRPC1/TRPC4 proteins contribute to Ca2+ entry in mouse cardiac fibroblasts. I 
studied cardiac fibroblasts to get a hint of their contribution for the neurohumoral-induced 
cardiac hypertrophy. I established in our group a protocol for the isolation and culture 
mouse cardiac fibroblasts. The purity of the fibroblast culture (~95%) assed by positive 
P4HB stained cells was comparable with other groups using the same cellular marker 
(Thum et al., 2008) or using other fibroblasts markers like vimentin (Jaffré et al., 2009). In 
addition, the tested fibroblasts were negative for α-SM actin and α-actinin, arguing against 
differentiation to a myofibroblasts phenotype during the first passages, and that there 
were no cardiomyocyte cells present. Few cells showed an unspecific perinuclear staining 
were stained with CD31. Cardiac fibroblasts have their origin in various cell lineages and 
tissue niches which explains the limitation of the current markers to characterize these 
cells (Snider et al., 2009; Zeisberg and Kalluri, 2010). For example, Vimentin is a common 
marker used to characterize cardiac fibroblasts that is also found in endothelial cells and 
in macrophages, cells commonly obtained in the first steps of the fibroblast culture that 
can reduce culture purity (Landeen et al., 2007; Jaffré et al., 2009).  
 
With these P4HB-positive cells I started the establishment of a protocol to measure 
changes in intracellular calcium concentrations after agonist stimulation using 
fluorescence methods with the calcium indicator FURA-2, since changes in intracellular 
calcium concentration may affect the release of hypertrophy inducing agonists. After 
testing different conditions in wild type cells were obtained rapid responses after 
stimulation with isoproterenol, ATII or serotonin. The variability of these agonist responses 
among cells was too high, possibly explained by loss of expression of the corresponding 
receptors during culture. Therefore, I used a simpler protocol to test the calcium entry 
triggered by store depletion using Thapsigargin treatment in the absence of extracellular 
calcium, and re-adding Ca2+ to the extracellular solution to measure Ca2+ entry, as it was 
done in many cell types by others to characterize the TRPC functionality (Liu et al., 2007). 
From the first results I observed that the calcium release from internal stores was not 
impaired in cells from TRPC1/TRPC4 (-/-)2 mice, but the calcium entry component 
produced after including Ca2+ in the extracellular medium was considerably reduced in a 
population of cells with a characteristic fibroblast morphology and not in larger cells with a 
morphology resembling myofibroblasts. 
 
Even, if the reduced Store-Operated Ca2+-Entry could be assigned to a specific fibroblast 
subtype it would be necessary to determine if there is a functional defect in cells deficient 
for TRPC1 and TRPC4 channels after stimulation by cardiac fibroblasts-specific and/or 
hypertrophy inducing agonists. Moreover, in this case will be helpful to test if the release 
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of cytokines or growth factors is affected after isoproterenol or ATII stimulation in cardiac 
fibroblasts from TRPC1/TRPC4 deficient mice since this is a proposed mechanism 
mediating the hypertrophy development through non-myocyte cells (Jaffré et al., 2009).  
 
6.2 Role of TRPC channels in platelet aggregation: Analysis of TRPC-deficient 
mice 
 
To study if TRPC proteins play a functional role in mouse platelets I established in our 
group protocols to isolate mouse platelets for expression and in vitro aggregation analysis. 
The use of several mouse lines deficient for different TRPC proteins allowed us to 
circumvent the lack of specific TRPC agonist and antagonist and to test anti-TRPC 
antibodies for specificity. We included in our platelet aggregation study TRPC compound 
knockout mouse lines because of three reasons; first, it has been reported that TRPC 
channels form functional units composed by different TRPC proteins (Strübing et al., 
2001; Ambudkar et al., 2006) and that different TRPC proteins could interact in platelets 
(Brownlow and Sage, 2005); second, the deletion of one TRPC can be compensated by 
up regulated expression of other TRPC (Dietrich et al., 2005; Sel et al., 2008); and third, 
the use of compound deficient mouse lines facilitates the phenotype screening and 
reduces the number of mice used to obtain blood, an special issue for platelet studies in 
mice where the amount of blood is a limiting factor in case of mice. 
 
Different TRPs are expressed in murine platelets. Using murine platelets from wild 
type mice we identified TRPC6 proteins that were not present in preparations from TRPC6 
deficient mice. In similar experiment we detected also TRPM4 proteins in murine platelets. 
I amplified transcripts from TRPC1 and TRPC6 using RNA isolated from washed platelets. 
Also, transcripts from these two channels in addition to TRPM4 and TMEM-2 were 
amplified using platelets sorted by FACS. Because platelets have small amounts of 
mRNA (McRedmond et al., 2004) it was required to isolate high number of cells for RNA 
isolation and RT-PCR. From FACS experiments we determined that the platelet 
preparation was highly pure (>99.9%) and with platelets sorted by FACS the expression 
pattern of TRPC channels was not different compared to the obtained from RNA isolated 
from washed platelets. Therefore, we can assume that our RT-PCR expression analysis 
using RNA isolated from high number of washed platelets corresponds to the expression 
pattern in platelets. We did not amplify transcripts of other TRPC channels beyond TRPC1 
and TRPC6. It does not mean indeed that they are not expressed in platelets because a 
limitation of this approach is that platelets are anucleated fragments that do not synthesize 
RNA restricting the detection of platelet’s transcripts. On the other hand, the expression of 
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other TRPC proteins analyzed by western blot and various anti-TRPC antibodies 
produced similar protein patterns between platelet preparations from wild type and the 
corresponding TRPC-deficient control. Or, like in case of TRPC5 we did not detect TRPC5 
proteins in platelet preparations using antibodies that have been proven to detect TRPC5 
proteins specifically in other cellular or tissue preparation. Despite the power of protein 
detection by western blot using control samples from knockout mice this method is 
constricted to the generation of specific antibodies which is a time and effort consuming 
process. The expression of several TRPC proteins has been reported in the literature in 
mouse and human platelets (Table i4) and specific functions are proposed for these 
proteins in these channels in these cells, especially for TRPC1 and TRPC6 (Authi, 2007). 
In most cases the reported expression experiments did not include proper controls of 
antibody specificity and this issue has been discussed specifically for TRP expression in 
platelets due to controversial published results (Sage et al., 2002; Authi et al., 2002; Authi, 
2007; Varga-Szabo et al., 2008b). Only in one report the protein expression of TRPC1 
and TRPC6 proteins in mouse platelets included platelet preparations from TRPC1-/- and 
TRPC6-/- as proof of the validity of the antibodies Varga-Szabo and collaborators (2008b). 
 
A protocol allowing analysis of platelet aggregation in vitro. As a functional assay we 
decided to use the turbidimetric in vitro assay. In this case I also established the protocol 
that resulted to be a reliable method as previously reported (Jarvis, 2004). Most of the 
experiments were done using washed platelets. This kind of preparation allows testing 
platelet aggregation independent of coagulation factors present in the plasma. In addition, 
a higher number of experiments can be performed with a smaller number of mice 
compared to experiments using platelet rich plasma. Because the method was used for 
the first time in out group I compared initially the aggregation responses of platelets from 
wild type mice of a mixed 129SvJ/C57Bl6 genetic background. These wild type mice with 
the mixed genetic background were used as control mice to compare the aggregation of 
platelets from most of the TRPC-deficient mouse lines. The platelet aggregation 
experiments were focused on analyzing the effect of the four main platelets agonists ADP, 
Thromboxane A2, thrombin and collagen ADP which have signaling pathways linked to 
PLC activity that can activate TRPC channels in many cell types (Minke, 2006; Ambudkar 
and Ong, 2007). The aggregation results obtained with wild type platelets with these four 
agonists were consistent and reproducible between different experimental series. Only 
small but significant differences in the in vitro aggregation between platelets from female 
and from male mice were observed, especially at some ADP concentrations. This 
observation was not surprising since it has been reported that platelets from female mice 
are intrinsically more sensitive than those from male mice, and washed platelets from 
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female mice aggregate more than those from male mice after ADP stimulation (Leng et 
al., 2004). For both genders concentration-response curves of platelet aggregation 
parameters were obtained. However, it was not possible to obtain intermediate 
aggregation responses in terms of maximal aggregation and aggregation area for 
thrombin and the TxA2 analogue U46619, despite that different concentrations were 
tested. The very steep dose-response curve obtained with these agonists indicates that in 
this test the response after thrombin or U46619 stimulation was basically an all or nothing 
response. In contrast, the platelet shape change presented dose dependent responses for 
all agonists. In case of ADP and collagen the maximal aggregation and area showed 
continuously increasing responses over a large range of agonist concentrations for 
platelets of both genders. The differences among agonists could be explained by 
differences of their action during the thrombus formation. Beyond differences in platelet 
aggregation between genders we observed that platelet counts in female mice were 
significantly lower compared to male mice with a mixed 129SvJ/C57Bl6 genetic 
background. In addition, platelet counts from C57Bl6N male mice were higher than those 
from 129SvJ male mice. These differences pointed out one more time the importance of 
characterizing the wild type mouse lines that are going to be used to compare the 
responses from TRPC-deficient mice, since wild type mice of different genetic background 
vary substantially in terms of platelet counts. A survey including platelet counts of both 
genders from 27 mouse inbred strains showed that in 56% of the strains platelet count 
were higher in male mice, in 18% of the strains the platelet count were higher in female 
mice and in the 26% the counts were similar between both genders (Peters et al., 2006); 
obviously, the observed differences in platelet counts were not determined by the gender 
but by the genetic background of the mice. 
 
TRPC6-/-, TRPC5-/- and TRPC1-/- mice have unaltered platelet aggregation in vitro. 
A screening of platelet aggregation using 13 mouse lines including single and compound 
TRPC deficient mouse lines was carried out. I used platelets from both genders in most 
cases and the four main platelet activating agents ADP, TxA2 analogue, thrombin and 
collagen. The deletion of TRPC1, TRPC3, TRPC4 or TRPC6 proteins did not produced 
differences in platelet counts. The platelet aggregation screening was initially focused on 
TRPC6 deficient platelets because of the strong TRPC6 protein expression that we 
detected in mouse platelets. Surprisingly, no differences were identified in the in vitro 
aggregation in any concentration of the four agonists tested in platelets obtained from 
both genders. Furthermore, these results were conducted using TRPC6-deficient mice on 
both a C57Bl6/N and a mixed C57/Svj genetic background, which makes a possible 
masking effect due to the genetic background of the mice unlikely. TRPC1 expression 
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was also detected in mouse platelets but no obvious differences in aggregation were 
observed in TRPC1-/- platelets. Expression of TRPC5 that was reported by other groups 
(see Table i4) could not be confirmed by our RT-PCR analysis. Also, using our anti-
TRPC5 antibodies we did not detected TRPC5 in mouse platelets. In this line, I did not 
find altered aggregation in platelets from TRPC5-/- mice after stimulation with most 
relevant concentrations of ADP, thrombin, collagen or U46619. It is possible that the lack 
of one these TRPC proteins is compensated by changes in expression of other TRPC 
protein or by redundant function of other TRPC proteins. For these reasons I used 
platelets from TRPC1/TRPC6 (-/-)2,  and platelets from TRPC3/TRPC6 (-/-)2 mice because 
specifically in TRPC6-/- mice it was found increased TRPC3 expression (Dietrich et al., 
2005). Additional evidence to this came from others who reported that TRPC1-/- platelets 
had no impairment in SOCE or agonist induced calcium entry, and in platelet activation 
(Varga-Szabo et al., 2008b). It has been proposed that TRPC6 proteins are an important 
component of calcium entry in platelets and consequently for platelet activation (Hassock 
et al., 2002; Jardín et al., 2008b), but from our results the single deletion of these proteins 
produced no obvious aggregation defect.  
 
TRPC1, TRPC3 and TRPC6 proteins are crucial regulators for platelet aggregation 
induced by ADP, TxA2 and thrombin. Platelets from TRPC1/TRPC6 (-/-)2 and 
TRPC3/TRPC6 (-/-)2 mice presented a consistent reduction in the ADP-induced 
aggregation. Additionally, impaired responses to the TxA2 analogue U46619 and to 
thrombin were observed in these platelets, but no reduction was detected after collagen 
stimulation. The common characteristic among ADP, TxA2 and thrombin is that these 
agonist activate signaling pathways downstream of receptors coupled to Gq proteins 
(Offermanns, 2006). The signaling downstream of Gq activation includes activation of 
cation channels which could be formed by TRPC proteins. Therefore, there could be a 
shared signaling between ADP, TxA2 and thrombin that activate the same pool of 
channels. Also, when platelets are stimulated by thromboxane or thrombin they secrete 
granules that contain ADP and thereby amplify platelet responses in a paracrine and 
auotocrine manner (Savi and Herbert, 1996).  
 
The reduction in ADP-induced aggregation is probably the main difference observed in 
TRPC1/TRPC6 and TRPC3/TRPC6 deficient platelets so far. When I compared the ADP-
induced aggregation from both groups the reduction was more prominent in platelets from 
TRPC3/TRPC6 (-/-)2 mice, and specially in female mice. If single deletion of TRPC1 and 
TRPC6 produced no obvious aggregation defect and TRPC1/TRPC6 and TRPC3/TRPC6 
deficient platelets did not aggregate normally, I speculated that the deletion of all three 
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TRPC proteins produced an aggravated phenotype, especially after ADP stimulation. Very 
recently TRPC1/TRPC3/TRPC6 deficient mice were obtained and were viable and fertile. 
Platelets from these mice showed impaired responses to ADP, thrombin and U46619, but 
no the reduction in a similar range compared to the one registered for TRPC3/TRPC6 
deficient platelets. Obviously, the remaining part of the aggregation is mediated by 
channels independent of TRPC1, TRPC3 and TRPC6. If TRPC4 proteins may contribute 
as suggested by Brownlow and Sage (2005) or Wakabayashi et al. (2006), this could be 
tested in TRPC1/TRPC3/TRPC4/TRPC6 deficient mice, although this possibility seems 
unlikely based on the unchanged aggregation in TRPC4/TRPC6 (-/-)2 mice that were 
observed after stimulation with these agonists. 
 
Since platelets can secrete ADP after stimulation with agonists like thromboxane or 
thrombin (Li et al., 2004b) and our most prominent difference in aggregation were 
obtained after ADP stimulation, we hypothesized that U46619- and thrombin-impaired 
responses in TRPC1/TRPC6 and TRPC3/TRPC6 deficient platelets could be at least in 
part secondary due to impaired ADP signaling. One supporting argument came from our 
results with TRPC3/TRPC6 deficient platelets where we observed that the substantial 
reduction in U46619-induced aggregation observed, became much smaller when the 
experiments were done in a ten-fold increased Apyrase concentration. Apyrase 
hydrolyses ADP and therefore can reduce the secreted ADP; therefore, the above 
experiments suggest a significant contribution of ADP signaling in the TRPC3/TRPC6 
mediated aggregation induced by U46619. 
 
TRPC1, TRPC3 and TRPC6 mediate ADP-induced platelet aggregation through P2Y1 
receptors. Since we hypothesized that the TRPC function is linked to ADP signaling we 
focused on the signaling pathway activated by this agonist. Stimulation of platelets with 
ADP leads to activation of both P2Y1 and P2Y12 receptors. P2Y1 receptor is coupled to Gq 
proteins and it is responsible for the ADP-induced calcium transients (Fabre et al., 1999; 
León et al., 1999). The P2Y12 receptor is coupled to Gi proteins and is linked to cAMP 
regulation after ADP stimulation, but it does not regulate calcium transients (Foster et al., 
2001; André et al., 2003). To dissect between these signaling pathways I performed 
experiments with platelets from mice that received Clopidogrel to block P2Y12 receptors at 
a dose that proved to be effective in rats (Savi et al., 1992). First, to test the effects of this 
dose in mice experiments using wild type mice were done. From those results we could 
conclude, first, that Clopidogrel was effective to block effectively the ADP-induced 
platelets aggregation in vitro, and second, we showed that effects of the vehicle used to 
solve Clopidogrel can be neglected allowing us to skip the use of vehicle treated mice and 
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reduced the number of mice in these experiments. In TRPC1/TRPC6 (-/-)2 and 
TRPC3/TRPC6 (-/-)2 mice pre-treated with Clopidogrel ADP-induced platelet aggregation 
was markedly reduced at all investigated concentrations of ADP. This reduction after in 
ADP-induced aggregation was much more pronounced than under conditions without 
blocking of P2Y12 receptors indicating that ADP induces activation of TRPC1/TRPC6 and 
TRPC3/TRPC6 channel complexes via P2Y1 receptors. This finding is in good agreement 
with the observation that the deletion or pharmacological blocking of P2Y1 and not P2Y12 
abolished the ADP-induced changes in intracellular calcium transients (Offermanns, 2006; 
Gachet, 2008) which could be mediated by channels composed of combinations of 
TRPC1, TRPC3 and TRPC6 proteins (Birnbaumer, 2009). Comparison of intracellular 
Ca2+ concentration in platelets from wild type, TRPC1/TRPC6, TRPC3/TRPC6 and 
TRPC1/TRPC3/TRPC6 deficient mice after ADP stimulation could help to prove this.  
 
TRPC1, TRPC3 and TRPC6 channels are expressed in mammalian megakaryocytes 
(Table i5), the precursor cells of platelets. Evidence supporting a link between TRPC 
activation through ADP receptors comes from the study of murine megakaryocytes. In 
murine megakaryocytes ADP activates a non-selective cation channel with a current-
voltage relationship similar to currents displayed by cells overexpressing TRPC6 proteins, 
suggesting a role for TRPC6 in the cation influx after P2Y receptor activation (Carter et al., 
2006). It was suggested that physiological agonists will evoke Ca2+ influx through a 
combination of TRPC6 and Orai1 channels in platelets and megakaryocytes (Tolhurst et 
al., 2008). It was proposed that in murine platelets Orai1 and STIM1 are the main 
components of the SOCE (Varga-Szabo et al., 2008a; Braun et al., 2009). However, the 
presented evidence was restricted to the signaling pathway downstream the GPVI, 
leaving open a role for TRPC channels in other signaling pathways. The calcium entry in 
STIM1 and Orai1 deficient platelets was not completely reduced after ADP, U46619 or 
thrombin stimulation. Moreover, the in vitro aggregation responses to these agonists were 
not affected in Orai1 and STIM1 deficient platelets. Therefore, it was proposed that a Ca2+ 
entry pathway in platelets different from Orai1 channels may be involved after stimulation 
with these agonists (Gilio et al., 2010b). From a study of PKCα-/- platelets it was 
suggested by Harper and coworkers (2010) that the mouse platelet SOCE pathway 
conducts Na+ because they observed a TG-induced Na+ entry in mouse platelets. If Na+ is 
also conducted within the SOCE in platelets and Orai1 is highly selective for Ca2+ there 
should be other cation channels contributing to the Store operated entry in mouse 
platelets. This also points to a possible role of TRPC proteins in mouse platelet since 
these proteins are able to form channels that conduct cations including Na+ 
(Venkatachalam and Montell, 2007).  
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7. Conclusions 
 
From the evidence presented in this thesis using TRPC-deficient mice it can be concluded 
that distinct TRPC proteins were identified as crucial regulators for cardiac hypertrophy 
development and platelet aggregation. 
 
TRPC1 and TRPC4 proteins regulate the development of neurohumoral-induced 
cardiac hypertrophy. In conclusion, a reliable set of protocols to evaluate in vivo and in 
vitro the causative role of TRPC proteins in the development of neurohumoral-induced 
cardiac hypertrophy was established and characterized. This was complemented by 
expression analysis of TRPC channels in the mouse heart, cardiomyocytes and 
fibroblasts. We detected TRPC6 proteins in mouse heart using preparations from TRPC6 
deficient mice as control of antibody specificity. We found a differential expression pattern 
between cardiomyocytes and fibroblasts with restricted expression of TRPC1 to 
cardiomyocytes, and expression of TRPC1, TRPC3, TRPC4 and TRPC6 in non myocyte 
cells consisting of 95% cardiac fibroblasts.  
 
From experiments with TRPC3/TRPC6 deficient mice we conclude that deletion of both 
proteins in mice did not reduce the hypertrophy responses induced by isoproterenol and 
ATII. In contrast, TRPC1/TRPC4 deficient mice have a significant reduced neurohumoral-
induced hypertrophy produced by Iso and ATII, respectively. Deletion of either TRPC1 or 
TRPC4 proteins can be compensated. We could rule out that the reduced hypertrophy 
response of TRPC1/TRPC4 deficient mice after isoproterenol treatment was due to 
individual deletion of TRPC1 or TRPC4 proteins. Differences in renal renin secretion, in 
basal plasma angiotensinogen levels or in blood pressure regulation during isoproterenol 
infusion could be ruled out. I showed that ATII signaling, possible through regulation of 
heart rate or Ca2+ signaling in cardiac fibroblast are altered in TRPC1/TRPC4 (-/-)2 mice. 
These changes may contribute to the reduced hypertrophy development induced by 
isoproterenol and ATII in TRPC1/TRPC4 (-/-)2 mice. 
 
The neurohumoral-induced cardiac hypertrophy by isoproterenol is a complex process 
mediated by different organs and cell types. This work presented evidence that both 
TRPC1 and TRPC4 proteins are positive regulators of the neurohumoral-induced cardiac 
hypertrophy development, but the cellular mechanisms still remain elusive (Figure 42). 
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Figure 42. The isoproterenol-induced cardiac hypertrophy requires TRPC1 and TRPC4 
proteins. Among the systemic effects of isoproterenol are: 1) Direct stimulation of the heart and its 
different cell types which produce positive chronotropic and ionotropic responses, stimulation of the 
local RAAS and secretion of growth factors involved in cardiac hypertrophy development, between 
other responses. 2) Stimulation of renin secretion from kidneys resulting in an increase on 
circulating levels of angiotensin II that can act on the heart. 3) Changes on blood pressure by direct 
stimulation of blood vessels and by increasing circulating angiotensin II. From the results of this 
thesis using TRPC-deficient mice it is suggested that TRPC1 and TRPC4 positively regulate the 
Iso-induced cardiac hypertrophy. Possibly, TRPC proteins play a role in cells like fibroblasts 
mediating signaling that end up in the stimulation of cardiomyocytes and the hypertrophy 
development. My experiments showed that pathways 1 and 3 seem unlikely to contribute for 
TRPC1/TRPC4 mediated induction of cardiac hypertrophy by isoproterenol. ATI: Angiotensin I; 
ATII: Angiotensin II; ACE: Angiotensin Converting Enzyme. 
 
 
TRPC1, TRPC3 and TRPC6 proteins are crucial regulators ADP-induced platelet 
aggregation through P2Y1 signaling. To study platelets from TRPC-deficient mice 
protocols for platelet isolation and turbidimetric aggregometry were established in our 
group. In vitro platelet aggregation triggered by ADP, TxA2 analogue U46619, thrombin 
and collagen was first characterized with platelets from wild type mice and then used for 
the analysis of platelets from several TRPC single and compound mouse lines. Using 
highly pure washed platelet preparation we analyzed the expression of several TRPC in 
mouse platelets and we were able to detect TRPC6 proteins in platelet from wild type but 
not from TRPC6-/- mice. Transcripts from TRPC1 and TRPC6 were amplified. The 
deletion of TRPC1, TRPC3, TRPC4 or TRPC6 did not affect platelet counts in mice. 
Unexpectedly, the deletion of either TRPC1 or TRPC6 proteins did not affect platelet 
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aggregation. From experiments with mouse lines that lack TRPC4/TRPC6 or TRPC5 
proteins a relevance of TRPC4 and TRPC5 proteins for ADP-, TxA2-, thrombin- or 
collagen-induced aggregation of murine platelet seems dubious at this point.   
 
In TRPC3/TRPC6 (-/-)2 as well as in TRPC1/TRPC6 (-/-)2 mice the aggregation induced 
by ADP and the TxA2 analogue U46619 was significantly reduced. In addition, the 
thrombin-induced aggregation was defective in TRPC3/TRPC6 deficient mice. No 
differences in collagen-induced aggregation were observed in platelets both genotypes. 
The defects observed in platelet aggregation after stimulation with the TxA2 analogue or 
thrombin in these two mouse lines included an impaired ADP-mediated aggregation 
induced by the secreted ADP, since both agonists stimulates ADP secretion in platelets 
and the differences were ameliorated in experiments with higher concentrations of the 
ADP hydrolyzing enzyme Apyrase. The reduction in the ADP-induced platelet aggregation 
in platelets from TRPC3/TRPC6 and TRPC1/TRPC6 deficient mice markedly increased 
when the mice were pre-treated with Clopidogrel. Therefore, TRPC1, TRPC3 and TRPC6 
proteins could be identified as regulators in platelet aggregation mediated by ADP and 
P2Y1 receptors (Figure 43) and could thereby complement the GPVI-mediated pathway 
triggered by collagen that depends on Orai1/Stim1 proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADP
P2Y1
Gαq
P2Y12TRPC1/TRPC3/TRPC6
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Figure 43. Model of ADP mediated platelet aggregation and the possible role of TRPC 
channels. In mouse platelets ADP stimulates P2Y1 receptors that are coupled to Gq proteins and 
are responsible for the ADP-induced Ca2+ transients. ADP also stimulates P2Y12 receptors that 
coupled to Gi proteins and are target of a metabolite of the antithrombotic drug Clopidogrel. In 
platelets from TRPC1/C6 (-/-)2 and TRPC3/C6 (-/-)2 mice pre-treated with Clopidogrel there was a 
~60-80% reduction in the aggregation response measured by the area under the aggregation curve 
(see Figures 40 and 41). Therefore, TRPC1, TRPC3 and TRPC6 proteins are required for the 
ADP-induced platelet activation. Possibly, these TRPC proteins are involved in the full platelet 
activation after ADP stimulation mediating intracellular signaling by cation influx into the platelets. 
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Appendices 
 
Appendix A. Materials and reagents 
Reagent Catalog number Company/Supplier
Acetic acid 222140025 Acrös
Acetylcholine chloride A6625 Sigma
ADP (Sodium salt) A2754 Sigma
Ammonium oxalate monophosphate 221716 Sigma
Angiotensin  II, human 05-23-0101 Calbiochem 
Angiotensin  II, human A9525 Sigma
anti-αIIbβ3 (FITC labelled) M025-1 emfret analytics
anti-α-actinin (mouse monoclonal) A7811 Sigma
anti-α-smooth muscle actin ab15734 abcam
anti-CD31 (mouse monoclonal) ab24590 abcam
anti-mouse (goat IgG)-AlexaFluor®594 A11005 Invitrogen/Molecular Probes
anti-P4HB 11245-1-AP Acris
anti-rabbit (goat IgG)-AlexaFluor®488 A11008 Invitrogen/Molecular Probes
Apyrase from potato grade VII A6535 Sigma
Avertin (2,2,2-tribromoethanol) 90710 Fluka
BDM (2,3-Butanedione monoxime) B0753 Sigma
Bradykinin B3259 Sigma
Bromophenol Blue A3640,0005 AppliChem
BSA (albumin fraction V pH 7.0) A1391,0250 AppliChem
CaCl2-2H2O 5239.1 Carl Roth
Citric acid A2344,1000 AppliChem
Clopidogel hydrogensulfate BN0680 BIOTREND (Switzerland )
Collagen (Kollagenreagens Horm®) 1130630 Nycomed (Austria)
DAPI, dilactate D3571 Invitrogen/Molecular Probes
DePex 18243 Serva
DNAse (Deoxiribonuclease I ) D4527 Sigma
DTT D9163 Sigma
EDTA disodium salt 2H2O A1104,1000 AppliChem
EGTA E4378 Sigma
Ethanol 99% 702543 Universität des Saarlandes
Ethanol absolute 32205 Sigma
Ethidium Bromide 2218.2 Carl Roth
Eosin Y-solution 0.5% aqueous X883.1 Carl Roth
Eukitt 3989 Fluka
Fetal Calf Serum (FCS) 10270-106 Gibco
Fibrinogen from human plasma F3879 Sigma
FURA-2-AM F1221 Invitrogen/Molecular Probes
Glucose (D+) monohydrate 6780.1 Carl Roth
Glucose (D+) anhydrous X997.2 Carl Roth
Glycine 3908.3 Carl Roth
Glycerin (Glycerol) A2957 AppliChem
HCl 37% 20252.420 AnalaR Normapur - VWR
Hepes 9105.4 Carl Roth
Isoflurane HDG9623 Baxter  
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Reagent Catalog number Company/Supplier
(±)-Isoproterenol hydrochloride I5627 Sigma
Kanamycin Sulphate K 1377 Sigma
KCl 701080 or A1164 Grüssing / AppliChem
KH2PO4 26.936.320 VWR
Liberase TM (Research grade) 05 401 127 001 Roche
Liberase Blendzyme 4 Discontinued Roche
M199 Earle's salts and L-Glutamine 31153-026 Gibco
Mayer Hemalaum solution T865.2 Carl Roth
Methanol 20.847.320 AnalaR Normapur - VWR
MgCl2-6H2O 2189.2 Carl Roth
MgSO4-7H2O 1.058.861.000 Merck
Mygliol (Neutralöl 812) 1304M-01998 mLiter (Apotheke UKS)
NaCl 0.9% (sterile) 2350748 Braun
NaCl 27.810.295 VWR
NaHCO3 12143 Grüssing 
Na-Heparin (5000 I.E/ml) B.Braun Melsungen AG
Na-Heparin (25000 I.E/ml) pzn-7833909 Rathipharm
Na2HPO4 (2H2O) 1.065.801.000 Merck
NaOH 12.155 Grüssing / AppliChem
Na-pyruvat 8793.2 Carl Roth
Paraplast® (tissue embeding medium) A6330 Sigma
Paraformaldehyde (PFA) P6148 Sigma
PBS Ca2+/Mg2+ free (Dulbecco's-PBS) 14190-094 Gibco
Penicillin/Streptomycin 15140-122 Gibco
Penicillin/Streptomycin P4333 Sigma
(L)-Phenylephrine hydrochloride P6126 Sigma
Picric acid solution 80.456 Fluka
Prostacyclin (PGI2) sodium salt P6188 Sigma
Proteinase K A3830 AppliChem
Serotonin hydrochloride H9523 Sigma
Sirius Red (Direct Red 80) 365548 Sigma
Tamoxifen T5648 Sigma
TaqPolymerase — Home Made
Terg-A-Zyme 1304 Alconox Inc.
Tertiary amylalcohol 1.009.991.000 Merck
Thapsigargin T-9033 Sigma
Thrombin from bovine plasma T 4648 Sigma
Tris 4855.2 Carl Roth
Tris pH8.3 A4281 AppliChem
Tri-Sodium Citrate Dihydrated 3580.1 Carl Roth
Trypsin 10X/EDTA 154000-054 Gibco
Tween 20 A7564.0500 AppliChem
U46619 (9,11-Dideoxy-11α,9α-
epoxymethanoprostaglandin F2α ) D8174 Sigma
Urea A1360,1000 AppliChem
Vectashield mountig media H-1400 Linaris
Xylene 4436.1 Carl Roth
Xylene-Cyanol A1408,0010 AppliChem  
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Appendix B. Solutions  
 
- 10X PCR buffer (store RT): 
 Tris pH 8.3   100mM 
 MgCl2    15mM 
 KCl    500mM 
 
- Tail-Lysis buffer (in ddH2O): 
 10X PCR buffer  10% (v/v) 
 Proteinase K (10mg/ml) 2% (v/v) 
 
- 10X Loading buffer for DNA electrophoresis 
 20g Urea 
 5ml EDTA 0.5M pH 8.0 
 0.5ml Tris 1M pH 7.0 
 0.25% Bromophenol blue 
 0.25% Xylene-Cyanol 
 Complete 50ml with d-diH2O (warm ~60°C during stirring) 
 
- Avertin (2,2,2-tribromoethanol) stock solution (Store RT, dark):  
1g 2,2,2-tribromoethanol 99%  
 0.63ml tertiary amylalcohol 
Incubate at 65° in order to get tribromoethanol into solution 
 
Ready to use solution: 
                      - 60µl stock solution + 5ml NaCl 0.9% (Incubate 65°C)  
Dose: 0.5mg/g body weight or 25µl/g body weight (From 2010 this solution is prepared 2X 
concentrated to reduce the i.p injected volume into the mice).  
 
- PBS 1X (pH 7.4, autoclaved) 
 NaCl    137mM 
 KCl    2.7mM 
 Na2HPO4   8.1mM 
 KH2PO4   1.8mM 
Adjust pH with HCl 
 
- PBST: 1ml Tween-20 in 1 litter PBS (pH 7.4). 
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- PFA 4% (pH 7.4) in PBS always prepared one day before its use and solved during 
constant stirring at ~60°C for several hours. Store at 4°C. 
 
- Picrosirius red solution 
Sirius Red 0.1% in Picric Acid (0.5g Sirius Red in 500ml, stirring o/n in a dark bottle and 
controlling that the final pH is 2.0, use NaOH 10N for this) 
 
Solutions for cardiac myocytes/fibroblasts isolation:  
- Solution A: 
NaCl    134mM 
Glucose   11mM 
KCl    4mM 
MgSO4-7H2O   1.2mM 
Na2HPO4-2H2O  1.2mM 
Hepes    10mM 
Prepared with autoclaved d-diH2O, filtrated with Vacuum filter (Filtropur V50 0.45µm-
500ml No. 83.1823, Sarstedt) and pH adjusted to 7.36 with NaCl 10N. A 10X filtered and 
sterile solution without glucose can be stored for months at 4°C. 
  
- Solution A+: Solution A with 200µM EGTA, filtered and saturated with Carbogen (5% 
CO2/ 95% O2) for at least 15min at RT. For isolation of cardiomyocytes that were not 
going to be used for functional analysis was included 10mM of BDM (2,3-Butanedione 
monoxime), a reversible myosin AT-Pase inhibitor 
 
- Solution A++extra: 4-5% BSA (alternatively 5% FCS) in Solution A supplemented with 
DNAase solution (100µl DNAse per 100ml final volume) of and 12.5µM CaCl2 from a 
100mM solution. The solution is sterile filtered (Filtropur V25 0.2 -250ml, Sarstedt) before 
adding the DNAse solution. It is gassed before use with Carbogen and kept at 37°C 
during its use.  
 
- DNAse solution in Tris-buffer 
Deoxyribonuclease I  4KU/ml  
NaCl    50mM 
MgCl2    10mM 
DTT    1mM 
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The DNAse, NaCl, MgCl2 and DTT are solved in a final volume of 5ml Tris-buffer (10mM) 
and 5ml of Glycerin are added to complete 10ml. The solution is kept in 200µl aliquots at  
-20°C. 
 
- Liberase stock solution prepared with autoclaved d-diH2O at a final concentration of 
10mg/ml and 200µl aliquots kept at -20°C. 
 
- Macrophage’s solution:  
DPBS (Ca2+/Mg2+ free) 100ml 
EDTA    2 mM 
BSA    0.5% 
The solution is sterile filtered (Filtropur V25 0.2 -250ml, No83.1822.001, Sarstedt) and is 
maintained at 4°C during its use. Frozen aliquots can be stored at -20°C. 
 
- Medium 199-complete 
  Penicillin/Streptomycin 1:200 
Kanamycin   1:1000 
FCS    10% 
The FCS is sterile filtrated (Filtropur V25 0.2µm -250ml, Sarstedt) to remove debris and 
50ml aliquots are maintain at -20°C. Kanamycin is solved (50mg/ml) in d-diH2O, sterile 
filtrated with a syringe filter (0.22µm Fisherbrand, Fisher Scientific Cat.No. 09-719A) and 
aliquots are stored at -20°C. 
 
- Trypsin 1X (Trypsin/EDTA 10X Gibco 15400-054) obtained solving the 10X 1:10 in PBS 
Ca2+/Mg2+ free with EDTA 0.2mM. Thaw just before its use, preferably use fresh aliquots 
always.  
 
- Krebs-Henseleit solution (for organ bath): 
NaCl    118mM 
NaHCO3   24.88mM 
KCl    4.7mM 
Glucose   5.56mM 
Na-pyruvat   1mM 
MgSO4-7H2O   1.64mM 
KH2PO4   1.18mM 
CaCl2    1.8mM 
The pH is adjusted with HCl to 7.2 and the solution is gassed constantly during its use. 
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- Tyrode’s modified (FB’s calcium imaging): 
Hepes    5mM 
NaCl    137mM 
KCl    2mM 
NaHCO3   12mM 
Na2HPO4-2H2O  0.3mM 
MgCl2-6H2O    1mM 
Glucose    5mM 
CaCl2    1.8mM 
Filtrate the solution, afterwards check the pH and adjust to 7.4 with NaOH 10N. 
 
- ACD (Acid-Citrate-Dextrose): 
Tri-Sodium Citrate-2H2O 2.5% (85.01mM)  
Citric acid   1.4% (72.87mM) 
Glucose   2% (100.92mM)  
The solution is prepared with autoclaved d-diH2O and then can be maintained at 4°C. 
 
- Platelet’s solution: 
Hepes    5mM 
NaCl    137mM 
KCl    2mM 
NaHCO3   12mM 
Na2HPO4-2H2O   0.3mM 
MgCl2-6H2O   1mM 
Glucose   4.54mM 
CaCl2    2mM 
BSA    0.35% (w/v) 
Always prepared fresh in small volume (30ml) and gassed with carbogen, the pH is then 
7.4. Keep warm at 37°C during its use.  
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Appendix C. ECG analysis from TRPC1/TRPC4 (-/-)2 mice 
 
During cardiac hypertrophy experiments with TRPC-deficient mice ECGs before and at 
the end of the hypertrophy induction were recorded. Differences in heart rate from wild 
type and TRPC1/TRPC4 (-/-)2 mice treated with isoproterenol were observed (Figure 10). 
In addition, from the analysis of ECG traces performed in these mice a reduced QT 
interval in TRPC1/TRPC4 (-/-)2 mice was observed (Figure 1Ap, Ba). However, due to 
differences in heart rate between wild type and TRPC1/TRPC4 (-/-)2 mice a corrected QT 
interval was calculated revealing a difference in the QT interval only between the saline 
treated groups (Figure 1Ap, A and Bb-c). It is difficult to interpret this observation since 
only little about the electric physiology of the mouse heart and more over about short QT 
syndromes in mice have been described. In humans short QT syndromes have been only 
related with mutations in few potassium channels (Schulze-Bahr and Breithardt, 2005). 
Regarding the role of TRPC proteins in the regulation of the cardiac electrophysiology not 
now much is known. It has been described that the murine Sino-Atrial Node (SAN) 
displays store-operated Ca2+ activity. This was correlated with the expression of several 
TRPC transcripts including TRPC1 and TRPC4 in the SAN, in addition to expression 
assessed by immunocytochemestry of pacemaker cells (Ju et al., 2007). Although, the 
specificity of the antibodies used has not been fully proved. To define if the reduced QT 
interval observed in TRPC1/TRPC4 deficient mice is a reproducible observation, in the 
future it will be required to analyze ECG recordings of these mice using different ECG 
leads as recommended by Dr. Hans-Ruprecht Neuberger from the Cardiology 
Department. With dose measurements further experiments could be planned to determine 
if these TRPC proteins are involved in the electrophysiology of the heart.   
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Figure 1Ap. ECG analysis from TRPC1/TRPC4 (-/-)2 mice during cardiac hypertrophy 
induction by isoproterenol. ECG recordings from wild-type and from TRPC1/TRPC4 (-/-)2 mice 
were obtained at the 6th day of Iso-30 treatment under anesthesia. (A) Representative original ECG 
traces of mean cardiac cycles from 10 beats recorded in wild type and in TRPC1/TRPC4 (-/-)2 
mice. The different ECG waves P, Q, R, S and T and limits of the wave’s intervals used for the 
analysis are depicted. In these kind of recordings a shorter duration of the QT interval from 
TRPC1/TRPC4 (-/-)2 saline treated mice was observed. (B) Statistical analysis of the QT interval 
duration. In Ba the QT interval, in Bb the QT corrected (QTc) interval using the formula 
QTc=QT/√RRx10 from Mitchell et al. (1998) and in Bc dot plot from the QTc interval where each 
dot represents data from one mouse. n=: number of mice.**p<0.01, ***p<0.001 and ns (not 
significant) according to the one-way ANOVA. 
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